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Platelet activation and aggregation at sites of vascular injury is critical to prevent excessive 
blood loss, but may also lead to life-threatening ischemic disease states, such as myocardial 
infarction and stroke. Glycoprotein (GP) VI and C-type lectin-like receptor 2 (CLEC-2) are 
essential platelet activating receptors in hemostasis and thrombo-inflammatory disease 
which signal through a (hem)immunoreceptor tyrosine-based activation motif (ITAM)-
dependent pathway. The adapter molecules Src-like adapter protein (SLAP) and SLAP2 are 
involved in the regulation of immune cell receptor surface expression and signaling, but their 
function in platelets is unknown. As revealed in this thesis, single deficiency of SLAP or 
SLAP2 in mice had only moderate effects on platelet function, while SLAP/SLAP2 double 
deficiency resulted in markedly increased signal transduction, integrin activation, granule 
release, aggregation, procoagulant activity and thrombin generation following (hem)ITAM-
coupled, but not G protein-coupled receptor activation. Slap-/-/Slap2-/- mice displayed 
accelerated occlusive arterial thrombus formation and a dramatically worsened outcome after 
focal cerebral ischemia. These results establish SLAP and SLAP2 as critical inhibitors of 
platelet (hem)ITAM signaling in the setting of arterial thrombosis and ischemic stroke. 
GPVI has emerged as a promising novel pharmacological target for treatment of thrombotic 
and inflammatory disease states, but the exact mechanisms of its immunodepletion in vivo 
are incompletely understood. It was hypothesized that SLAP and SLAP2 may be involved in 
the control of GPVI down-regulation because of their role in the internalization of immune cell 
receptors. As demonstrated in the second part of the thesis, SLAP and SLAP2 were 
dispensable for antibody-induced GPVI down-regulation, but anti-GPVI treatment resulted in 
prolonged strong thrombocytopenia in Slap-/-/Slap2-/- mice. The profound thrombocytopenia 
likely resulted from the powerful platelet activation which the anti-GPVI antibody induced in 
Slap-/-/Slap2-/- platelets, but importantly, not in wild-type platelets. These data indicate that 
the expression and activation state of key modulators of the GPVI signaling cascade may 
have important implications for the safety profile and efficacy of anti-GPVI agents. 
Small GTPases of the Rho family, such as RhoA and Cdc42, are critically involved in the 
regulation of cytoskeletal rearrangements during platelet activation, but little is known about 
the specific roles and functional redundancy of both proteins in platelet biogenesis. As shown 
in the final part of the thesis, combined deficiency of RhoA and Cdc42 led to marked 
alterations in megakaryocyte morphology and the generation of platelets of heterogeneous 
size and granule content. Despite severe hemostatic defects and profound thrombo-
cytopenia, circulating RhoA-/-/Cdc42-/- platelets were still capable of granule secretion and the 
formation of occlusive thrombi. These results implicate the existence of both distinct and 






Die Aktivierung und Aggregation von Thrombozyten nach einer Gefäßverletzung ist 
entscheidend, um einen starken Blutverlust zu vermeiden. Diese Prozesse können aber 
auch zu lebensbedrohlichen ischämischen Erkrankungen führen, wie beispielsweise 
Myokardinfarkt und Schlaganfall. Die aktivatorischen Thrombozytenrezeptoren Glykoprotein 
(GP) VI und C-type lectin-like receptor 2 (CLEC-2) spielen eine wichtige Rolle im Prozess 
der Hämostase und Thrombo-Inflammation. Die Aktivierung beider Rezeptoren leitet eine 
(hem)immunoreceptor tyrosine-based activation motif (ITAM)-abhängige Signalkaskade ein. 
Die Adapterproteine Src-like adapter protein (SLAP) und SLAP2 sind an der Regulation der 
Oberflächenexpression von Immunzellrezeptoren und der Steuerung nachgeschalteter 
Signalwege beteiligt, aber ihre Funktion in Thrombozyten ist unbekannt. In dieser Arbeit 
wurde gezeigt, dass die Einzeldefizienz von SLAP oder SLAP2 in Mäusen einen milden 
Effekt auf die Thrombozytenfunktion hatte. Hingegen führte das Fehlen beider Proteine zu 
deutlich verstärkter Signaltransduktion, Integrinaktivierung, Freisetzung von Granula, 
Aggregation, prokoagulatorischer Aktivität und Thrombingenerierung nach (hem)ITAM-
abhängiger, aber nicht G-Protein-gekoppelter Rezeptoraktivierung. Die SLAP/SLAP2-
Doppeldefizienz ging mit beschleunigter Bildung okklusiver arterieller Thromben und 
dramatisch verschlechtertem Zustand nach fokaler zerebraler Ischämie einher. Diese 
Ergebnisse etablieren SLAP und SLAP2 als essentielle Inhibitoren des (hem)ITAM-
Signalwegs in arterieller Thrombose und im ischämischen Schlaganfall. 
GPVI wird zunehmend als vielversprechender neuer pharmakologischer Angriffspunkt für die 
Behandlung von thrombotischen und entzündlichen Erkrankungen betrachtet. Die genauen 
Mechanismen der Herabregulierung von GPVI nach Antikörper-Gabe in vivo sind jedoch 
unvollständig aufgeklärt. Im Hinblick auf die Rolle von SLAP und SLAP2 in der 
Internalisierung von Immunzellrezeptoren wurde die Hypothese aufgestellt, dass beide 
Adapterproteine entscheidend an der Herabregulierung von GPVI beteiligt sein könnten. Im 
zweiten Teil dieser Dissertation wurde aber gezeigt, dass SLAP und SLAP2 nicht erforderlich 
sind für die Depletion von GPVI. Dagegen ging die Antikörper-induzierte Herabregulierung 
von GPVI mit lang anhaltender starker Thrombozytopenie in Slap-/-/Slap2-/- Mäusen einher. 
Der anti-GPVI-Antikörper induzierte eine starke Aktivierung von Slap-/-/Slap2-/- Thrombo-
zyten, nicht aber von Wildtypthrombozyten, was eine mögliche Erklärung für die schwere 
Thrombozytopenie lieferte. Diese Ergebnisse weisen darauf hin, dass die Expression und 
der Aktivierungszustand von Molekülen, die die Feinregulierung der GPVI-Signalkaskade 
steuern, wichtige Auswirkungen auf das Sicherheitsprofil und die Wirksamkeit von an GPVI 





Kleine GTPasen der Rho-Proteinfamilie, wie z.B. RhoA und Cdc42, sind maßgeblich an der 
Regulation von Umstrukturierungen des Zytoskeletts während der Aktivierung von 
Thrombozyten beteiligt. Dennoch ist wenig über spezifische und überlappende Funktionen 
von RhoA und Cdc42 während der Thrombozyten-Biogenese bekannt. Der letzte Teil der 
Arbeit befasste sich mit den Auswirkungen einer Doppeldefizienz von RhoA und Cdc42 in 
Megakaryozyten. Das Fehlen beider Proteine führte zu einer dramatisch veränderten 
Megakaryozytenmorphologie und zur Produktion von Thrombozyten heterogener Größe und 
Granulainhaltes. Trotz markanter Thrombozytopenie und stark beeinträchtigter Hämostase in 
den RhoA-/-/Cdc42-/- Mäusen waren zirkulierende Thrombozyten in der Lage, ihre Granula 
freizusetzen, und die Bildung okklusiver Thromben war weitestgehend unverändert. Diese 
Ergebnisse implizieren, dass RhoA und Cdc42 sowohl unterschiedliche als auch 








Platelets are small anucleate discoid-shaped blood cells with a diameter of 3-4 µm in 
humans and 1-2 µm in mice. Platelets are constantly produced by their bone-marrow 
resident precursors, the megakaryocytes (MKs), to maintain a normal range of circulating 
platelets (150 x 103 – 400 x 103 platelets/µl in humans and ~1000 x 103 platelets/µl in mice). 
The life span of platelets is restricted to 10 days in humans and up to 5 days in mice. Aged, 
dysfunctional or pre-activated platelets are cleared from the circulation by resident 
macrophages in the spleen and liver.1 Most of the circulating platelets never undergo 
adhesion before they are removed from the circulation. However, upon damage to the vessel 
wall, platelets come into contact with components of the exposed extracellular matrix (ECM) 
which induces their activation, adhesion and aggregation followed by the formation of a 
thrombus that seals vessels lesions, minimizes blood loss and prevents infection. In 
pathological conditions, however, uncontrolled thrombus formation can occur that may lead 
to acute ischemic disease states, such as myocardial infarction and stroke, which currently 
represent the leading causes of death and permanent disability worldwide.2 Therefore, 
platelet activation needs to be tightly regulated by a complex interplay between activating 
and inhibitory mechanisms in platelets that ensure controlled spatial and temporal 
responses. 
 
1.1. Platelet activation and thrombus formation 
Besides their essential role in primary hemostasis and thrombus formation, platelets are 
critically involved in several other (patho)physiological processes, including lymphatic 
development, cancer metastasis, wound healing, angiogenesis and maintenance of the 
vascular integrity during inflammation. These distinct functions arise from the diverse cargo 
present in platelet granules. Platelets contain different types of granules, including 
lysosomes, α-, dense and the recently described t-granules.3,4 Lysosomes store enzymes 
necessary for the degradation of proteins, carbohydrates and lipids. Dense granules contain 
many inorganic substances, including adenine nucleotides, polyphosphates, bioactive 
amines and Ca2+. α-granules are the most abundant platelet granules. They store adhesion 
proteins (most notably fibrinogen, P-selectin, von Willebrand factor (VWF)), coagulation 
factors, growth factors and chemokines (e.g. platelet factor (PF) 4). In addition, platelets 
contain a surface-connected or open canalicular system (OCS) which provides a membrane 
source for surface area increase following platelet activation and shape change, a dense 





glycogen stores, an actin-based cytoskeletal network and a peripheral band of microtubule 
coils.5 
 At sites of vascular injury, several subendothelial matrix components or proteins 
adsorbed onto exposed tissue, including VWF, fibrillar collagens, fibronectin and laminin, 
come into contact with the flowing blood which initiates platelet adhesion and activation, 
eventually leading to thrombus formation, a process which can be subdivided into three 
major steps: (1) initial contact to the exposed ECM (tethering); (2) cellular activation and 
release of second-wave mediators; (3) firm adhesion to the ECM and thrombus growth 
(Figure 1).6 The initial capture of circulating platelets to exposed components of the ECM at 
sites of vascular injury is mediated by the interaction of the glycoprotein (GP) Ib-V-IX 
receptor complex with VWF immobilized on collagen.7 GPIbα-VWF interactions are essential 
for initial platelet tethering under conditions of high shear flow (> 500 s-1), found e.g. in 
arterioles or stenotic arteries, but cannot mediate firm adhesion to the ECM and lead instead 
to rapid deceleration of circulating platelets.7 Platelet adhesion and aggregation exclusively 
depend on GPIb-VWF interactions at very high shear rates (> 10,000 s-1).8-10 Platelet 
deceleration enables the binding of collagen to GPVI, the central activating platelet collagen 
receptor.11 GPVI-collagen interactions initiate a powerful intracellular signaling cascade 
characterized by a rise in cytosolic Ca2+ concentration, surface exposure of negatively 
charged procoagulant phosphatidylserine (PS), cytoskeletal rearrangements, mobilization of 
α- and dense granules and subsequent release of secondary platelet agonists, including 
adenosine diphosphate (ADP) and thromboxane A2 (TxA2).12,13 Concomitantly, exposed 
tissue factor (TF) triggers thrombin generation that is further enhanced by PS exposure on 
the platelet surface which provides high-affinity binding sites for coagulation factors and 
serves as a membrane substrate for the tenase and prothrombinase complexes.14 In 
addition, thrombin generation is supported by the release of negatively charged inorganic 
polyphosphates (PolyP) from dense granules that potently activate coagulation factor XII 
(FXII, Hageman factor) – the starting point of the intrinsic coagulation pathway.15 ADP, TxA2 
and locally generated thrombin act in an autocrine and paracrine manner on G protein-
coupled receptors (GPCRs) and thus reinforce cellular activation and recruit additional 
circulating platelets to the growing thrombus. Finally, the extra- and intracellular signaling 
events induce the conformational change of integrin adhesion receptors, most notably αIIbβ3 
(GPIIb/IIIa), from a low to a high affinity state, thereby mediating firm platelet adhesion, 
aggregation and thrombus growth.6 Besides αIIbβ3, platelets also express the integrins 
αVβ3, α2β1, α5β1 and α6β1.16 Integrin αIIbβ3 binding to fibrinogen enables bridging of 
adjacent cells and thus essentially contributes to thrombus stabilization. In addition, integrin 





of ligands, including fibronectin, VWF, thrombospondin and vitronectin, which is further 
supported by binding of β1-integrins to collagen, laminin and fibronectin.17 
 
Figure 1. Model of platelet adhesion to the ECM and subsequent thrombus formation. At sites of 
vascular injury, initial contact (tethering) of platelets with components of the ECM predominantly 
depends on the interaction between GPIb and VWF. In the next step, GPVI-collagen interactions 
trigger cellular activation and conversion of integrins to a high-affinity state. Second-wave mediators 
(such as ADP and TxA2) are released. Tissue factor triggers thrombin generation which also induces 
cellular activation. Finally, activated platelet integrins facilitate firm platelet adhesion to the ECM. 
Enhanced release of soluble second-wave agonists amplifies integrin activation on adherent platelets 
and sustains thrombus growth. ADP, adenosine diphosphate; TxA2, thromboxane A2, VWF, von 
Willebrand factor; TF, tissue factor; GPRC, G protein-coupled receptors, CLEC-2: C-type lectin-like 
type II. Taken from: Nieswandt et al., 2011.12 
 Platelet activation can occur through two major pathways, depending on the initial 
stimulus (Figure 2). As mentioned above, soluble agonists, such as ADP, TxA2 and thrombin, 
operate via receptors that couple to heterotrimeric G proteins (Gq, G12/13, Gi).18 The second 
major route leading to powerful cellular activation involves engagement of 
(hem)immunoreceptor tyrosine-based activation motif (ITAM)-bearing receptors and is 
introduced in detail in Section 1.2. Both signaling pathways culminate in the activation of 
phospholipase C (PLC) isoforms, leading to hydrolysis of phosphatidyl-
inositol-4,5-bisphosphate (PIP2) to inositol-3,4,5-trisphosphate (IP3) and diacyl glycerol 
(DAG) which results in elevation of cytosolic Ca2+ concentration, integrin activation, platelet 






Figure 2. Major signaling pathways in platelets. Soluble agonists, including ADP, TxA2 and 
thrombin, mediate effects via receptors that couple to heterotrimeric G proteins (Gq, G12/13, Gi) and 
activate downstream effectors. Adhesion receptors, such as GPVI, CLEC-2 and active integrins, 
induce PLCγ2 activation upon ligand binding. Both signaling pathways culminate in integrin activation, 
platelet shape change, aggregation and secretion. PI3K, phosphatidylinositol-3-kinase; PIP2, 
phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; IP3, inositol-
3,4,5-trisphosphate; AC, adenylyl cyclase; DAG, diacylglycerol; PLC, phospholipase C; CLEC-2: 
C-type lectin-like type II; PAR, protease-activated receptor; ADP, adenosine diphosphate; GDP, 
guanosine diphosphate; GTP, guanosine triphosphate; GEF, guanine nucleotide exchange factor; 
RhoA, Ras homolog gene family, member A; Fg, fibrinogen; TF, tissue factor; TxA2, thromboxane A2; 
VWF, von Willebrand factor; LAT, linker for activation of T cells; Syk, spleen tyrosine kinase; SFK, Src 
family kinase. Taken from: Stegner and Nieswandt, 2010.19 
 
1.2. (Hem)ITAM signaling in platelets 
An ITAM represents a highly conserved sequence defined by the presence of 2 Yxx(L/I) 
motifs separated by 6-12 amino acids which can be found in the cytosolic chain of several 
hematopoietic immunoglobulin receptors, including Fc receptors (FcR), T and B cell 





initiates the phosphorylation of both tyrosine residues in the ITAM which in turn serves as a 
starting point for a signaling cascade that consists of a number of kinases, adapter proteins 
and effector molecules. Human platelets express three ITAM-bearing receptors: GPVI, 
FcγRIIA and the hemITAM receptor C-type lectin-like receptor 2 (CLEC-2). Platelet activation 
through FcγRIIA has important implications in the pathogenesis of several diseases related to 
immune-mediated thrombocytopenia and thrombosis syndromes. However, mouse platelets 
lack FcγRIIA. Since the receptor signals through a similar pathway as GPVI, specifically 
GPVI signaling will be discussed in further detail in the following section. 
 
1.2.1. GPVI 
The central activating collagen receptor GPVI is a 62 kDa MK-/platelet-specific type I 
transmembrane protein that belongs to the Ig superfamily of surface receptors.21 GPVI is 
non-covalently associated with the disulphide-linked homodimeric FcRγ-chain through a salt 
bridge. Each FcRγ-chain contains one copy of a classical ITAM which thereby serves as the 
signal transducing subunit of the GPVI/FcRγ receptor complex.11 The FcRγ-chain is 
indispensable for both GPVI expression and the initiation of downstream signaling.22 GPVI is 
expressed at approximately 4000-6000 copies per platelet partially in a monomeric and 
dimeric form;23 the latter binds collagen with high affinity.24 The cytosolic tail of GPVI contains 
a calmodulin binding motif and a proline-rich region (PRR) that is recognized by the Src 
homology 3 (SH3) domain of the Src family tyrosine kinases (SFK) Fyn and Lyn.25,26 
 Ligand-induced crosslinking of GPVI leads to phosphorylation of the two tyrosine 
residues within the ITAM on the FcRγ-chain predominantly by the SFK Lyn.27,28 
Phosphorylation of the FcRγ-chain ITAM is followed by the recruitment, phosphorylation and 
activation of the SH2 domain-containing spleen tyrosine kinase (Syk) which initiates a 
downstream signaling cascade composed of a series of adapter proteins, including linker for 
activation of T cells (LAT) and SH2-containing leukocyte protein 76 (SLP-76), that ultimately 
results in the activation of effector enzymes, including phosphoinositol (PI)-3-kinases and 
PLCγ2 (Figure 3).29 
GPVI has emerged as an attractive potential target for antithrombotic therapy, as its 
deficiency, blockade or antibody-induced depletion provides powerful protection from 
experimental arterial thrombosis without affecting platelet hemostatic functions.13,30 Similarly, 
patients with a congenital GPVI deficiency or autoantibody-induced receptor loss suffer from 
only a mild bleeding disorder, while platelet aggregation following stimulation with collagen is 
abolished.13,31 Besides its crucial role in occlusive arterial thrombosis in different animal 





inflammatory disease states, including ischemic stroke,32 loss of vascular integrity at sites of 
inflammation,33 rheumatoid arthritis,34 glomerulonephritis35 and atheroprogression.36,37 
 
Figure 3. (hem)ITAM signaling in platelets. The type I transmembrane protein GPVI is non-
covalently associated with the ITAM-bearing FcRγ-chain. Ligand binding induces phosphorylation of 
the ITAM by SFKs, followed by the recruitment and activation of Syk. Syk phosphorylation triggers a 
downstream signaling cascade that consists of kinases, adapter and effector molecules. This pathway 
culminates in the activation of PLCγ2. The C-type lectin-like type II (CLEC-2) contains a single YXXL 
sequence (hemITAM) in its cytoplasmic tail which is phosphorylated by Syk. Following hemITAM 
phosphorylation, SFKs and Syk cooperatively modulate a signaling cascade similar to that found 
downstream of GPVI. SFK, Src family kinase; Syk, spleen tyrosine kinase; LAT, linker for activation of 
T cells; Grb2, growth factor receptor-bound protein 2; Gads, Grb2-related adapter downstream of Shc; 
SLP-76, SH2-containing leukocyte protein 76; PLCγ2, phospholipase C γ2; PM, plasma membrane. 
Taken from: Stegner et al., 2014.38 
Current GPVI targeting strategies under development focus on three different 
approaches. They include blockade of the GPVI-collagen interaction, immunodepletion of 
GPVI via monoclonal antibodies and interference with key signaling molecules downstream 
of GPVI, such as the tyrosine kinase Syk.38 Immunodepletion by monoclonal anti-GPVI 
antibodies (JAQ1-3) induces specific and irreversible removal of the receptor from the 
surface of murine platelets, resulting in a GPVI-knockout-like phenotype for at least two 
weeks which is accompanied only by a short thrombocytopenia.39,40 The process of antibody-
induced GPVI down-regulation in vivo is still incompletely understood, but ectodomain 
shedding by members of the a disintegrin and metalloproteinase (ADAM) family and 
internalization/degradation seem to be the principal mechanisms involved in irreversible 
removal of GPVI from the surface of circulating platelets.39,41,42 Both pathways involved in 
targeted GPVI down-regulation require functional signaling through the ITAM in the 
FcRγ-chain, but downstream signaling events likely diverge.41,43 
Despite compelling experimental evidence which documents the potential of GPVI as a 
promising antithrombotic and anti-inflammatory target, the safety profile of an anti-GPVI 
therapy has to be carefully assessed. For instance, GPVI immunodepletion severely 
compromises hemostatic functions in mice deficient in the hemITAM receptor CLEC-2,33,44 









The second (hem)ITAM-containing receptor on mouse platelets CLEC-2 is an ~32 kDa 
type II transmembrane protein which signals via phosphorylation of a single conserved YxxL 
motif (hemITAM) in its cytoplasmic tail. CLEC-2 is highly expressed on MKs and platelets 
(~2000 copies per platelet) and additionally at lower levels on some immune cells.29,46 
CLEC-2 has been identified as the receptor for the powerful platelet activating snake venom 
toxin rhodocytin47 and the sialoglycoprotein podoplanin48 which remains the only currently 
known endogenous ligand of CLEC-2. Interestingly, however, podoplanin is not expressed 
on platelets and vascular endothelial cells and therefore, it has been proposed that a hitherto 
unidentified CLEC-2 ligand may exist which presumably becomes exposed or released at 
sites of injury or on growing thrombi and thus contributes to CLEC-2-dependent thrombus 
stabilization.49 
 CLEC-2 is expressed as a homodimer on resting platelets and clustering of the receptor 
following ligand binding induces powerful cellular activation.50 Receptor engagement of 
CLEC-2 triggers a signaling cascade which involves similar molecules downstream of Syk 
like the GPVI pathway (Figure 3).29 Importantly, recent studies suggested a significant 
difference in the proximal events in GPVI and CLEC-2 signaling. As indicated above, 
phosphorylation of the ITAM on the FcRγ-chain is mediated by SFKs, followed by the 
recruitment, phosphorylation and activation of Syk, whereas Syk is essential for 
phosphorylation of the hemITAM, with SFKs being predominantly involved in the regulation 
of downstream signaling events.51 
 Initial studies on the role of CLEC-2 in thrombosis and hemostasis implicated that the 
receptor might become a target for antithrombotic therapy.49,52 Immunodepletion of CLEC-2 
from circulating platelets49 or genetic ablation of the receptor52 was accompanied by a 
significant protection of mice in models of occlusive arterial thrombosis, but only by a 
moderate increase in bleeding times. However, recent studies demonstrated a previously 
unrecognized functional redundancy of GPVI and CLEC-2 in hemostasis and the 
maintenance of vascular integrity at sites of inflammation.33,44 These findings have obvious 
implications regarding the suitability of the hemITAM receptor as a safe antithrombotic target. 
Furthermore, CLEC-2 plays a crucial role in a plethora of other (patho)physiological 
processes, including tumor metastasis, maintenance of the integrity of high endothelial 
venules, development of lymph nodes and blood/lymph vessel separation.53-56 Genetic 





lymphatics and severe edema formation,52,57 a phenotype which strongly resembles that 
observed during embryonic development in mice lacking key (hem)ITAM-signaling 
molecules, including Syk, SLP-76 and PLCγ2, and importantly, podoplanin.54 Recent studies 
which took advantage of tissue-specific deletion approaches identified that (hem)ITAM-
signaling in platelets mediates blood/lymphatic separation and further documented that 
interactions between platelet CLEC-2 and podoplanin on lymphatic endothelial cells play an 
essential role in this process.57,58 
Similar to GPVI, CLEC-2 can be immunodepleted from the surface of murine platelets by 
a monoclonal antibody (INU1).44,49,59 Antibody-induced CLEC-2 down-regulation is 
accompanied by a receptor loss for > 5 days post treatment and a severe thrombocytopenia 
during the first 24-48 h after antibody administration.44,49,59 Experimental evidence suggests 
that the mechanism by which antibody-induced CLEC-2 down-regulation in mice occurs is 
through SFK-triggered receptor internalization in vitro and in vivo, whereas the concomitantly 
occurring thrombocytopenia is, to a large extent, Syk-dependent.59 Syk blockade thus reveals 
the possibility to mechanistically uncouple targeted CLEC-2 down-regulation from the 
therapeutically undesired thrombocytopenia. 
 
1.2.3. Attenuation of (hem)ITAM signaling 
Platelet function in vivo is negatively regulated by several mechanisms. Bioactive nitric oxide 
(NO) and prostacyclin (PGI2) produced in endothelial cells support restriction of thrombus 
growth to the damaged areas and prevent further spreading in healthy vessels.60 A naturally 
occurring intrinsic mechanism to dampen tonic signaling through (hem)ITAM receptors 
involves the action of receptors bearing an immunoreceptor tyrosine-based inhibitory motif 
(ITIM) defined by the consensus sequence L/I/V/SxYxxL/V.61 ITIM is commonly found in pairs 
separated by 15 to 30 amino acid residues.61 In hematopoietic cells, ITIM-bearing receptors 
inhibit ITAM signaling through recruitment of the tandem SH2 domain-containing protein 
tyrosine phosphatases (SHP), SHP-1 and SHP-2, and the single SH2 domain-containing 
inositol 5-phosphatases (SHIP), SHIP1 and SHIP2.61 Platelets express a few ITIM-bearing 
proteins, including platelet endothelial cell adhesion molecule-1 (PECAM-1), G6b-B, TREM-
like transcript-1 (TLT-1) and carcino-embryonic antigen-related cell adhesion molecule-1 
(CEACAM1) and CEACAM2.29,62 Some ITIM-containing receptors, e.g. PECAM-1 and 
G6b-B, bear an immunoreceptor tyrosine-based switch motif (ITSM) in their cytoplasmic tail 
in addition to the ITIM.63 ITSM is characterized by the consensus TxYxxV/I which can be 
tyrosine phosphorylated by SFKs and can subsequently bind to SHP-1, SHP-2 and SHIP.64 
PECAM-1, CEACAM1 and CEACAM2 play a minor inhibitory role in (hem)ITAM signaling in 





integrity during inflammation by facilitating platelet aggregation and preventing hemorrhage 
at sites of vascular injury.68 It has been suggested that G6b-B is a critical negative regulator 
of ITAM signaling in mature MKs and thus decisively contributes to platelet production and 
reactivity.69 Furthermore, studies in G6b-B-deficient mice may help to resolve the question of 
how MKs remain relatively refractory to the ECM-rich environment, although they are 
equipped with the same repertoire of receptors as platelets.69 
 
1.3. Src-like adapter proteins (SLAP) 
SLAP and SLAP2 constitute a family of adapter proteins that are expressed in multiple 
organs and cell types, but their function has been most extensively studied in lymphocytes. 
Mouse and human Slap genes are located on the thyroglobulin gene locus on chromosome 
15 D2 and 8q22.3, respectively,70,71 and code for a protein of 34 kDa. Slap2 is found on 
chromosome 2 H1 (mouse) and 20q11.23 (human).72 Alternative translation initiation of both 
murine and human Slap2 determines the expression of 2 protein isoforms of 28 and 25 kDa, 
with the latter isoform lacking the myristoylation sequence and serine-rich region at the 
N-terminus.72-74  
 SLAP mRNA is expressed in heart, brain, spleen, thymus, bone marrow, lung, liver, 
skeletal muscle and kidney.71,75-77 Likewise, SLAP2 mRNA expression was detected in 
lymphatic organs, including thymus, lymph nodes and spleen, in a variety of hematopoietic 
cells of both lymphoid and myeloid lineages in the bone marrow and the peripheral blood, as 
well as in liver and lung.73-75 SLAP family members share structural similarities with SFKs 
which are characterized by the presence of a unique N-terminal region, an SH3-domain and 
an SH2-domain. The SH3 and the SH2 domain are highly homologous to the SH3 and SH2 
domain of Lck, sharing 55% and 50% amino acid sequence identity, respectively.78 Unlike 
SFKs, SLAP and SLAP2 lack a C-terminal kinase domain.75 However, the C-terminal tail has 
been suggested to facilitate interactions between SLAP and the E3 ubiquitin ligase c-Cbl and 
thus enable SLAP to participate in the negative regulation of receptor expression and 
signaling.79 In addition, the C-terminus of SLAP mediates dimerization of the protein and is 
essential for the negative regulation of the TCR (see below).79 SLAP and SLAP2 share 






Figure 4. Sequence similarities between members of the Src-like adapter protein (SLAP) family. 
Amino acid identity in percentage found in the N-terminus, SH3 and SH2 domain and the C-terminal 
region of SLAP and SLAP2 in humans (left panel) and mice (right panel). Modified from: Dragone et 
al., 2009.75 
 Different pull-down assays identified that SLAP interacts with proximal components of the 
TCR and BCR complexes, including TCRζ and Igα, as well as with the SFK Lck and the E3 
ubiquitin ligase c-Cbl.78,80-82 Similarly, SLAP2 has been demonstrated to interact with TCRζ, 
Lck and c-Cbl, but also with the colony-stimulating factor-1 receptor (CSF-1R) on 
macrophages.73,74,83-85 Pull-down approaches and yeast-two-hybrid screens following 
overexpression studies identified a plethora of further interacting partners of SLAP/SLAP2, 
but many of these putative interactions have not been validated in primary cells yet and the 
functional consequences remain elusive.75 
 Initial experiments in knockout mice demonstrated that SLAP plays and important 
function in T lymphocyte maturation through regulation of TCR levels during the CD4+CD8+ 
double positive stage of thymus development.86 Further mechanistic studies revealed that the 
negative regulation of TCR levels by SLAP likely occurs through contribution to the 
degradation of TCRζ and inhibition of the recycling of TCR complex components back to the 
cell surface.80 A decisive step in this process is the phosphorylation of the cytoplasmic 
domain of TCRζ. Lck has been identified as the critical SFK that is required for SLAP to 
negatively regulate TCR expression levels through interactions with the phosphorylated form 
of TCRζ80 or CD3ε.81 Similarly, overexpression of SLAP2 in Jurkat T cells resulted in 
decreased surface expression of CD3ε, demonstrating that SLAP2 serves as a negative 
regulator of TCR levels, presumably through functional cooperation with the ubiquitin ligase 
c-Cbl.74 Furthermore, SLAP is critically involved in B cell development, since it essentially 
contributes to the maintenance of normal BCR levels and intact signaling during B cell 
maturation.87 Mechanistically, the fine-tuning of BCR levels during B cell development occurs 
through the cooperative action of SLAP and c-Cbl, whereby SLAP likely facilitates 
interactions between c-Cbl and antigen-bound components of the BCR complex.82 In 
addition, SLAP modulates the surface expression and stability of receptors which belong to 
the receptor tyrosine kinase (RTK) family, including CSF-1R,84,85 Flt388 and EPHA2.89 Of 
note, recent studies indicated that this naturally occurring inhibitory mechanism controlled by 





Little is known about the function of SLAP family members in platelets other than that 
upon platelet stimulation specifically with the GPVI activating snake venom protein convulxin, 
SLAP2 co-immunoprecipitates with c-Cbl, Syk and LAT.90 However, the functional 
consequences of these putative interactions remained unknown. 
 
1.4. Platelet biogenesis 
Platelets are constantly produced by their bone marrow (BM) resident precursors, MKs, in a 
unique and complex process that remains poorly understood.91 Recent developments in 
imaging with two-photon microscopy have yielded significant progress in visualization of 
proplatelet formation in situ,92,93 thereby overcoming one of the obstacles in MK biology 
research – the inaccessibility of MKs in their natural environment in the BM which is the 
primary site of thrombopoiesis. Besides the BM, MKs are also found in spleen and lung. 
Mature MKs reach a diameter of 50-100 µm in humans and up to 50 µm in mice and 
represent only approximately 0.1‰ of all nucleated cells in the BM.91 
 MKs belong to the myeloid cell lineage and differentiate from pluripotent hematopoietic 
stem cells (HSCs) which give rise to two types of precursor cells: burst-forming unit (BFU) 
cells and colony-forming unit (CFU) cells.94 The development of both cell types culminates in 
the formation of immediate MK precursor cells (CFU-Meg). The cytokine thrombopoietin 
(Thpo) is the primary regulator of thrombopoiesis.95 Thpo signals through the c-Mpl receptor 
on MKs and platelets. Hepatocytes are the major source of Thpo and its production is 
critically regulated by signaling through the hepatic Ashwell-Morell receptor which recognizes 
and removes aged platelets.96 Importantly, however, mice deficient in c-Mpl or Thpo still 
successfully produce platelets,97 indicating that MK maturation and platelet biogenesis can 
occur independently of Thpo and implicating the involvement of additional factors. For 
instance, the cytokines interleukin (IL-) 3, IL-6, IL-11 and, especially during acute platelet 
needs, IL-1α,98 granulocyte macrophage colony-stimulating factor (GM-CSF) and the 
chemokines stromal cell–derived factor-1 (SDF-1) and PF4 have been demonstrated to 
contribute to MK maturation.94,99  
MKs undergo a complex maturation process before they obtain the capacity to release 
platelets. MK development involves nuclear proliferation during which MKs become polyploid 
through several rounds of endomitosis (cycles of DNA replication without cell division) – a 
unique process which depends on Thpo.3 Endomitosis leads to a DNA content of 4n to 128n 
in a single polylobulated nucleus before final maturation and proplatelet formation can take 
place. Concomitantly, maturation of MKs includes cytoplasm enlargement, the synthesis of 





system (DMS) – an elaborate meshwork of membrane channels containing cisternae and 
tubules that serve as a membrane reservoir for proplatelet production (Figure 5).100,101 
Subsequently, substantial MK cytoplasm remodeling occurs prior to proplatelet formation and 
final fission leading to the release of discoid platelets. After proplatelet release, the MK 
nucleus is extruded and degraded.3 
Figure 5. Ultrastructure of a mature BM MK. 
The ultrastructure of mature MKs in the bone 
marrow is characterized by the presence of a 
well-organized demarcation membrane system 
(DMS), as depicted in the transmission electron 
microscopy image. DMS provides a membrane 
reservoir for proplatelet formation. The peripheral 
zone (PZ) is devoid of membrane invaginations 
and organelles and provides the demarcation of 
the MK from surrounding cells. N, nucleus. Bar: 
1.7 µm. 
The exact mechanisms of platelet 
generation from MKs are still incompletely 
understood. However, recent in vivo studies 
provide cumulative evidence in favor of the 
following model of thrombopoiesis: Mature 
MKs reside in the vicinity of sinusoidal blood vessels into which they extend and release 
proplatelets that consist of platelet-sized swellings connected by thin cytoplasmic bridges 
(shaft).91 Final shaping and fragmentation of proplatelets into platelets likely occurs through 
shear forces in the blood stream.92 The process of proplatelet fragmentation remains 
enigmatic, but recent work demonstrated that shedding of platelets into the circulation is 
supported by exposure to a high concentration of sphingosine 1-phosphate.93 
 Proplatelet formation requires substantial cytoskeletal rearrangements. Microtubules 
which consist of αβ-tubulin dimers are the key components of the machinery that drives 
proplatelet elongation.102,103 In addition, microtubules line the proplatelet shaft and enable the 
transport of organelles and granules into the proplatelets.104 Proplatelet bending and 
bifurcation depends on actin polymerization,105 but otherwise little is known about the role of 
the actin cytoskeleton during MK maturation. Small GTPases of the Rho family have been 
established as critical regulators of cytoskeletal rearrangements in various cell types.106 
However, the role of these proteins in the reorganization of the MK actin and tubulin 






1.5. Small GTPases of the Rho family 
Mammalian Rho GTPases comprise a family of 20 proteins which belong to the Ras 
superfamily of monomeric 20-25 kDa guanosine-5'-triphosphate (GTP-) binding proteins 
which are best documented for their important functions in the control of cytoskeletal 
rearrangements (Figure 6).106 Rho GTPases cycle between a GTP-bound (active) and a 
guanosine diphosphate (GDP-) bound (inactive) state. The switch between both forms is 
regulated by three sets of proteins: Guanine nucleotide-exchange factors (GEFs) promote 
the exchange of GDP to GTP. GTPase-activating proteins (GAPs) accelerate the hydrolysis 
of GTP to GDP and thus inhibit Rho GTPase activation. Guanine nucleotide-dissociation 
inhibitors (GDIs) sequester GDP-bound Rho GTPases away from regulators and target 
proteins and thus prevent spontaneous activation.107 In their active, GTP-bound form, Rho 
GTPases interact with effector proteins and thus modulate a plethora of processes, including 
vesicle transport, microtubule dynamics, adhesion and migration.106,107 
 
Figure 6. The Rho GTPase cycle and signal transduction pathways. (left panel) Activation and 
regulation of Rho GTPases. Rho GTPases cycle between an inactive, GDP-bound, and an active, 
GTP-bound, state in which they can interact with effector molecules. GEFs mediate the exchange of 
GDP to GTP. GAPs trigger the hydrolysis of Rho GTP to GDP and thus inhibit Rho GTPase activation. 
GDIs induce sequestering of Rho proteins away from regulators and target proteins and thus prevent 
interactions. (right panel) Overview of common and diverging signaling pathways of RhoA and Cdc42 
in the regulation of cytoskeletal rearrangements. GEFs, guanine nucleotide-exchange factors; GAPs, 
GTPase-activating proteins; GDIs, guanine nucleotide-dissociation inhibitors; RhoA, Ras homolog 
gene family, member A; Cdc42, cell division control protein 42 homolog; ROCK, Rho-associated 
protein kinase; MLC, myosin light chain; LIMK, LIM domain kinase; PAK, p21-activated kinase; mDia, 






A substantial body of knowledge about the functions of Rho GTPases in cell biology has 
been gained by overexpression studies, knockdown approaches or pharmacological 
inhibition of Rho GTPases or their downstream effector molecules. Many of these studies 
have yielded contradictory results, likely due to off-target effects of some of these 
approaches. In recent years, mouse models with tissue- or lineage-specific deletion of Rho 
GTPase genes have greatly facilitated investigations on the role of Rho GTPases and have 
provided valuable insights into the functions of these proteins in vivo.109 
 
1.5.1. Rho GTPases in platelets 
RhoA (Ras homolog gene family, member A), Cdc42 (cell division control protein 42 
homolog) and Rac1 (Ras-related C3 botulinum toxin substrate 1) are the best characterized 
Rho GTPases in platelet biology. As mentioned in Section 1.1. (Figure 2), soluble agonists, 
such as thrombin, ADP and TxA2, operate via receptors that couple to heterotrimeric G 
proteins (Gq, G12/13, Gi).18 Upon agonist binding, Gq activates PLCβ isoforms, leading to 
increased levels of cytoplasmic calcium and activation of the protein kinase C (PKC) via 
formation of IP3 and DAG, respectively.18 G13 regulates the Rho/Rho-kinase pathway 
resulting in myosin light chain (MLC) phosphorylation and initiation of platelet shape 
change.110 RhoA mediates platelet shape change from discoid to spherical following 
activation.111,112 GTP-bound RhoA binds to and activates Rho-associated protein kinase 
(ROCK) that induces actin remodeling, ROCK phosphorylation and inactivation of the MLC 
phosphatase which results in a net increase in MLC phosphorylation.111 Alternatively, Gq 
signaling directly stimulates MLC kinase activation and MLC phosphorylation.111 Studies in 
MK-/platelet-specific RhoA-deficient mice revealed that RhoA is essential for G13-mediated 
shape change and contributes to G13/Gq-dependent integrin αIIbβ3 activation, granule 
release and clot retraction which in vivo translates into contribution to arterial thrombus 
formation and stability.112 
 Cdc42 has been established as a regulator of filopodia formation, exocytosis and 
secretion.106,107 Studies in MK-/platelet-specific mice yielded unexpected results, as filopodia 
formation on fibrinogen was unaltered in Cdc42-deficient platelets.113 By contrast, Cdc42 
deficiency led to decreased filopodia formation on VWF, suggesting a unique role of Cdc42 
downstream of GPIb. Unexpectedly, lack of Cdc42 in platelets resulted in increased 
secretion from α- and dense granules which was associated with enhanced thrombus 
formation ex vivo under flow and in vivo in a model of arterial thrombosis.113 In sharp 
contrast, Cdc42 excision in all hematopoietic cells introduced by a different approach 






 The findings that platelet Cdc42 is not essential for filopodia formation led to the 
hypothesis that the newly characterized Rho GTPase Rif (RhoF) might be responsible for 
filopodia generation.113 However, Rif was found to be dispensable for filopodia formation and 
for platelet function in general (Goggs et al., 2013115 and Sebastian Dütting, unpublished). 
 The role of Rac1 in platelet biology has been extensively studied. Of note, many initial 
studies relied on the powerful inhibition of Rac1 by pharmacological substances which have 
been recently demonstrated to exert profound off-target effects.116 Rac1 has been 
established as the Rho GTPase critical for lamellipodia formation in platelets.117,118 In 
addition, Rac1 controls the GPVI-PLCγ2 activation axis and thus contributes to GPVI-
dependent thrombus formation under flow and in models of experimental arterial 
thrombosis.117,118 Likewise, RhoG, the GTPase most closely related to Rac, has been 
demonstrated to contribute to GPVI signaling and GPVI-mediated thrombus formation in 
vivo.119,120 
 Although Rho GTPases have common binding partners and share similar signaling 
pathways, little is known about functional cooperation of different Rho GTPases in platelet 
production and function. 
 
1.5.2. Rho GTPases in megakaryopoiesis and platelet biogenesis 
Despite intensive research in recent years, little is known about the mode of action of Rho 
GTPases in platelet biogenesis. Overexpression experiments using a dominant-negative or 
constitutively active form of RhoA demonstrated that RhoA activation inhibits in vitro 
proplatelet formation via ROCK, the main effector of RhoA.121 Likewise, interference with 
RhoA downstream signaling by inhibition of MLC phosphorylation or deletion of the 
myosin IIA heavy chain resulted in increased proplatelet formation.122,123 Importantly, MYH9 
mutations in the motor head domain of myosin IIA lead to macrothrombocytopenia in 
humans.124 In line with these findings, mice deficient in PSMC1, an essential subunit of the 
26S proteasome, exhibited abolished proplatelet formation in vitro and in situ and severe 
thrombocytopenia which was attributed to upregulation and hyperactivity of RhoA.125 
Conversely, inhibition of RhoA or its downstream target ROCK during concomitant 
proteasome blockade rescued proplatelet formation.125 Equally, treatment of 
PSMC1-deficient mice with potent ROCK inhibitors ameliorated the severe thrombocytopenia 
observed in these animals.125 
Surprisingly, the moderate thrombocytopenia observed in RhoA-deficient mice112,126 
suggested that RhoA is necessary for platelet production which contradicts results obtained 





molecules. However, the moderately decreased life span in these mice implied that 
increased removal of RhoA-deficient platelets from the circulation likely contributes to the 
observed phenotype. Of note, the impact of genetic ablation of RhoA on MK biology has not 
been extensively investigated yet and studies utilizing conditional knockout mice only 
identified a minor shift to higher mean ploidy levels and slightly increased numbers of BM 
MKs in RhoA-deficient mice.112,126 Thus, the role of RhoA in platelet biogenesis remains 
elusive. 
 Similarly, little is known about the role of other Rho GTPases in platelet production other 
than that deficiency of Cdc42 leads to a moderate reduction of platelet counts, suggesting 
that Cdc42 likely plays a role in platelet biogenesis.113,114 Importantly, more direct evidence 
for a contribution of Rho GTPases to thrombopoiesis came from a recent study which 
emphasized a previously unrecognized functional redundancy between Cdc42 and Rac1 in 
MK development and platelet production.127 Lack of Rac1 or Cdc42 had no or only a mild 
effect on circulating platelet counts and morphology, whereas combined deficiency of both 
proteins resulted in a severe macrothrombocytopenia caused by defective proplatelet 
formation, markedly altered ultrastructure of MKs and platelets and a striking defect in 
microtubule structure. These studies support the notion that Rho GTPases are critically 
involved in platelet biogenesis and may have partially overlapping functions in the control of 
MK maturation and thrombopoiesis. 
 
1.6. Aim of the study 
The (hem)ITAM-containing receptors GPVI and CLEC-2 have been increasingly recognized 
as essential regulators of hemostasis and thrombo-inflammatory disease states. However, 
little is known about the contribution of downstream signaling molecules modulating receptor 
activity. SLAP and SLAP2 are involved in the regulation of immune cell surface expression 
and signaling, but their function in platelets is unknown. In the first part of this thesis, the 
contribution of both adapter proteins to platelet activation and their specific role in 
hemostasis, arterial thrombosis and ischemic stroke was investigated. 
 GPVI has emerged as a promising antithrombotic target because immunodepletion or 
blockade of the receptor provides profound protection in different models of experimental 
thrombosis without affecting hemostatic functions. However, the exact mechanisms 
underlying targeted GPVI down-regulation and the involvement of downstream signaling 
molecules remain incompletely understood. Therefore, the role of SLAP and SLAP2 in 





 The Rho GTPases RhoA and Cdc42 have been identified as critical players in platelet 
physiology, as they have key functions in cytoskeletal rearrangements during cellular 
activation and degranulation. However, possible overlapping and distinct roles of both Rho 
GTPases in the regulation of platelet biogenesis and function have remained elusive. 
Conditional knockout mice with MK-/platelet-specific deficiency in RhoA and Cdc42 were 
generated and analyzed in the third part of this thesis. 
 
 




2. Materials and Methods 
2.1. Materials 
2.1.1. Kits, reagents and cell culture material 
 
Reagent Company 
A23187 AppliChem (Darmstadt, Germany) 
Adenosine diphosphate (ADP) Sigma-Aldrich (Schnelldorf, Germany) 
Agarose Roth (Karlsruhe, Germany) 
Amersham® Hyperfilm®, ECL GE Healthcare (Little Chalfont, UK) 
Ammonium persulphate (APS) Roth (Karlsruhe, Germany) 
Apyrase (Grade III) Sigma-Aldrich (Schnelldorf, Germany) 
Bovine serum albumin (BSA) AppliChem (Darmstadt, Germany) 
Bovine serum albumin (BSA), low endotoxin PAA (Cölbe, Germany) 
Brij® O10 Sigma-Aldrich (Schnelldorf, Germany) 
Clodronate Clodronate Liposomes (Haarlem, The 
Netherlands) 
Collagen Horm® suspension + SKF sol. Takeda (Linz, Austria) 
cOmplete, Mini protease inhibitor cocktail 
(# 11836153001) 
Roche Diagnostics (Mannheim, Germany) 
Convulxin Enzo Life Sciences (Lörrach, Germany) 
Cryo-Gel Leica Biosystems (Wetzlar, Germany) 
Dade® Innovin (tissue factor) Siemens Healthcare Diagnostics (Deerfield, 
IL, USA) 
DAPI Life Technologies (Darmstadt, Germany) 
dNTP Mix (10 mM) Life Technologies (Darmstadt, Germany) 
EDTA AppliChem (Darmstadt, Germany) 
Eosin Y solution (# 318906) Sigma-Aldrich (Schnelldorf, Germany) 
Epinephrine Sigma-Aldrich (Schnelldorf, Germany) 
Epon 812 Roth (Karlsruhe, Germany) 
Fat-free dry milk AppliChem (Darmstadt, Germany) 
FeCl3∙6 H2O Roth (Karlsruhe, Germany) 
Fentanyl Janssen-Cilag (Neuss, Germany) 
Fibrinogen from human plasma (# F3879) Sigma-Aldrich (Schnelldorf, Germany) 
Fibrinogen from human plasma (# F4883) Sigma-Aldrich (Schnelldorf, Germany) 
Flumazenil AlleMan Pharma (Pfullingen, Germany) 
Fluoroshield™ Sigma-Aldrich (Schnelldorf, Germany) 
Fluoroshield™ with DAPI Sigma-Aldrich (Schnelldorf, Germany) 





GeneRuler DNA Ladder Mix Life Technologies (Darmstadt, Germany) 
Glutaraldehyde solution (25%) Science Services (Munich, Germany) 
Hematoxylin solution (# MHS32) Sigma-Aldrich (Schnelldorf, Germany) 
Heparin sodium Ratiopharm (Ulm, Germany) 
HEPES (4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid) 
Life Technologies (Darmstadt, Germany) 
Histopaque®-1077 Sigma-Aldrich (Schnelldorf, Germany) 
IGEPAL® CA-630 Sigma-Aldrich (Schnelldorf, Germany) 
Immobilon-P transfer membrane, PVDF, 
0.45 µm 
Merck Millipore (Darmstadt, Germany) 
Indomethacin Sigma-Aldrich (Schnelldorf, Germany) 
Isofluran CP® cp-pharma (Burgdorf, Germany) 
Medetomidine Pfizer (Karlsruhe, Germany) 
Midazolam Roche (Grenzach-Wyhlen, Germany) 
Midori Green Advanced DNA stain Nippon Genetics Europe (Düren, Germany) 
Mouse Thrombopoietin DuoSet (# DY488) R&D Systems (Abingdon, UK) 
Naloxon AlleMan Pharma (Pfullingen, Germany) 
nProtein A Sepharose 4 Fast Flow GE Healthcare (Little Chalfont, UK) 
NuPAGE® LDS Sample Buffer (4x) Life Technologies (Darmstadt, Germany) 
NuPAGE® Novex® 4-12% Bis-Tris Gels, 
1mm, 10 well, 15 well 
Life Technologies (Darmstadt, Germany) 
PageRuler Prestained Protein Ladder 
(# 26616, 26619) 
Life Technologies (Darmstadt, Germany) 
Paraformaldehyde (PFA) Sigma-Aldrich (Schnelldorf, Germany) 
Phenol/chloroform/isoamyl alcohol Roth (Karlsruhe, Germany) 
Phire Hot Start II DNA Polymerase 
(# F-124S) 
Life Technologies (Darmstadt, Germany) 
Propidium iodide Life Technologies (Darmstadt, Germany) 
Prostacyclin (PGI2) Calbiochem (Bad Soden, Germany) 
Protease inhibitor cocktail (# P8340) Sigma-Aldrich (Schnelldorf, Germany) 
Proteinase K, recombinant, PCR grade 
(20 mg/ml) 
Life Technologies (Darmstadt, Germany) 
RayBio Mouse PF-4 (CXCL4) ELISA Kit 
(# ELM-PF4-1) 
Raybiotech (Norcross, GA, USA) 
Refludan® (Lepirudin) Bayer Schering Pharma AG (Wuppertal, 
Germany) 
RNase A (# R4875) Sigma-Aldrich (Schnelldorf, Germany) 
Rotiphorese® Gel 30 (37,5:1) acrylamide Roth (Karlsruhe, Germany) 
SeeBlue® Plus2 pre-stained standard Life Technologies (Darmstadt, Germany) 





Sodium orthovanadate Sigma-Aldrich (Schnelldorf, Germany) 
SpheroTM AccuCount fluorescent particles Spherotech (Fulda, Germany) 
Streptavidin-HRP (# 016-030-084) Jackson ImmunoResearch (West Grove, 
PA, USA) 
Taq DNA polymerase (5 U/µl without BSA) 
(# EP0282) 
Life Technologies (Darmstadt, Germany) 
TEMED (N,N,N',N'-Tetramethylethylen-
ediamine)  
Roth (Karlsruhe, Germany) 
Thrombin from human plasma 
(# 10602400001) 
Roche Diagnostics (Mannheim, Germany) 
TMB substrate reagent set BD Biosciences (Heidelberg, Germany) 
Tween® 20 Roth (Karlsruhe, Germany) 
U-46619 Enzo Life Sciences (Lörrach, Germany) 
Western Lightning® Plus-ECL PerkinElmer (Baesweiler, Germany) 
 
Collagen-related peptide was kindly provided by Dr. Steve Watson (University of 
Birmingham, UK). Rhodocytin was a generous gift from Dr. Johannes Eble (University 
Hospital, Frankfurt, Germany). All other non-listed chemicals were obtained from AppliChem 
(Darmstadt, Germany), Roth (Karlsruhe, Germany) or Sigma-Aldrich (Schnelldorf, Germany). 
 
Consumables, cell culture material, kits Company 
12-well cell culture plate Greiner Bio-One (Frickenhausen, Germany) 
18 G x 11/2 in., 20 G x 11/2 in, 22 G x 11/2 in. 
needles 
BD Biosciences (Heidelberg, Germany) 
Dynabeads® Untouched™ Mouse CD4 Life Technologies (Darmstadt, Germany) 
Fetal calf serum (FSC) Sigma-Aldrich (Schnelldorf, Germany) 
Iscove's Modified Dulbecco's Medium 
(IMDM) 
Life Technologies (Darmstadt, Germany) 
Nunc-Immuno™ MediSorp™, F96-Wells Thermo Scientific (Schwerte, Germany) 
MTF; F96-Wells Hartenstein (Würzburg, Germany) 
Penicillin/Streptomycin Life Technologies (Darmstadt, Germany) 
PGA 5-0 prolene sature Resorba (Nuremberg, Germany) 
Phosphate-buffered saline (PBS) Life Technologies (Darmstadt, Germany) 
Syringe filter (0.22 µm and 0.45 µm) Roth (Karlsruhe, Germany) 
 
Recombinant thrombopoietin was generated as previously described.128 





2.1.2.1. Purchased primary and secondary antibodies 
Antibody Company 
Donkey anti-rat IgG-FITC (# 112095068) Jackson ImmunoResearch (West Grove, 
PA, USA) 
Donkey anti-rabbit IgG-HRP, MinX 
(# 711035152) 
Jackson ImmunoResearch (West Grove, 
PA, USA) 
Donkey anti-rat IgG-HRP (# 712035153) Jackson ImmunoResearch (West Grove, 
PA, USA) 
Goat anti-rabbit IgG-HRP (# 7074) Cell Signaling (Danvers, MA; USA) 
Goat anti-rat IgG + IgM (# 112005044) Jackson ImmunoResearch (West Grove, 
PA, USA) 
Goat anti-SLAP (C-19) (# sc-1215) Santa Cruz (Heidelberg, Germany) 
Hamster anti-mouse/rat CD29 (β1-Integrin)-
FITC (clone HMβ1-1) (# 102206) 
BioLegend (Fell, Germany) 
Mouse anti-Cdc42 (clone 44) (# 610928) BD Biosciences (Heidelberg, Germany) 
Mouse anti-phosphotyrosine (clone 4G10) Merck Millipore (Darmstadt, Germany) 
Mouse anti-RhoA (# ARH03) Cytoskeleton (Denver, CO, USA) 
Mouse anti-α-tubulin Alexa F488 
(clone B-5-1-2) (# 322588) 
Life Technologies (Darmstadt, Germany) 
Phalloidin-Atto647N (# 65906) Sigma-Aldrich (Schnelldorf, Germany) 
Platelet depletion antibody (# R300) Emfret Analytics (Eibelstadt, Germany) 
Polyclonal rabbit anti-human VWF 
(# A0082) 
DAKO (Hamburg, Germany) 
Polyclonal rabbit anti-human VWF-HRP 
(# P0226) 
DAKO (Hamburg, Germany) 
Rabbit anti-actin (# A2066) Sigma-Aldrich (Schnelldorf, Germany) 
Rabbit anti-GAPDH (# 9545) Sigma-Aldrich (Schnelldorf, Germany) 
Rabbit anti-goat IgG-HRP (# P0449) DAKO (Hamburg, Germany) 
Rabbit anti-mouse IgG-HRP (# P0260) DAKO (Hamburg, Germany) 
Rabbit anti-phospho-PLCγ2 (Y759) (# 3874) Cell Signaling (Danvers, MA; USA) 
Rabbit anti-phospho-Syk (Y525/526) 
(clone C87C1) (# 2710) 
Cell Signaling (Danvers, MA; USA) 
Rabbit anti-total-Lyn (clone C13F9) (# 2796) Cell Signaling (Danvers, MA; USA) 
Rabbit anti-total-PLCγ2 (Q-20) (# sc-407) Santa Cruz (Heidelberg, Germany) 
Rabbit anti-total-Syk (clone D1I5Q) 
(# 12358) 
Cell Signaling (Danvers, MA; USA) 
Rat anti-mouse CD105 (endoglin) 
(clone MJ7/18) (# 120402) 
BioLegend (San Diego, CA, USA) 
  





Rat anti-mouse CD11b (clone M1/70) 
(# 557394) 
BD Biosciences (Heidelberg, Germany) 
Rat anti-mouse CD16/CD32 (clone 2.4G2) 
(# 553142) 
BD Biosciences (Heidelberg, Germany) 
Rat anti-mouse CD3 molecular complex 
(clone 17A2) (# 555273) 
BD Biosciences (Heidelberg, Germany) 
Rat anti-mouse CD45R/B220 
(clone RA3-6B2) (# 557390) 
BD Biosciences (Heidelberg, Germany) 
Rat anti-mouse erythroid cells 
(clone TER-119) (# 553670) 
BD Biosciences (Heidelberg, Germany) 
Rat anti-mouse Ly-6G/C (clone RB6-8C5) 
(# 557445)  
BD Biosciences (Heidelberg, Germany) 
Rat anti-tubulin (clone YL1/2) (# MAB1864) Merck Millipore (Darmstadt, Germany) 
 
The polyclonal rabbit anti-SLAP2 antibody was kindly provided by Dr. Jane McGlade 
(University of Toronto, Canada).74 
 
2.1.2.2. Monoclonal rat antibodies generated or modified in our laboratory 
 
Antibody Clone Isotype Antigen Reference 
p0p4 15E2 IgG2b GPIbα 129 
p0p3 7A9 IgG2a GPIbα 129 
DOM2 89H11 IgG2a GPV 130 
p0p6 56F8 IgG2b GPIX 130 
JAQ1 98A3 IgG2a GPVI 22 
JAQ2 21G10 IgG2a GPVI 40 
JAQ3 0E3 IgG2a GPVI 40 
INU1 11E9 IgG1 CLEC-2 49 
ULF1 97H1 IgG2a CD9 unpublished 
LEN1 12C6 IgG2b α2 22 
EDL1 57B10 IgG2a β3 129 
JON2 14A3 IgG2a αIIbβ3 130 
JON/A 4H5 IgG2b αIIbβ3 131 
MWReg30 5D7 IgG1 αIIbβ3 132 
WUG 1.9 5C8 IgG1 P-selectin 40 
     





Slap-/-, Slap2-/-, Slap-/-/Slap2-/- mice were generated as previously described86,133 and have 
been backcrossed ten generations onto the BALB/c background. BALB/cJRj mice used as 
recipients in platelet transfer experiments were purchased from Janvier Labs (Saint-
Berthevin, France). Gp6-/- mice were generated in our laboratory as previously described44 
and were intercrossed with Slap-/-/Slap2-/- mice. Slap-/-/Slap2-/-/Gp6+/- and litter-matched 
Slap-/-/Slap2-/-/Gp6+/+ on a mixed BALB/c/Sv129/C57BL/6 background were used in this 
study. Lat-/- mice have been described previously.134 Sykfl/fl,59 RhoAfl/fl 135 and Cdc42fl/fl 136 
mice were intercrossed with mice carrying the platelet factor 4 (PF4)–Cre transgene (Pf4-
Cre+/-)137 to generate animals lacking Syk, RhoA or Cdc42, respectively, specifically in MKs 
and platelets. If not stated otherwise, 8-to-12-week-old mice of either sex were used in 
experiments. Animal studies were approved by the district government of Lower Frankonia 
(Bezirksregierung Unterfranken). 
 
2.1.4. Buffers and media 
If not stated otherwise, all buffers were prepared in deionized water obtained from a MilliQ 
Water Purification System (Millipore, Schwalbach, Germany). pH was adjusted with HCl or 
NaOH. 
 
Cacodylate buffer, pH 7.2 
Sodium cacodylate 0.1 M 
 
CATCH buffer, pH 7.2 
HEPES 25 mM 
EDTA 3 mM 
BSA  3.5% 
in PBS  
 
Coating buffer (ELISA), pH 9.5 
NaHCO3 85 mM 
Na2CO3 15 mM 
 




Decalcification buffer, pH 7.4 
EDTA 10% 
in PBS  
 
Fluorescent thrombin substrate (Thrombin generation assay) 
Z-GGR-AMC 2.5 mM 
HEPES 20 mM 
NaCl 140 mM 




Sodium cacodylate, pH 7.2 0.1 M 
Glutaraldehyde 2.5% 
PFA  2% 
 
Laemmli sodium dodecyl sulfate (SDS) sample buffer (4x) 






β-mercaptoethanol (reducing conditions) 20% 
 
Laemmli running buffer for SDS-PAGE 
Tris 0.25 M 
Glycine 1.92 M 
SDS 35 mM 




Loading dye solution (6x) for analysis of PCR products 






Lysis buffer for DNA isolation 
Tris base 100 mM 
EDTA 5 mM 
NaCl 200 mM 
SDS 0.2% 
add Proteinase K (20 mg/ml) 100 µg/ml 
 
Lysis buffer for immunoprecipitation (2x) 
NaCl 150 mM 
Tris, pH 7.5 20 mM 
Brij O10 1% 
NaF 10 mM 
Na3VO4 1 mM 
protease inhibitor cocktail 1% 
 
Lysis buffer for platelet lysates, pH 8.0 
Tris, pH 7.4 15 mM 
NaCl 155 mM 
EDTA 1 mM 
NaN3 0.005% 
IGEPAL CA-630 1% 
protease inhibitor cocktail 1% 
  




Lysis buffer (2x) for tyrosine phosphorylation studies, pH 7.5 
NaCl 300 mM 
Tris 20 mM 
EGTA 2 mM 
EDTA 2 mM 
NaF 10 mM 
Na3VO4 4 mM 
IGEPAL CA-630 1% 
protease inhibitor cocktail 1% 
 




recombinant thrombopoietin  50 ng/ml 
recombinant hirudin 50 µg/ml 
 
3-(N-morpholino)propanesulfonic acid (MOPS) buffer (20x) 
MOPS 1 M 
Tris base 1 M 
SDS 69.3 mM 
EDTA 20.5 mM 
 
Phosphate-buffered saline (PBS), pH 7.14 
NaCl 137 mM 
KCl 2.7 mM 
KH2PO4 1.5 mM 
Na2HPO4 x 2H2O 8 mM 
 
PBS-T (Wash buffer for ELISA) 
PBS (1x)  
Tween® 20 0.1% 
 




PHEM buffer, pH 6.9 
PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)) 60 mM 
HEPES 25 mM 
EGTA 10 mM 
MgCl2 2 mM 
 
PRP reagent (Thrombin generation assay) 
HEPES 20 mM 
NaCl 140 mM 
BSA 0.5% 
tissue factor (TF) 3 pM 
 
Semi-dry transfer buffer 
Tris-Ultra 75 mM 
glycine 80 mM 
methanol 40% 
 
Separating gel buffer (SDS-PAGE), pH 8.8 
Tris-HCl 1.5 M 
 
Sodium citrate, pH 7.0 
Sodium citrate 0.129 M 
 
Stacking gel buffer (SDS-PAGE), pH 6.8 
Tris-HCl 0.5 M 
 
Stripping buffer (“mild”), pH 2.0 
SDS 1% 
Glycine 25 mM 
in PBS  
 




TAE buffer (50x) 
Tris base 0.2 M 
Acetic acid 5.7% 
EDTA (0.5 M) 10% 
 
TE buffer 
Tris base 10 mM 
EDTA 1 mM 
 
Tris-buffered saline (TBS), pH 7.3 
Tris-HCl 20 mM 
NaCl 137 mM 
 
TBS-T (Wash buffer for Western blotting) 
TBS (1x)  
Tween® 20 0.1% 
 
Tyrode-HEPES buffer, pH 7.4 
NaCl 134 mM 
Na2HPO4 0.34 mM 
KCl 2.9 mM 
NaHCO3 12 mM 
HEPES 5 mM 
MgCl2 1 mM 









2.2.1. Isolation of genomic DNA from mouse ears 
Ear punches were lysed in 500 µl lysis buffer containing 100 µg/ml Proteinase K. The 
samples were incubated overnight (o/n) at 56 ºC and constantly shaken at 900 rpm 
(Eppendorf Thermomixer). Phenol/chloroform/isoamyl alcohol mixture (500 µl) was added to 
each sample. The reaction tubes were shaken well by hand and centrifuged at 10,620 g for 
10 min at room temperature (RT). The upper phase was transferred to reaction tubes 
containing 500 µl isopropanol and thoroughly shaken by hand. Following a centrifugation 
step at 18,000 g for 10 min at 4 ºC, the supernatant was discarded and the DNA pellet was 
washed with 70% ethanol and centrifuged again at 18,000 g for 10 min at 4 ºC. The DNA 
pellet was dried at 37 ºC for 30 min and solubilized in 70 µl TE buffer for 30 min at 37 ºC 
under stirring. Genotyping was accomplished by a polymerase chain reaction (PCR) using a 
mixture of primers indicated below. 
 
Pipetting scheme for SLAP WT, SLAP KO and SLAP2 WT PCR (20 µl final volume): 
1 µl DNA template 
2 µl 10x Taq buffer (+ KCl, - MgCl2) 
2 µl MgCl2 (stock: 25 mM) 
0.5 µl dNTPs (stock: 10 mM) 
2 µl forward primer (1:10 in H2O, stock: 1 µg/ml) 
2 µl reverse primer (1:10 in H2O, stock: 1 µg/ml) 
0.1 µl Taq polymerase (5 U/µl) 
10.4 µl H2O 
Primers for genotyping of Slap-/- mice: 
SLAP fwd: 5’ – CACTATGCCCTTTACCTTCT – 3’ 
SLAP WT rev: 5’ – ACAGTGGGCTATTACAGGAC – 3’ 
SLAP NEO rev: 5’ – TGGCTACCCGTGATATTGCTGAAGA – 3’ 
Resulting band sizes: 
WT locus: 565 bp (SLAP fwd + SLAP WT rev) 
KO locus: 242 bp (SLAP fwd + NEO rev) 
Pipetting scheme for SLAP2 KO PCR (20 µl final volume): 
1 µl DNA template 
4 µl 5x Phire® reaction buffer (Thermo Scientific) 
0.4 µl dNTPs (stock: 10 mM) 
2 µl forward primer (stock: 10 µM) 
2 µl reverse primer (stock: 10 µM) 
0.6 µl DMSO (stock: 100 %) 
0.4 µl Phire® Hot Start II DNA polymerase  
9.6 µl H2O 




Primers for genotyping of Slap2-/- mice: 
WT allele: 
SLAP2 WT fwd: 5’ – AGCCGCTGACCATCATCTCT – 3’ 
SLAP2 WT rev: 5’ – CTCTGCCTGAGACTTCCG – 3’ 
KO allele: 
SLAP2 KO fwd: 5’ – ACCGAGTACAAGCCCACG – 3’ 
SLAP2 KO rev: 5’ – CAGGCACCGGGCTTGC – 3’ 
Resulting band sizes: 
WT locus: 350 bp (SLAP2 WT fwd + SLAP2 WT rev) 
KO locus: 550 bp (SLAP2 KO fwd + SLAP2 KO rev) 
 
Program for SLAP WT, SLAP KO and SLAP2 WT PCRs: 
94 ºC 7 min  
94 ºC 1 min  
55.5 ºC 1 min 35 cycles 
68 ºC 1 min 30 s  
72 ºC 10 min  
4 ºC ∞  
Program for SLAP2 KO PCR: 
98 ºC 30 s  
98 ºC 5 s  
64.3 ºC 5 s 35 cycles 
72 ºC 7 s  
72 ºC 1 min  
4 ºC ∞  
 
Pipetting scheme for LAT PCR (50 µl final volume): 
1 µl DNA template 
5 µl 10x Taq buffer (+ KCl, - MgCl2) 
5 µl MgCl2 (stock: 25 mM) 
1 µl dNTPs (stock: 10 mM) 
0.5 µl forward primer (1:10 in H2O, stock: 1 µg/ml) 
0.5 µl reverse primer (1:10 in H2O, stock: 1 µg/ml) 
0.5 µl Taq polymerase (5 U/µl) 
36.5 µl H2O 
 
Primers for genotyping of Lat-/- mice: 
LAT fwd: 5’ – AGCACCTTTCCAGAGCCAACA – 3’ 
LAT WT rev: 5’ – TCATCCAGTTCCGCAAAGCTT – 3’ 
LAT NEO rev: 5’ – GCATCGCCTTCTATCGCCTTC – 3’ 
  




Resulting band sizes: 
WT locus: 300 bp (LAT fwd + LAT WT rev) 
KO locus: 575 bp (LAT fwd + NEO rev) 
 
Program for LAT PCR: 
95 ºC 5 min  
95 ºC 1 min  
60 ºC 1 min 35 cycles 
72 ºC 2 min  
72 ºC 5 min  
4 ºC ∞  
 
Pipetting scheme for detection of the Syk floxed allele by PCR (25 µl final volume): 
1 µl DNA template 
2.5 µl 10x Taq buffer (+ KCl, - MgCl2) 
2.5 µl MgCl2 (stock: 25 mM) 
1 µl dNTPs (stock: 10 mM) 
1 µl forward primer (1:10 in H2O, stock: 100 pmol/µl) 
1 µl reverse primer (1:10 in H2O, stock: 100 pmol/µl) 
0.25 µl Taq polymerase (5 U/µl)  
15.75 µl H2O 
 
Primers for genotyping of Sykfl/fl mice: 
Syk fl fwd: 5’ – GGTGCCTACAGGTCTACAGC – 3’ 
Syk fl rev: 5’ – AACCTGGTAATTTCATAACAGC – 3’ 
Resulting band sizes: 
WT locus: 198 bp  
Floxed locus: 285 bp  
 
Program for Syk floxed PCR: 
96 ºC 3 min  
94 ºC 30 s  
56 ºC 30 s 35 cycles 
72 ºC 1 min  
72 ºC 10 min  
4 ºC ∞  
  




Pipetting scheme for detection of the Cdc42 floxed allele by PCR (50 µl final volume): 
2 µl DNA template 
5 µl 10x Taq buffer (+ KCl, - MgCl2) 
5 µl MgCl2 (stock: 25 mM) 
2 µl dNTPs (stock: 10 mM) 
2 µl forward primer (1:10 in H2O, stock: 1 µg/ml) 
2 µl reverse primer (1:10 in H2O, stock: 1 µg/ml) 
0.5 µl Taq polymerase (5 U/µl) 
31.5 µl H2O 
 
Primers for genotyping of Cdc42fl/fl mice : 
Cdc42 fl fwd: 5’ - ATGTAGTGTCTGTCCATTGG – 3’ 
Cdc42 fl rev: 5’ – TCTGCCATCTACACATACAC – 3’ 
Resulting band sizes: 
WT locus: 200 bp  
Floxed locus: 300 bp  
 
Program for Cdc42 floxed PCR: 
95 ºC 2 min  
95 ºC 30 s  
63 ºC 30 s 10 cycles 
(-1 °C each cycle)  
72 ºC 45 s  
   
95 ºC 30 s  
53 ºC 30 s 35 cycles 
72 ºC 45 s  
72 ºC 4 min  
4 ºC ∞  
 
Pipetting scheme for detection of the RhoA floxed allele by PCR (20 µl final volume): 
2 µl DNA template 
2 µl 10x Taq buffer (+ KCl, - MgCl2) 
0.6 µl MgCl2 (stock: 25 mM) 
0.4 µl dNTPs (stock: 10 mM) 
0.2 µl forward primer (undiluted, stock: 1 µg/ml) 
0.2 µl reverse primer (undiluted, stock: 1 µg/ml) 
0.2 µl Taq polymerase (5 U/µl) 
14.4 µl H2O 




Primers for genotyping of RhoAfl/fl mice: 
RhoA fl fwd: 5’ - AGCCAGCCTCTTGACCGATTTA – 3’ 
RhoA fl rev: 5’ – TGTGGGATACCGTTTGAGCAT – 3’ 
Resulting band sizes: 
WT locus: 297 bp  
Floxed locus: 393 bp  
 
Program for RhoA floxed PCR: 
94 ºC 2 min  
94 ºC 30 s  
55 ºC 30 s 35 cycles 
72 ºC 30 s  
72 ºC 10 min  
4 ºC ∞  
 
Pipetting scheme for detection of the PF4-Cre transgene by PCR (25 µl final volume): 
 
1 µl DNA template 
2.5 µl 10x Taq buffer (+ KCl, - MgCl2) 
2.5 µl MgCl2 (stock: 25 mM) 
1 µl dNTPs (stock: 10 mM) 
1 µl forward primer (1:10 in H2O, stock: 1 µg/ml) 
1 µl reverse primer (1:10 in H2O, stock: 1 µg/ml) 
0.25 µl Taq polymerase (5 U/µl) 
15.75 µl H2O 
 
Primers: 
PF4-Cre fwd: 5’ - CCCATACAGCACACCTTTTG – 3’ 
PF4-Cre rev: 5’ – TGCACAGTCAGCAGGTT – 3’ 
Resulting band sizes: 
WT: no band  
PF4-Cre+ : 450 bp  
 
Program for PF4-Cre PCR: 
95 ºC 5 min  
95 ºC 30 s  
58 ºC 30 s 35 cycles 
72 ºC 45 s  
72 ºC 5 min  
4 ºC ∞  




Four µl 6x loading dye solution were added to 20 µl DNA product and the samples were 
analyzed on a 1.5% agarose gel.  
 
2.2.2. Generation of plasma samples 
Capillaries were anti-coagulated with sodium citrate or heparin and 100 µl blood was 
collected in tubes containing 100 µl heparin or Na-citrate. Samples were centrifuged for 
5 min at 700 g, platelet-poor plasma was spun down for 5 min at 18,000 g and erythrocyte- 
and debris-free supernatants were immediately used for experiments or frozen at -20 °C. 
 
2.2.3. Biochemistry 
2.2.3.1. Western blotting (Immunoblotting) 
Platelet-rich plasma (PRP) was obtained as described in Section 2.2.4.3. PRP was spun 
down at 700 g for 5 min and platelet pellets were washed twice in 5 mM EDTA/PBS. Pellets 
were solubilized in lysis buffer containing 1% IGEPAL CA-630 in a concentration of 
1 x 106 platelets/µl and were lysed for 1 h on ice. Detergent-insoluble debris was removed by 
centrifugation at 18,000 g for 10 min, before 4x Laemmli SDS sample buffer was added to 
the supernatant and samples were boiled for 5 min at 95 °C. Proteins were separated by 
SDS-PAGE on polyacrylamide gels with a 10% or 12% separating part and a 4% stacking 
part. A total of 7.5 x 106 platelets per sample were loaded onto a gel, run in Laemmli buffer 
and blotted onto polyvinylidene difluoride (PVDF) membranes for 1 h with 0.8 mA/cm2 
membrane using semi-dry transfer systems. To prevent unspecific binding, membranes were 
blocked for 1 h at RT in 5% non-fat dried milk powder or 5% BSA dissolved in 
TBS/0.1% Tween® 20 (TBS-T) and then incubated o/n at 4 ºC with primary antibodies. 
Membranes were washed 3x 15 min in TBS-T and incubated for 1 h at RT with horseradish 
peroxidase (HRP)-conjugated secondary antibodies. Upon extensive washing in TBS-T, 
membranes were developed using an enhanced chemiluminescence (ECL) detection system 
with autoradiography films or digitally on a Fluorchem™ Q device (Protein Simple, Santa 
Clara, CA, USA). If HRP-conjugated primary antibodies were used, membranes were 
incubated with the respective antibody for 1 h at RT. To re-probe a membrane, blots were 
incubated in stripping buffer for 30 min at RT, washed thoroughly in TBS-T, blocked and 
subsequently probed with antibodies. Actin, GAPDH or GPIIIa (integrin β3) levels were used 
as loading control. 
  




2.2.3.2. Tyrosine phosphorylation studies 
For identification of tyrosine phosphorylated proteins in platelets, washed platelets in 
suspension (1.4 x 108 platelets) were used. Platelets were prepared as described in Section 
2.2.3.1. To avoid protein dephosphorylation by phosphatases present in certain preparations 
of BSA, platelets were washed once with Tyrode’s buffer with BSA and all subsequent 
washing steps were carried out in Tyrode’s buffer without BSA. To prevent aggregation, 
2 U/mL apyrase, 5 mM EDTA and 10 µM indomethacin were added to the platelet 
suspension. Platelets were stimulated with convulxin or rhodocytin under stirring. Reaction 
was stopped at different time points by the addition of ice-cold 2x lysis buffer and samples 
were lysed for 30 min on ice. Cell debris was removed by centrifugation at 18,000 g. 
NuPAGE® 4x LDS buffer supplemented with β-mercaptoethanol was added to the 
supernatant. Samples were incubated at 70 ºC for 10 min and separated by SDS-PAGE on 
NuPAGE® 4-12% Bis-Tris gradient gels (Invitrogen) under reducing conditions. Gels were run 
in 1x MOPS buffer at 4 °C and proteins subsequently transferred onto a PVDF membrane. 
Membranes were blocked for 1 h at RT and then incubated o/n at 4 ºC with anti-
phosphotyrosine antibody, clone 4G10, or with phospho-specific antibodies detecting anti-
phospho-PLCγ2 (Y759) and anti-phospho-Syk (Y525/526). Rabbit anti-mouse 
immunoglobulins-HRP or goat-anti-rabbit-IgG HRP-conjugated antibodies and ECL were 
used for visualization. Actin levels or the respective non-phosphorylated proteins were used 
as loading control. Densitometry was conducted by volume analysis using ImageJ (version 
1.46r, ImageJ software, National Institutes of Health, Bethesda, MD, USA). 
 
2.2.3.3. Immunoprecipitation 
Washed platelets in suspension (3 x 108) were prepared as described in Section 2.2.3.1. and 
subsequently treated with 2 U/ml apyrase, 5 mM EDTA and 10 µM indomethacin to prevent 
aggregation. Platelets were stimulated for 20 s with 0.5 µg/ml convulxin or left unstimulated 
at 37ºC under stirring. Reactions were terminated by the addition of ice-cold 2x lysis buffer. 
Samples were lysed for 1 h at 4ºC. Detergent-insoluble debris was removed by centrifugation 
at 16,000 g for 10 min and the supernatant was pre-cleared twice with protein A-Sepharose 
for 30 min at 4ºC. Samples were rotated with an anti-Lyn antibody (1 µg/sample) pre-coated 
to protein A-Sepharose for 1 h at 4ºC. Sepharose beads were pelleted, washed 4 times for 
5 min with 1x lysis buffer and 2x non-reducing Laemmli SDS-sample buffer was added to the 
beads. Samples were boiled for 5 min and subsequently centrifuged for 10 min at 18,000 g. 
Supernatants were collected and samples were run on 12% SDS-PAGE gels, transferred 
onto a PVDF membrane and incubated with antibodies. 




2.2.3.4. sGPVI ELISA 
Nunc-Immuno™ MediSorp™ plates were coated o/n with 50 µl JAQ2 antibody (20 µg/ml), 
blocked with 5% milk/TBS-T for 2 h at 37 °C and washed twice with washing buffer. Mice 
were injected intravenously (i.v.) with JAQ1-IgGbiotin (2 µg/g body weight (BW)) and blood 
samples were collected in heparin in Tris-buffered saline (TBS) (20 U/ml, pH 7.3) at the 
indicated time points. Plasma was isolated as described in Section 2.2.2., applied to the 
plates, incubated for 90 min at RT and washed extensively. Plates were incubated with HRP-
labeled streptavidin for 45 min at RT, washed extensively and developed using 3,3,5,5-
tetramethylbenzidine (TMB) substrate. The reaction was stopped by the addition of 
0.5 M H2SO4. Optical densities were measured on a Multiskan Ex device (Thermo Electron 
Corporation, Braunschweig, Germany). Absorbance was read at 450 nm and the 620 nm 
filter served as reference wavelength. Samples from Gp6-/- mice were measured in parallel 
as negative control. 
 
2.2.3.5. Determination of platelet VWF and PF4 secretion by ELISA 
Washed platelets were prepared as described in Section 2.2.4.3., diluted in Tyrode’s 
buffer + 2 mM Ca2+ (5 x 105/µl) and were stimulated with 0.1 U/ml thrombin for 15 min at 
37 °C under stirring. Samples were centrifuged for 5 min at 700 g and platelet aggregate-free 
supernatants were spun down for 5 min at 18,000 g.  
For determination of VWF secretion, MTF ELISA plates were coated with 10 µg/ml rabbit 
anti-human antibody o/n at 4 °C and blocked with 5% BSA for 90 min at 37 °C. Sample 
dilutions were incubated for 2 h at 37 °C. After extensive washing with TBS-T, samples were 
incubated with an HRP-coupled rabbit anti-human VWF antibody. This anti-VWF antibody 
has been shown to cross-react with mouse VWF. After washing, ELISA plates were 
developed using TMB substrate and the reaction was stopped by the addition of 0.5 M 
H2SO4. 
Platelet PF4 secretion levels were determined using a RayBio Mouse PF-4 (CXCL4) 
ELISA Kit according to the manufacturer’s instructions. PF4 microplates pre-coated with anti-
mouse PF4 were supplied together with the ELISA kit. Standards and samples (1:100 
dilution) in duplicate were pipetted onto the microplates (100 µl/well) and incubated for 
150 min at RT. After extensive washing with the provided washing buffer, wells were 
incubated with a biotinylated anti-mouse PF4 antibody for 1 h at RT with gentle shaking. 
Wells were extensively washed again, incubated with HRP-labeled streptavidin for 45 min at 
RT with gentle shaking and developed with TMB substrate for 30 min at RT in the dark with 
gentle shaking. Reactions were stopped by the addition of stop solution (0.2 M H2SO4). 




Optical densities were measured on a Multiskan Ex device (Thermo Electron Corporation, 
Braunschweig, Germany). Absorbance was read at 450 nm and the 620 nm filter served as 
reference wavelength. 
 
2.2.4. In vitro analyses of platelet function 
2.2.4.1. Determination of platelet count, size and surface protein 
expression 
To measure platelet count, size and surface protein expression, 50 µl blood were drawn from 
the retro-orbital plexus of anesthetized mice using heparinized capillaries and collected in a 
tube containing 300 µl heparin in Tris-buffered saline (TBS) (20 U/ml, pH 7.3). Blood was 
diluted 1:20 with Ca2+-free Tyrode’s buffer or 1x PBS and stained for 12 min with saturating 
amounts of fluorophore-conjugated antibodies described in Section 2.1.2.2. If unconjugated 
antibodies were used, samples were incubated with 10 µg/ml of the respective primary 
antibody for 12 min at RT. Reactions were stopped by the addition of 2 ml 1x PBS, samples 
spun down for 5 min at 700 g, supernatant discarded and blood pellet was subsequently 
incubated for 12 min at RT with saturating amounts of fluorescein isothiocyanate (FITC)-
labeled secondary antibodies. In both cases, staining was stopped by the addition of 500 µl 
1x PBS. Data were collected on a FACSCalibur (BD Biosciences, Heidelberg, Germany) and 
analyzed using FlowJo v7 software (FlowJo, LLC, Ashland OR, USA). Alternatively, platelet 
count and volume were determined on a Sysmex KX-21N™ Hematology Analyzer (Sysmex 
Europe, Norderstedt, Germany). 
For determination of platelet counts prior to platelet transfer experiments (Section 
2.2.5.3.), magnetic beads were used and platelet counts were calculated according to the 






= 𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜 𝑐𝑛𝑐𝑐𝑐 𝑝𝑛𝑛 µ𝑐 
A = number of events for the test sample; B = number of events for the fluorescent particles; 
C = number of fluorescent particles per 50 µl (according to current batch of magnetic beads); 
D = volume of test sample initially used in µl. 




2.2.4.2. Flow cytometric analysis of platelet activation responses 
Whole blood was collected as described in Section 2.2.4.1. Ca2+-free Tyrode’s buffer (650 µl) 
was added to each sample and blood was centrifuged twice at 700 g for 5 min at RT and 
resuspended in Ca2+-free Tyrode’s buffer. Finally, samples were resuspended in 750 µl 
Tyrode’s buffer + 2 mM Ca2+. Washed blood (50 µl) or washed platelets (50 µl with 
0.2 x 105 platelets/µl, preparation as described in Section 2.2.4.3.), were incubated with the 
respective agonist (10-fold concentrated) and saturating amounts of a 1:1 mixture of 
phycoerythrin (PE)-coupled 4H5 (anti-activated αIIbβ3) and FITC-coupled 5C8 (anti-P-
selectin) antibodies. Samples were incubated for 7 min at 37 ºC and additionally for 7 min at 
RT. If necessary (e.g. low platelet counts), samples were additionally incubated for 3 min at 
RT with saturating amounts of a “gating” antibody (anti-GPIX-DyLight 649-conjugate). 
Reactions were stopped by the addition of 500 µl 1x PBS. Data were collected on a 
FACSCalibur (BD Biosciences, Heidelberg, Germany) and analyzed using FlowJo v7 
software (FlowJo, LLC, Ashland OR, USA). 
 
2.2.4.3. Preparation of washed platelets 
Mice were bled under isoflurane anesthesia from the retro-orbital plexus with heparin-coated 
capillaries and blood was collected in 300 µl heparin/TBS (20 U/ml, pH 7.3). PRP was 
obtained by two centrifugation steps of 7 min at 800 rpm (Eppendorf Centrifuge 5415 C; 80 g 
without brake). PRP was spun down at 700 g for 5 min in the presence of prostacyclin (PGI2) 
(0.1 µg/ml) and apyrase (0.02 U/ml). The platelet pellet was resuspended in Ca2+-free 
Tyrode’s buffer containing PGI2 (0.1 µg/ml) and apyrase (0.02 U/ml) and incubated at 37 ºC 
for 10 min. This washing step was repeated and the platelet count of the suspension was 
determined using a Sysmex hematology analyzer. After centrifugation, the pellet was 
resuspended in Ca2+-free Tyrode’s buffer containing apyrase (0.02 U/ml) to adjust the 




Washed platelets (50 µl with 5 x 105 platelets/µl) were diluted into 110 µl Tyrode-HEPES 
buffer containing 2 mM Ca2+ and 100 µg/ml human fibrinogen (F3879). Fibrinogen-free 
Tyrode-HEPES buffer was used for aggregation studies with thrombin. Alternatively, 
heparinized PRP was used for investigation of ADP-induced aggregation. Agonists were 
added at indicated concentrations to the continuously stirring (1000 rpm) platelet suspension. 




Light transmission was recorded on a Fibrintimer 4-channel aggregometer (APACT 
Laborgeräte und Analysensysteme, DiaSys Deutschland, Flacht, Germany) for 10 min and 
was expressed in arbitrary units with buffer representing 100% transmission and washed 
platelet suspension or PRP representing 0% transmission, respectively. 
 
2.2.4.5. Luminometric measurement of ATP release 
Washed platelets (80 µl with 5 x 105 platelets/µl) were diluted into 160 µl Tyrode-HEPES 
buffer containing 2 mM Ca2+ and incubated with Luciferase-Luciferin reagent under stirring 
conditions (1200 rpm), followed by addition of an agonist. ATP release and aggregation were 
measured simultaneously in a Lumi-aggregometer (Chrono-Log, Havertown, PA, USA). 
 
2.2.4.6. Platelet adhesion on fibrinogen under static conditions 
Rectangular glass coverslips (24 x 60 mm) were coated with 100 µg/ml human fibrinogen 
(F4883) diluted in sterile 1x PBS o/n at 4 °C under humidified conditions. Coverslips were 
blocked with 1% BSA/PBS for 2 h at RT and extensively washed with Tyrode-HEPES buffer 
containing 2 mM Ca2+. Washed platelets (70 µl with 3 x 105 platelets/µl for early time points 
and 30 µl with 3 x 105 platelets/µl for late time points) were stimulated with thrombin 
(0.01 U/ml final concentration) and allowed to spread for the indicated time points at RT. 
Platelets were fixed with 4% paraformaldehyde (PFA) in 1x PBS and visualized with a Zeiss 
Axiovert 200 inverted microscope (100x/ numerical aperture (NA) = 1.4 oil objective, Zeiss, 
Oberkochen, Germany) using differential interference contrast (DIC) microscopy. 
Alternatively, platelets were fixed with PHEM buffer supplemented with 4% PFA and 1% 
IGEPAL CA-630, stained with anti-human-VWF-FITC, anti-α-tubulin Alexa F488 (B-5-1-2) 
and phalloidin-Atto647N, mounted with Fluoroshield and visualized using a Leica TCS SP5 
confocal microscope (Leica Microsystems, Wetzlar, Germany). 
 
2.2.4.7. Platelet adhesion on collagen under flow conditions 
Rectangular cover slips (24 x 60 mm) were coated with 200 µg/ml fibrillar type I collagen 
(Horm) o/n at 37 °C and blocked for 1 h at RT with 1% BSA/PBS, rinsed with Tyrode-HEPES 
buffer containing 2 mM Ca2+ and gently fixed in a transparent flow chamber with a slit depth 
of 50 µm. Heparinized whole blood (700 µl blood in 300 µl heparin/TBS) was diluted with 
Tyrode-HEPES buffer containing 2 mM Ca2+ (two parts heparinized blood, one part buffer). 
Platelets were labeled with a DyLight 488 conjugated anti-GPIX Ig derivative (0.2 µg/ml) for 5 
min at 37 °C and blood was filled into a 1 ml syringe which was connected to the flow 




chamber. Perfusion was accomplished using a pulse-free pump under high shear stress 
equivalent to a wall shear rate of 1000 s-1 for 4 min. Microscopic phase-contrast images were 
recorded in real-time during perfusion. Thereafter, coverslips were washed by a 2 min 
perfusion with Tyrode-HEPES buffer containing 2 mM Ca2+ at the same shear rate. Phase-
contrast and fluorescence images were obtained from at least seven different collagen-
containing microscopic fields for each sample using a Zeiss Axiovert 200 inverted 
microscope (40x objective, NA = 0.75; Zeiss Oberkochen, Germany) and analyzed offline 
using Metavue software (Visitron, Puchheim, Germany). Thrombus formation under flow was 
characterized by the mean percentage of total area covered by thrombi (= surface coverage), 
and as the mean integrated fluorescence intensity per mm2 (= thrombus size). 
 
2.2.4.8. Analysis of phosphatidylserine (PS)-exposing platelets 
Under flow conditions: 
Rectangular cover slips (24 x 60 mm) were coated with 200 µg/ml fibrillar type I collagen 
(Horm) and blocked with 1% BSA. Heparinized whole blood was supplemented with 
additional 5 U/ml heparin and perfused over collagen coated coverslips through transparent 
flow chamber at a shear rate of 1000 s-1 as described above (Section 2.2.4.7.). The flow 
chamber was rinsed for 4 min with Tyrode-HEPES buffer containing 2 mM CaCl2, 5 U/ml 
heparin, and 0.25 µg/ml annexin A5-DyLight 488. The flow chamber was rinsed for additional 
2 min with Tyrode-HEPES buffer supplemented with 2 mM CaCl2 and 5 U/ml heparin, before 
phase-contrast and fluorescence images were obtained using a Zeiss Axiovert 200 inverted 
microscope (40x objective, NA = 0.75; Zeiss Oberkochen, Germany) and analyzed offline 
using Metavue software (Visitron, Puchheim, Germany). Procoagulant activity was defined 
as the ratio of surface coverage of PS-exposing platelets (annexin A5-DyLight 488 staining of 
platelets) to the total surface covered by platelets. 
 
Under static conditions: 
Washed platelets were diluted into Tyrode-HEPES buffer containing 2 mM Ca2+ (50 µl with 
0.5 x 105 platelets/µl) and incubated with agonists for 15 min at 37 ºC in the presence of 
saturating amounts of Alexa F488-coupled annexin A5. Reactions were stopped by the 
addition of 500 µl Tyrode-HEPES buffer containing 2 mM Ca2+, data were immediately 
collected on a FACSCalibur (BD Biosciences, Heidelberg, Germany) and analyzed using 
FlowJo v7 software (FlowJo, LLC, Ashland OR, USA). 
 




2.2.4.9. Thrombin generation assay 
Thrombin generation was quantified in citrate-anticoagulated PRP (1 x 105 platelets/µl). PRP 
preparations were pooled from 2-4 mice with the same genotype. Platelets were activated 
with the indicated agonists for 10 min at 37°C. After stimulation, samples (4 vol) were 
transferred to a polystyrene 96-well plate containing 1 vol of thrombin calibrator or PRP 
reagent. Coagulation was started by adding 1 vol fluorescent thrombin substrate. Thrombin 
generation was measured according to the calibrated automated thrombogram method as 
previously described.139 Samples were run in duplicate. Thrombin generation assays were 
performed by Sarah Schießl in our laboratory. 
 
2.2.5. In vivo analyses of platelet function 
2.2.5.1. Determination of platelet life span 
Mice were injected i.v. with a DyLight 488-conjugated anti-GPIX-derivative (0.2 µg/g BW) for 
mice with normal peripheral platelet counts and 0.1 µg/g BW for KO mouse strains with 
endogenous platelet counts of < 50% of WT control). The anti-GPIX antibody labels 
circulating platelets without interfering with platelet activation in vitro or in vivo.130 The 
antibody concentration applied was sufficient to label only circulating, but not newly 
generated platelets. Platelet clearance from the circulation was determined by daily blood 
withdrawal and subsequent flow cytometric analysis of the percentage of fluorescently 
labeled platelets. 
 
2.2.5.2. Platelet depletion 
Platelet depletion prior to platelet transfer: 
Thrombocytopenia was induced in BALB/c WT mice by i.v. injection of anti-GPIbα antibodies 
(platelet depletion antibody, 0.15 µg/g BW). This low dosis of the platelet depletion antibody 
had no effect on the distribution of immune cell populations, hemoglobin or hematocrit levels 
over a period of 5 d after platelet depletion (data not shown). Peripheral platelet counts were 
determined by flow cytometry 12 h after platelet depletion as described above (Section 
2.2.4.1.) using fluorescent particles. Mice with < 2.5% endogenous platelet counts were 
selected for platelet transfer experiments. 





Thrombocytopenia was induced by intraperitoneal (i.p.) injection of a platelet depletion 
antibody (2 µg/g BW; 1 µg/g BW for KO mouse strains with endogenous platelet counts of 
< 50% of WT control) and blood samples were collected at indicated time points until 
peripheral platelet counts recovered to values prior to platelet depletion. 
 
2.2.5.3. Adoptive platelet transfer 
Washed platelets from several donor mice were pooled and 109 platelets in 200 µl Tyrode’s 
buffer were transferred i.v. to WT mice. Purity and resting state of the platelet suspension 
was ascertained by flow cytometry and microscopic inspection. Contamination by other blood 
cell types was further excluded using a fully automated hematology analyzer (Sysmex 
KX-21N™, Sysmex Europe, Norderstedt, Germany). Peripheral platelet counts were 
determined 30 min after platelet transfer and mice were subsequently subjected to FeCl3-
injury of the carotid artery, or 30 min of transient middle cerebral artery occlusion (tMCAO) 
(see below). 
 
2.2.5.4. White blood cell transfer 
WT and Slap-/-/Slap2-/- donor mice were treated with 0.5 µg/g body weight of platelet 
depleting anti-GPIbα antibodies 90 min prior to blood collection. White blood cells were 
isolated using a Histopaque® gradient (Sigma-Aldrich), washed in PBS/0.2% BSA and 106 
cells in 100 µl PBS/0.2% BSA were transferred i.v. into WT mice which were subsequently 
subjected to 30 min of tMCAO. 
 
2.2.5.5. Macrophage depletion 
Mice were treated i.v. with clodronate-encapsulated or PBS-encapsulated liposomes 
(2 µl/g  BW). Platelet counts and size were determined by flow cytometry prior to and 24, 48, 
72 and 96 h after treatment.  
 
  




2.2.5.6. Tail bleeding time 
Saline method: 
Mice were anesthetized, 1 mm of the tail tip was cut off with a scalpel and the tails were 
immersed in 0.9% isotonic saline (37 °C). The time until cessation of bleeding (no blood flow 
for 1 min) was determined.  
 
Filter paper method: 
Mice were anesthetized and 1 mm of the tail tip was cut off with a scalpel. Tail bleeding was 
monitored by gently absorbing blood on filter paper at 20 s intervals without making contact 
with the wound site. Bleeding was determined to have ceased when no blood was observed 
on the paper. Experiments were stopped manually after 20 min by cauterization to prevent 
excessive blood loss. 
 
2.2.5.7. Splenectomy 
Platelet counts were determined by flow cytometry and/or using a Sysmex hematology 
analyzer before surgical splenectomy. Mice were anesthetized by i.p. injection of triple 
anesthesia (medetomidine, midazolam, fentanyl) and placed in supine position on a heating 
pad to avoid hypothermia during surgery. Depth of anesthesia was ascertained by the 
application of a painful stimulus and forelimbs and hindlimbs were immoblized by adhesive 
bandages. The left upper abdominal cavity was exposed via a 1-cm-paramedian incision. 
After the spleen was identified, splenic arterial and venous supply was closed by ligation with 
knots placed with 5-0 prolene suture and the spleen was removed. The abdominal and skin 
incisions were closed with 5-0 prolene suture. Mice were monitored for 48 h for signs of 
internal bleeding and infection. After a recovery period of 7 d, platelet counts and size were 
followed over time and analyses of platelet and MK ultrastructure, platelet surface receptor 
levels, activation state and hemostatic function were performed at the indicated time points. 
 
2.2.5.8. Intravital microscopy of thrombus formation in FeCl3-injured 
mesenteric arterioles 
Mice (4-to-5-week-old, 15–18 g) were anesthetized by i.p. injection of triple anesthesia 
(medetomidine, midazolam, fentanyl) and i.v. injected with 1.5 µg of a DyLight 488-
conjugated anti-GPIX-derivative to label platelets in vivo. The mesentery was then gently 
exteriorized through a midline abdominal incision. Mesenterial arterioles with a diameter 




between 35-60 µm were visualized with an inverted Axiovert 200 microscope (Zeiss, 
Oberkochen, Germany) (10x objective, NA = 0.30). The microscope was equipped with a 
100 W mercury arc lamp to measure fluorescence and a CoolSNAP-EZ camera. Injury was 
induced by topical application of a 3 mm2 filter paper saturated with 20% FeCl3. Adhesion 
and aggregation of fluorescently labeled platelets was monitored until complete vessel 
occlusion occurred for at least 1 min or for a maximum of 40 min. MetaMorph software 
(Visitron, Puchheim, Germany) was used to record and analyze the digital images. 
Experiments were conducted by Dr. Martina Morowski in our laboratory. 
 
2.2.5.9. Thrombus formation in FeCl3-injured carotid arteries 
An ultrasonic flow probe (0.5PSB699; Transonic Systems) was placed around the exposed 
carotid artery of anesthetized mice and thrombosis was induced by topical application of 
FeCl3 for 90 s. FeCl3 concentrations used were as follows: 2.5% for experiments with 
Slap-/-/Slap2-/- mice and 15% for RhoAfl/fl/Cdc42fl/fl Pf4-Cre+. For Slap-/-/Slap2-/- mice subjected to 
FeCl3–induced injury of the carotid artery after adoptive platelet transfer, 7.5% FeCl3 for 
1 min was used. Blood flow was monitored until complete blood vessel occlusion occurred 
for at least 2 min, or for a maximum of 30 min. Surgery was performed by Dr. Martina 
Morowski and Sarah Schießl. 
 
2.2.5.10. Mechanical injury of the abdominal aorta 
An ultrasonic flow probe (0.5PSB699; Transonic Systems) was placed around the abdominal 
aorta of anesthetized mice and thrombus formation was induced by a single firm 
compression with forceps for 10 s. Blood flow was monitored until complete blood vessel 
occlusion occurred for at least 5 min, or for a maximum of 30 min. Experiments were 
conducted by Dr. Martina Morowski. 
 
2.2.5.11. Transient middle cerebral artery occlusion (tMCAO) 
Surgery was carried out by Dr. Peter Kraft and Dr. Michael Schuhmann from the Department 
of Neurology (University of Würzburg) according to the recommendations in mechanism-
driven basic stroke research.140 Focal cerebral ischemia was induced in 8-to-12-week-old 
mice by a transient middle cerebral artery occlusion (tMCAO) as previously described.141 
Briefly, anesthesia was induced by 2% isoflurane in a 70% N2/30% O2 mixture and a servo-
controlled heating device was used to record and maintain body temperature during the 
surgical procedure. Operation time per animal was kept below 15 min. A silicon rubber–




coated 6.0 nylon monofilament (6021PK10, Doccol, Redlands, CA, USA) was advanced 
through the carotid artery up to the origin of the middle cerebral artery (MCA) causing an 
MCA infarction. After an occlusion time of 30 min, the filament was removed allowing 
reperfusion of the MCA territory. The extent of infarction was quantitatively assessed 24 h 
after reperfusion on 2,3,5-triphenyltetrazolium chloride (TTC) (2% (w/v) solution) stained 
brain sections. Global neurological outcome and motor function were evaluated by the 
Bederson score142 and the grip test,143 respectively. Planimetric measurements of infarcted 
areas (ImageJ software, National Institutes of Health, Bethesda, MD, USA) corrected for 
brain edema144 and assessment of functional outcome were performed in a blinded fashion 
by members of the laboratories of Prof. Dr. Guido Stoll and Prof. Dr. Christoph Kleinschnitz 
(Department of Neurology, University of Würzburg). 
 
2.2.6. Megakaryocyte (MK) studies 
2.2.6.1. In vitro differentiation and cultivation of fetal liver cell-derived MKs 
Embryonic day 13.5 – 14.5 (E13.5 – 14.5) mouse embryos were dissected in sterile 1x PBS. 
Fetal livers were transferred into 1 ml pre-warmed Iscove's Modified Dulbecco's Medium 
(IMDM) and homogenized by being twisted through an 18-gauge (18G) and a 22G needle 
with a 1 ml syringe. Cell suspensions were centrifuged at 900 rpm (Heraeus Multifuge 3S-R 
Thermo Scientific, Braunschweig, Germany) for 5 min at RT. The supernatant was discarded 
and cells were resuspended in 3 ml MK differentiation medium. Single-cell suspensions were 
divided into 3 wells per liver of a 12-well plate and cultured for 2 days at 37 °C and 5% CO2 
in a humidified incubator.  
On day 3 of culture, MKs were enriched by a 2-step density gradient filtration with 3% 
BSA (lower phase) and 1.5% BSA (upper phase). Cell suspensions were centrifuged at 
200 g for 5 min at RT. Cell pellets were resuspended in 1 ml pre-warmed IMDM, gently 
overlaid on the upper phase of the BSA gradient and incubated for 30-45 min at RT. 
Approximately 3.2 ml of the density gradient and cell suspension were removed and the 
lowest 800 µl containing sedimented MKs were diluted in 10 ml IMDM and centrifuged at 
200 g for 5 min at RT. Cell pellets were resuspended in 1 ml MK differentiation medium and 
incubated in a 12-well plate for additional 24 h at 37º C and 5% CO2 in a humidified 
incubator. On day 4 of culture, MKs were analyzed for proplatelet formation under a light 
microscope (20x objective). A minimum of 10 visual fields containing at least 10 differentiated 
MKs without contact inhibition were counted per well and the percentage of proplatelet-
producing MKs per visual field was determined. Images of proplatelet-forming MKs were 
acquired using a Zeiss Axiovert 200 imaging microscope (Zeiss, Oberkochen, Germany). 




2.2.6.2. In vitro differentiation and cultivation of bone marrow (BM)-derived 
MKs 
Hematopoietic stem cells were isolated by flushing BM cells from femora of male mice 
followed by a negative selection using a magnetic bead-based negative depletion kit 
(Dynabeads®, with a polyclonal sheep anti-rat IgG antibody bound to the beads surface) 
according to the manufacturer’s protocol (Life Technologies). MK precursor cells were 
enriched by removing other cell types using 0.5 µg/107 cells of the following rat anti-mouse 
antibodies which were coupled to the magnetic beads: CD45R/B220, TER-119, CD3, 
Ly-6G/C and CD11b. Cells were cultured in MK differentiation medium supplemented with 
50 ng/ml recombinant Thpo and 50 µg/ml recombinant hirudin at 37°C, 5% CO2 for 3 days, 
prior to MK purification using a 1.5%-3% BSA gradient as described in Section 2.2.6.1. 
 
2.2.6.3. Fluorescent staining of MKs 
Cultured MKs were spun onto glass slides (Shandon Cytospin 4, Thermo Scientific, 
Braunschweig, Germany), fixed and permeabilized with PHEM buffer supplemented with 4% 
PFA and 1% IGEPAL CA-630, stained with anti-α-tubulin Alexa F488 (B-5-1-2) and 
phalloidin-Atto647N, mounted with Fluoroshield containing DAPI, visualized using a Leica 
TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany) and further 
processed with ImageJ (version 1.46r, ImageJ software, National Institutes of Health, 
Bethesda, MD, USA). 
 
2.2.6.4. Hematoxylin/eosin staining of paraffin sections 
Spleen and femora of 8-to-12-week-old mice were fixed in 4% PFA/PBS o/n at 4 °C. Organs 
were washed in 1x PBS. Spleens were immediately dehydrated and embedded in paraffin, 
whereas femora were treated with decalcification buffer at RT for 5 days (daily exchange of 
buffer). Upon dehydration and paraffin embedding, organs were sectioned on a Microm HM 
355 (Walldorf, Germany) (section thickness 5 µm). Staining was performed at RT. For 
deparaffinization, slides were incubated twice in xylol for 3 min. Samples were rehydrated by 
treatment with decreasing concentrations of ethanol (100%, 96%, 90%, 80% and 70%) and 
deionized H2O (incubation for 2 min per step). Sections were stained with hematoxylin for 
30 sec and washed with tap water for 10 min prior to staining with 0.05% Eosin Y for 2 min. 
Slides were briefly washed in deionized H2O and dehydrated in ethanol in reverse order 
(70%, 80%, 90%, 96% and 100% ethanol), followed by incubation in xylol (2x 3 min). Slides 




were mounted with xylol-based medium (Eukitt®, Sigma-Aldrich). Images were acquired 
using a Leica DMI 4000 B imaging microscope (Wetzlar, Germany). 
 
2.2.6.5. Immunofluorescence staining of whole femora cryosections 
Mouse femora were isolated, fixed in 4% PFA/PBS containing 5 mM sucrose for 2 h at RT 
and subsequently transferred into 10% sucrose/PBS and dehydrated using a graded sucrose 
series (incubation in 10% sucrose/PBS, followed by 20% sucrose/PBS and 30% 
sucrose/PBS, respectively, for 24 h at 4 °C). Samples were embedded in Cryo-Gel and 
shock-frozen in liquid nitrogen. Cryosections were produced using a CryoJane tape transfer 
system (Leica Biosystems, Wetzlar, Germany). MKs were visualized using anti-GPIb 
antibodies, whereas endothelium was stained with an anti-CD105 antibody. Nuclei were 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Samples were visualized on a 
Leica TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany). 
 
2.2.6.6. Determination of MK ploidy 
Both femora of male mice were isolated and BM flushed and resuspended in 2 ml modified 
CATCH buffer. One tenth of the cell suspension was centrifuged for 5 min at 1200 rpm 
(Heraeus Multifuge 3S-R Thermo Scientific, Braunschweig, Germany) and resuspended in 
CATCH buffer containing 5% FSC/PBS. Unspecific binding sites were blocked by incubation 
with an anti-CD16/CD32 antibody (FcγRII/III, clone 2.4G2) for 15 min on ice. Subsequently, 
samples were stained with a FITC-conjugated anti-CD41 Ig derivative (clone MWReg30) or 
with an isotype-matched control rat anti-mouse antibody for 20 min on ice. Staining was 
stopped by the addition of CATCH buffer supplemented with 5% FSC/PBS. Cells were fixed 
in 1x PBS containing 1% PFA/0.1% EDTA for 10 min on ice, washed with 1x PBS, 
permeabilized in 0.1% Tween® 20/PBS for 10 min on ice and stained with a propidium iodide 
staining solution containing RNase A o/n at 4 °C in the dark. Data were collected on a 
FACSCalibur (BD Biosciences, Heidelberg, Germany) and analyzed using FlowJo v7 
software (FlowJo, LLC, Ashland OR, USA). 
 
2.2.6.7. Determination of plasma thrombopoietin (Thpo) levels 
Plasma Thpo levels were determined using a Mouse Thrombopoietin DuoSet kit (R&D 
Systems). 96-well microplates were coated o/n at 4 °C with 100 µl/well of a rat anti-mouse 
Thpo antibody diluted in 1x PBS (2 µg/ml final concentration). Wells were washed three 
times with PBS/0.05% Tween® 20 (PBS-T), subsequently blocked for 1 h at RT with 




1% BSA/PBS and washed again with PBS-T. Blood samples were collected in Na-citrate, 
plasma was isolated as described in Section 2.2.2. and diluted 1:4 in reagent diluent 
(1% BSA/PBS supplemented with 2% heat inactivated normal goat serum). Standards and 
samples were pipetted onto the microplates (100 µl/well) in duplicate and incubated for 2 h at 
RT. Upon extensive washing with PBS-T, wells were incubated with biotinylated goat anti-
mouse Thpo antibodies for 2 h at RT. Microplates were extensively washed with PBS-T, 
incubated with HRP-labeled streptavidin for 20 min at RT, washed again with PBS-T and 
developed with TMB substrate. Reactions were stopped by the addition of 1 M H2SO4. 
Optical densities were measured on a Multiskan Ex device (Thermo Electron Corporation, 
Braunschweig, Germany). Absorbance was read at 450 nm and the 620 nm filter served as 
reference wavelength. 
 
2.2.7. Electron microscopy 
2.2.7.1. Transmission electron microscopy (TEM) analysis of resting 
platelets in suspension 
For TEM analysis, PRP was isolated as described in Section 2.2.4.3. and let rest for 30 min 
at 37 °C in the presence of apyrase (0.02 U/ml). PRP was incubated with 2.5% glutar-
aldehyde in 0.1 M cacodylate buffer for 10 min at 37 ºC, 1 h at RT and at 4 ºC until further 
processing. Samples were washed 3 times for 5 min in 1 ml cacodylate buffer and 
subsequently centrifuged at 1500 g for 5 min at 37 °C. A 2% low melting agarose solution in 
cacodylate buffer was kept at 45 °C. After the final washing step, platelets were carefully 
resuspended in 1 ml 2% agarose solution and centrifuged at 18,000 g for 5 min at 37 °C. 
Approximately 100 µl agarose solution were retained, the remaining supernatant was 
discarded and samples were incubated on ice for 10 min. Hardened agarose pellets were cut 
into approximately 1 mm2 pieces and transferred into cacodylate buffer until fixation in 
1% osmium tetroxide (in cacodylate buffer) for 1 h at RT. Samples were washed twice with 
ddH2O and incubated in 2% uranyl acetate in ddH2O for 1 h at 4 °C. Upon extensive washing 
(3x ddH2O), samples were dehydrated in 70% (4x 5 min), 95% (3x 15 min) and 100% 
(3x 15 min) ethanol and incubated in 100% propylene oxide (2x 10 min), and subsequently in 
a 1:1 mixture of propylene oxide/epon for 1 h at RT under rotation. Two further incubation 
steps in epon at RT followed (for 2-3 h under rotation). Samples were embedded in gelatin 
capsules, left to harden for 48 h at 60 ºC and sectioned on an ultra microtom (Leica Ultracut 
UCT, Wetzlar, Germany) (section thickness 50 nm), contrasted and analyzed on a Zeiss 
EM900 transmission electron microscope (Zeiss, Oberkochen, Germany). 
 




2.2.7.2. TEM analysis of BM MKs in situ 
For TEM analysis of BM MKs, femora of mice were incubated in Karnovsky’s fixative for 
10 min at RT and subsequently o/n at 4 ºC under rotation. Femora were treated with 
decalcification buffer at RT for 5 days (daily exchange of buffer) and subsequently washed 
with 50 mM cacodylate buffer 3x 10 min at 4 ºC. Samples were then fixed with 2% osmium 
tetroxide in 50 mM sodium cacodylate (pH 7.2) for 2 h at 4 °C, washed with ddH2O and 
subsequently stained o/n with 0.5% aqueous uranyl acetate. Upon dehydration with ethanol 
and embedding in Epon 812, ultrathin sections were stained with 2% uranyl acetate (in 100% 
ethanol) followed by lead citrate as described.145 Samples were analyzed on a Zeiss EM900 
transmission electron microscope (Zeiss, Oberkochen, Germany). 
 
2.2.7.3. Transmission electron microscopy analysis of occlusive thrombi in 
FeCl3-injured carotid arteries 
The right carotid artery of wild-type (WT) and Slap-/-/Slap2-/- mice was injured by topical 
application of 5% FeCl3 for 1 min, or 10% FeCl3 for 1 min (only WT mice) and blood flow was 
monitored with a Doppler flow probe until complete vessel occlusion occurred for at least 
2 min, or for a maximum of 30 min as described in Section 2.2.5.9. Carotid arteries were 
excised, incubated in Karnovsky’s fixative, postfixed in 2% osmium tetroxide in 50 mM 
cacodylate buffer, dehydrated and embedded in epoxy resin. Semithin sections (0.5 µm) 
were stained in toluidine blue. Upon identification of the thrombus, ultrathin sections (50 nm) 
were prepared and stained with 2% uranyl acetate and lead citrate. Sections were analyzed 
on an EM900 electron microscope (Zeiss, Oberkochen, Germany). 
 
2.2.8. Statistical analyses 
Results are shown as mean ± SD from three individual experiments per group, unless 
indicated otherwise. Statistical analysis was conducted using the Student’s t-test, apart from 
the Fischer’s exact test which was applied to assess variance between non-occluded vessels 
in models of arterial thrombosis or in tail bleeding assays and the Mann-Whitney U test which 
was used for analysis of Bederson score and grip test after tMCAO. Differences between 
more than two groups were analyzed with one-way ANOVA with Dunnett’s T3 as post-hoc 







3.1. SLAP/SLAP2 prevent excessive platelet (hem)ITAM signaling in arterial 
thrombosis and ischemic stroke in mice 
SLAP proteins have been identified as negative regulators of TCR and BCR expression 
levels and signaling.75 Platelet GPVI/FcRγ signaling resembles the signaling pathways 
downstream of the TCR and BCR complexes. Therefore, it has been hypothesized that 
SLAP and SLAP2 might have the capacity to regulate (hem)ITAM signaling in platelets. This 
hypothesis has been initially tested in the laboratory of Dr. Michael Tomlinson (University of 
Birmingham, UK). It has been demonstrated that overexpression of SLAP or SLAP2 in a 
heterologous cell line almost completely inhibited GPVI and CLEC-2 signaling without 
affecting expression levels of transfected GPVI or CLEC-2.146 
 
3.1.1. Absence of SLAP or SLAP2 has only mild effects on platelet 
activation in vitro 
To extend these previous data obtained in a heterologous system and to further investigate 
the role of SLAP family proteins in platelet biology, mice deficient for SLAP86 or SLAP2133 
were analyzed. Western blot analysis confirmed the absence of SLAP in Slap-/- and of 
SLAP2 in Slap2-/- platelet lysates (Figure 7A and Figure 8A). Furthermore, upregulation of 
SLAP expression in Slap2-/- platelets was observed (increase by ~35% compared to WT 
platelets) (Figure 8A). The two SLAP2 protein bands of 25 and 28 kDa are in line with 
previous reports that alternative translation leads to the expression of two SLAP2 isoforms 
(Figure 7A, Figure 8A, arrowheads).72-74 Slap-/- and Slap2-/- mice had normal platelet counts 
and size (Table 3-1). 
Flow cytometric measurement of prominent platelet surface receptors and Western blot 
analysis showed slightly increased surface expression of GPVI in Slap-/- platelets, whereas 
CLEC-2 levels were slightly elevated in Slap2-/- platelets (Table 3-1, Figure 7B, Figure 8B). 
The effect of SLAP or SLAP2 deficiency on platelet activation was analyzed by aggregation 
studies and flow cytometric measurements of agonist-induced inside-out activation of αIIbβ3 






 WT Slap-/- WT Slap2-/- 
Platelets (nl-1) 985 ± 139 1106 ± 66 1145 ± 62 1215 ± 132 
MPV (fl) 5.64 ± 0.25 5.54 ± 0.15 5.56 ± 0.15 5.46 ± 0.17 
GPIb 337 ± 10 357 ± 31 335 ± 9 355 ± 25 
GPV 237 ± 15 254 ± 20 248 ± 5 258 ± 19 
GPIX 372 ± 19 380 ± 37 381 ± 6 404 ± 24 
CD9 1114 ± 19 1119 ± 63 1068 ± 20 1046 ± 20 
GPVI 55 ± 2 60 ± 2* 50 ± 3 50 ± 2 
CLEC-2 129 ± 5 126 ± 15 117 ± 2 127 ± 4† 
α2 41 ± 1 42 ± 1 43 ± 1 43 ± 1 
β1 97 ± 9 102 ± 4 109 ± 2 110 ± 6 
αIIbβ3 522 ± 46 558 ± 34 565 ± 15 549 ± 23 
WBC (nl-1) 8.00 ± 1.63 8.50 ± 1.91 9.20 ± 1.79 7.20 ± 1.10 
RBC (x 103 nl-1) 715 ± 30 830 ± 173 636 ± 63 584 ± 36 
HCT (%) 36.00 ± 1.63 42.00 ± 8.49 31.60 ± 2.97 32.00 ± 2.00 
HGB (g dl-1) 10.00 ± 0 13.00 ± 3.46 10.40 ± 0.89 10.40 ± 0.89 
Table 3-1. Analysis of surface expression of glycoproteins in WT, Slap-/- and Slap2-/- platelets. 
Diluted whole blood was stained with saturating amounts of fluorophore-labeled antibodies and 
platelets were analyzed by flow cytometry. Results express MFI ± SD (n = 4 mice per group) and are 
representative of 3 independent experiments. Basic blood parameters were analyzed on a Sysmex 
KX-21N™ Hematology Analyzer. MPV: mean platelet volume; WBC: white blood cells; RBC: red blood 
cells; HCT: hematocrit; HGB: hemoglobin. *P < .05, †P < .01. (Cherpokova et al., Blood 2015)146 
Stimulation of platelets with GPVI-specific agonists - collagen-related peptide (CRP) or 
the snake venom protein convulxin - or with the CLEC-2 agonist rhodocytin, resulted in 
slightly elevated integrin activation and α-granule release, in particular at high agonist 
concentrations (Figure 7C-D, Figure 8C-D). In contrast, activation responses to low 
concentrations of (hem)ITAM-specific agonists or to soluble agonists operating via G protein-
coupled receptors (GPCR), such as ADP, the thromboxane A2 analog U-46619 and 
thrombin, were normal. These results suggested a potential negative regulatory function for 
SLAP family proteins downstream of (hem)ITAM receptors in platelets, but functional 






Figure 7. Unaltered integrin activation, α-granule release and aggregation response of 
Slap-/- platelets. (A) Western blot analysis demonstrating absence of SLAP (left panel) and unaltered 
expression of SLAP2 (right panel) in Slap-/- platelets. Arrowheads indicate both SLAP2 isoforms (25 
and 28 kDa). Actin expression was used as loading control. (B) Western blot analysis of GPVI 
expression in Slap-/- platelets. GPIIIa expression was used as loading control and for quantification. 
Equal protein amounts were loaded and expression levels were quantified by densitometry with 
ImageJ software (NIH, USA) on 8 samples per genotype. Results represent mean ± SD. Expression 
levels were adjusted such that the GPVI-to-GPIIIa ratio in WT platelets was set to 1. (C) Flow 
cytometric analysis of activated integrin αIIbβ3 (binding of JON/A-PE) (left panel) and degranulation-
dependent P-selectin exposure (right panel) upon stimulation with the indicated agonists in WT and 
Slap-/- platelets. Results are expressed as MFI ± SD (n = 4 mice per group) and are representative of 4 
independent experiments. Dividing lines indicate separate measurements. (D) Washed platelets were 
activated with the indicated agonists and light transmission was recorded on a Fibrintimer 4-channel 
aggregometer. ADP measurements were performed in PRP. Aggregation traces representative of 2 
independent experiments with n = 3 are depicted. Arrows indicate addition of the respective agonist. 
U46, U-46619; A/U, ADP + U-46619; thr., thrombin; CVX, convulxin; CRP, collagen-related peptide; 







Figure 8. Unaltered integrin activation, α-granule release and aggregation response of 
Slap2-/- platelets. (A) Western blot analysis demonstrating increased expression of SLAP (left panel) 
and absence of SLAP2 (right panel) in Slap2-/- platelets. Arrowheads indicate both SLAP2 isoforms 
(25 and 28 kDa) in WT platelets. Actin expression was used as loading control and for quantification. 
(B) Western blot analysis of CLEC-2 expression in Slap2-/- platelets. GPIIIa expression was used as 
loading control and for quantification. (A, B) Equal protein amounts were loaded and expression levels 
were quantified by densitometry with ImageJ software (NIH, USA) on 10 (A) or 8 (B) samples per 
genotype. Results represent mean ± SD. Expression levels were adjusted such that SLAP-to-actin (A) 
or CLEC-2-to-GPIIIa (B) ratio in WT platelets was set to 1. (C) Flow cytometric analysis of activated 
integrin αIIbβ3 (binding of JON/A-PE) (left panel) and degranulation-dependent P-selectin exposure 
(right panel) upon stimulation with the indicated agonists in WT and Slap2-/- platelets. Results are 
expressed as MFI ± SD (n = 4 mice per group) and are representative of 4 independent experiments. 
Dividing lines indicate separate measurements. (D) Washed platelets were activated with the indicated 
agonists and light transmission was recorded on a Fibrintimer 4-channel aggregometer. ADP 
measurements were performed in PRP. Aggregation traces representative of 2 independent 
experiments with n = 3 are depicted. Arrows indicate addition of the respective agonist. U46, U-46619; 
A/U, ADP + U-46619; thr., thrombin; CVX, convulxin; CRP, collagen-related peptide; RC, rhodocytin. 
*P < .05; **P < .01; ***P < .001. (Cherpokova et al., Blood 2015)146 
 
3.1.2. Slap-/-/Slap2-/- platelets are hyperreactive to (hem)ITAM-specific 
agonists 
To assess a potential functional redundancy of the two adapter proteins, SLAP/SLAP2 





blot analysis of platelet lysates (Figure 9A). Slap-/-/Slap2-/- platelets exhibited a significant 
(P < .001) ~23% increase in surface expression of GPVI and ~15% increase in CLEC-2 
compared to WT controls, as determined by flow cytometry (Table 3-2) and confirmed by 
Western blot analyses (Figure 9B). Expression of all other major platelet surface receptors 
was unaltered (Table 3-2). 
 WT Slap-/-/Slap2-/- 
Platelets (nl-1) 1129 ± 201 1191 ± 199 
MPV (fl) 5.6 ± 0.26 5.53 ± 0.13 
GPIb 335 ± 12 306 ± 25 
GPV 357 ± 19 344 ± 34 
GPIX 536 ± 40 509 ± 37 
CD9 1437 ± 60 1464 ± 101 
GPVI 57 ± 2 70 ± 3* 
CLEC-2 109 ± 4 125 ± 4* 
α2 52 ± 2 53 ± 5 
β1 146 ± 7 154 ± 14 
αIIbβ3 528 ± 41 599 ± 55 
WBC (nl-1) 5.88 ± 1.45 5.6 ± 1.64 
RBC (x 103 nl-1) 638 ± 34 718 ± 145 
HCT (%) 32.48 ± 1.61 37.38 ± 7.06 
HGB (g dl-1) 9.94 ± 0.91 11.62 ± 2.02 
Table 3-2. Analysis of surface expression of glycoproteins in WT and Slap-/-/Slap2-/- platelets. 
Diluted whole blood was stained with saturating amounts of fluorophore-labeled antibodies and 
platelets were analyzed by flow cytometry. Results express MFI ± SD (n = 4 mice per group) and are 
representative of 5 independent experiments. Basic blood parameters were analyzed on a Sysmex 
KX-21N™ Hematology Analyzer. MPV: mean platelet volume; WBC: white blood cells; RBC: red blood 
cells; HCT: hematocrit; HGB: hemoglobin. *P < .001. (Cherpokova et al., Blood 2015)146 
Slap-/-/Slap2-/- platelets displayed a marked hyperreactivity in response to GPVI or 
CLEC-2 stimulation (Figure 9C, Figure 10A-B). This effect was most evident at sub-threshold 
concentrations of GPVI agonists - CRP, convulxin and collagen - and the CLEC-2 agonist 
rhodocytin, which did not induce activation of WT platelets, but resulted in integrin activation, 
α- and dense-granule secretion (assessed by ATP release upon activation) and robust 
aggregation of the mutant platelets. Importantly, activation responses to GPCR-specific 
agonists were unaltered in Slap-/-/Slap2-/- platelets (Figure 9C, Figure 10A-B). Together, 
these results indicated that SLAP and SLAP2 have redundant functions in the regulation of 






Figure 9. Increased integrin activation and α−granule release in Slap-/-/Slap2-/- platelets upon 
GPVI or CLEC-2 stimulation. (A) Western blot analysis demonstrating absence of SLAP and SLAP2 
in Slap-/-/Slap2-/- platelets. GPIIIa expression was used as loading control. Arrowheads indicate both 
SLAP2 isoforms (25 and 28 kDa) in WT platelets. (B) Western blot analysis of GPVI and CLEC-2 
expression in Slap-/-/Slap2-/- platelets. GPIIIa expression was used as loading control and for 
quantification. Equal protein amounts were loaded and expression levels were quantified by 
densitometry with ImageJ software (NIH, USA) on 12 samples per genotype. Results represent 
mean ± SD. Expression levels were adjusted such that GPVI-to-GPIIIa or CLEC-2-to-GPIIIa ratio in 
WT platelets was set to 1. (C) Flow cytometric analysis of activated integrin αIIbβ3 (binding of 
JON/A-PE) (left panel) and degranulation-dependent P-selectin exposure (right panel) upon 
stimulation with the indicated agonists in WT and Slap-/-/Slap2-/- platelets. Results are expressed as 
MFI ± SD (n = 4 mice per group) and are representative of 6 independent experiments. Dividing lines 
indicate separate measurements. U46, U-46619; A/U, ADP + U-46619; thr., thrombin; CVX, convulxin; 








Figure 10. Enhanced aggregation and dense granule release in Slap-/-/Slap2-/- platelets upon 
GPVI or CLEC-2 stimulation. (A) Washed platelets were activated with the indicated agonists and 
light transmission was recorded on a Fibrintimer 4-channel aggregometer. ADP measurements were 
performed in PRP. Aggregation traces representative of 3 independent experiments with n = 4 are 
depicted. Arrows indicate addition of the respective agonist. (B) Washed platelets were incubated with 
Luciferase-Luciferin reagent and ATP release was measured in a Lumi-aggregometer upon 
stimulation with thrombin, CRP or rhodocytin. Results are representative of 2 individual experiments 
with n = 4. Results represent mean ± SD. thr., thrombin; CRP, collagen-related peptide; RC, 
rhodocytin. (Cherpokova et al., Blood 2015)146 
To examine whether increased GPVI signaling in Slap-/-/Slap2-/- platelets can be 
explained by the elevated GPVI surface expression levels in SLAP/SLAP2-deficient mice, 
Slap-/-/Slap2-/-Gp6+/- mice were generated by crossing Slap-/-/Slap2-/- mice with Gp6-/- mice.44 
Flow cytometric and Western blot analyses confirmed that both surface and total GPVI 
expression levels in Slap-/-/Slap2-/-/Gp6+/- platelets were reduced by approximately 50% 
compared to platelets of Slap-/-/Slap2-/-/Gp6+/+ litter-matched mice and were also significantly 
lower than in WT platelets (Figure 11A-B). Despite reduced GPVI surface expression levels, 
Slap-/-/Slap2-/-/Gp6+/- platelets were markedly hyperreactive to GPVI agonists, as shown by 
analysis of integrin αIIbβ3 activation, P-selectin exposure and aggregation in response to 
GPVI-specific agonists, most notably at low and intermediate concentrations (Figure 11C-D). 
These results clearly demonstrated that the enhanced GPVI activation in SLAP/SLAP2 
deficient platelets occurs independently of the increased GPVI expression levels in these 






Figure 11. Increased GPVI signaling in Slap-/-/Slap2-/- platelets occurs independently of elevated 
GPVI expression levels. (A) Analysis of GPVI expression levels in WT, Slap-/-/Slap2-/-/Gp6+/- and 
Slap-/-/Slap2-/-/Gp6+/+ platelets. Diluted whole blood was stained with FITC-labeled JAQ1 antibody and 
platelets were analyzed by flow cytometry (n = 4 mice per group). (B) Western blot analysis of GPVI 
expression in WT, Slap-/-/Slap2-/-/Gp6+/- and Slap-/-/Slap2-/-/Gp6+/+ platelets. GPIIIa expression was 
used as loading control. (C) Detection of integrin αIIbβ3 activation (binding of JON/A-PE) (left panel) 
and α-granule release (right panel) in response to the indicated agonists in WT, Slap-/-/Slap2-/-/Gp6+/- 
and Slap-/-/Slap2-/-/Gp6+/+ platelets. Results are expressed as MFI ± SD (n = 4 mice per group). (C) 
Washed platelets were activated with CRP and light transmission was monitored on a Fibrintimer 4-
channel aggregometer. Results in all panels are representative of 3 independent experiments. A/U, 
ADP + U-46619; thr., thrombin; CVX, convulxin; CRP, collagen-related peptide; RC, rhodocytin. 
*P < .05; **P < .01; ***P < .001. (Cherpokova et al., Blood 2015)146 
To study the function of SLAP/SLAP2 in ITAM signaling in more detail, changes in protein 
tyrosine phosphorylation in WT, Slap-/-/Slap2-/-/Gp6+/- and Slap-/-/Slap2-/-/Gp6+/+ platelets were 
assessed upon stimulation with convulxin (Figure 12). SLAP/SLAP2 double deficiency was 
associated with enhanced and sustained tyrosine phosphorylation of key signaling molecules 
in the GPVI/ITAM activation pathway, including the FcRγ-chain, Syk (Y519/520) and PLCγ2 
(Y759). Increased phosphorylation of these proteins was observed also in 
Slap-/-/Slap2-/-/Gp6+/- platelets and thus largely independent of GPVI expression levels (Figure 
12). 
To address the mechanism by which SLAP proteins inhibit GPVI signaling, the 
hypothesis that SLAP proteins might compete with Src family kinases (SFKs) for binding to 
the GPVI/FcRγ signaling complex was tested. This assumption was based on the fact that 
Lyn and other SFKs are known to interact with GPVI,25,27 and because of the sequence 





domains). Indeed, strongly increased binding of Lyn to activated GPVI was detected in the 
absence of SLAP/SLAP2 compared to control (Figure 13), consistent with the increased 
tyrosine phosphorylation of downstream signaling proteins (Figure 12). 
 
Figure 12. Increased tyrosine phosphorylation of Syk and PLCγ2 upon stimulation of 
SLAP/SLAP2 deficient platelets with a GPVI-specific agonist. (A) WT, Slap-/-/Slap2-/-/Gp6+/- (HET) 
and Slap-/-/Slap2-/-/Gp6+/+ (HOM) platelets were stimulated with 0.5 µg/ml convulxin for the indicated 
time points. Whole-cell lysates were Western blotted and probed with the anti-phosphotyrosine 
antibody 4G10 or with phospho-specific antibodies. Staining of the respective non-phosphorylated 
proteins and actin served as loading control. (B) Expression levels of phosphorylated proteins were 
quantified by densitometry with ImageJ software (NIH, USA), normalized to the expression of the 
respective non-phosphorylated proteins and adjusted such that the values in WT samples after 1 min 
of stimulation were set to 1. Results are expressed as mean ± SD and are representative of 3 
independent experiments. CVX, convulxin. *P < .05; **P < .01. (Cherpokova et al., Blood 2015)146 
 
Figure 13. SLAP/SLAP2 attenuate Lyn 
binding to activated GPVI. Washed WT and 
Slap-/-/Slap2-/- (DKO) platelets were left 
unstimulated or, as indicated, stimulated with 
0.5 µg/ml convulxin (CVX) or 1 µg/ml 
rhodocytin (RC) for 20 s, lysed and proteins 
immunoprecipitated (IP) with Lyn were 
resolved by SDS-PAGE under non-reducing 
conditions and immunoblotted (Western blot, 
WB) for GPVI or Lyn. An immunoblot of whole 
cell lysate (WCL) loaded at 0.4% of Lyn 
immunoprecipitation input is also shown. Note 
that GPVI is detected as an ~65 kDa 
monomer and an ~120 kDa dimer, 
respectively. Dividing lines denote gaps 
between different sections and different exposure times of the same membrane. Results are 





Notably, markedly enhanced tyrosine phosphorylation of downstream signaling molecules 
was observed also upon stimulation of SLAP/SLAP2 deficient platelets with the CLEC-2 
specific-agonist rhodocytin (Figure 14). 
 
Figure 14. Increased tyrosine 
phosphorylation of Syk and PLCγ2 
upon stimulation of SLAP/SLAP2 
deficient platelets with a CLEC-2-
specific agonist. (A) WT and 
Slap-/-/Slap2-/- platelets were stimulated 
with 1 µg/ml rhodocytin (RC) for the 
indicated time points. Whole-cell lysates 
were Western blotted and probed with the 
anti-phosphotyrosine antibody 4G10 or 
with phospho-specific antibodies. Staining 
of the respective non-phosphorylated 
proteins and actin served as loading 
control. (B) Expression levels of 
phosphorylated proteins were quantified by 
densitometry with ImageJ software (NIH, 
USA), normalized to the expression of the 
respective non-phosphorylated proteins 
and adjusted such that the values in WT 
samples after 1 min of stimulation were set 
to 1. Results are expressed as mean ± SD 
and are representative of 3 independent 
experiments. RC, rhodocytin. *P < .05; **P < .01. (Cherpokova et al., Blood 2015)146 
The (hem)ITAM-bearing receptors GPVI and CLEC-2 share several similarities in 
proximal signaling events. It has been demonstrated that the key signaling molecule in the 
LAT signalosome, the adapter protein LAT, is critically involved in (hem)ITAM-dependent 
platelet aggregation, especially at low agonist concentrations.47,147 Due to the marked 
hyperreactivity in the (hem)ITAM signaling pathway and in particular because of the profound 
activation of the kinase Syk in the absence of SLAP/SLAP2, it was hypothesized that both 
adapter proteins might participate in the negative regulation of LAT-dependent PLCγ2 
phosphorylation and α-granule release. Platelets isolated from Slap-/-/Slap2-/-Lat-/- mice 
(Figure 15A), which were generated within another project (see Section 3.2.3.), displayed 
unaltered P-selectin exposure and aggregation compared to the respective WT control, in 
particular upon stimulation with intermediate concentrations of rhodocytin, at which 
responses of Lat-/- were completely abolished (Figure 15B-C). In line with the functional 
responses upon stimulation with rhodocytin, Slap-/-/Slap2-/-Lat-/- platelets exhibited enhanced 
phosphorylation of PLCγ2 (Figure 15D). By contrast, reductions in α-granule release and 
aggregation after stimulation with low concentrations of the potent GPVI-specific agonist 
convulxin could not be overcome in Slap-/-/Slap2-/-Lat-/- platelets (Figure 15B and data not 
shown), despite largely preserved phosphorylation of downstream signaling molecules 





activation downstream of CLEC-2 which appears to be controlled by interactions between 
SLAP/SLAP2 and Syk. 
 
 
Figure 15. SLAP/SLAP2 deficiency results in LAT-independent enhanced PLCγ2 
phosphorylation upon CLEC-2 stimulation. (A) Western blot analysis demonstrating absence of 
SLAP, SLAP2 and LAT in Slap-/-/Slap2-/-/Lat-/- platelets. GAPDH expression was used as loading 
control. (B) Flow cytometric analysis of degranulation-dependent P-selectin exposure upon stimulation 
with the indicated agonists. Results are expressed as MFI ± SD (n = 2 mice per group) and are 
representative of 3 independent experiments. (C) Washed platelets were activated with rhodocytin and 
light transmission was monitored on a Fibrintimer 4-channel aggregometer. (D) (Left panel) Platelets 
were stimulated with 0.5 µg/ml convulxin (C) or 1 µg/ml rhodocytin (R) for 2 min. Whole-cell lysates 
were Western blotted and probed with the anti-phosphotyrosine antibody 4G10 or with phospho-
specific antibodies. Staining of the respective non-phosphorylated proteins and GAPDH served as 
loading control. (Right panel) Expression levels of phosphorylated PLCγ2 upon CLEC-2 stimulation 
were quantified by densitometry with ImageJ software (NIH, USA), normalized to the expression of 
total PLCγ2 and adjusted such that the values in Lat+/+ samples were set to 1. Note that the 3 KO 
mouse strains were on a different WT background and therefore, the respective WT were used as 
control. Results in all panels are representative of 3 independent experiments. thr., thrombin; CVX, 






3.1.3. Markedly enhanced GPVI-dependent procoagulant activity in 
Slap-/-/Slap2-/- platelets 
Next, consequences of SLAP/SLAP2 deficiency on platelet adhesion to collagen and 
aggregate formation under flow were investigated using a whole blood perfusion system. 
Unexpectedly, WT and Slap-/-/Slap2-/- platelets formed aggregates to the same extent and 
with the same kinetics at intermediate shear rates of 1000 s-1 (Figure 16A-B). 
 GPVI signaling leads to a marked increase in cytosolic Ca2+ concentrations, subsequent 
surface exposure of procoagulant phosphatidylserine (PS) and resultant thrombin 
generation.13,14 To test whether SLAP/SLAP2 regulate the procoagulant activity of platelets, 
blood from WT and Slap-/-/Slap2-/- mice was anticoagulated, perfused over immobilized 
collagen at a shear rate of 1000 s-1 and PS exposure was determined by annexin-A5-
staining. The surface covered by collagen-adherent platelets was similar in WT and mutant 
samples, whereas PS exposure was markedly increased in Slap-/-/Slap2-/- blood (Figure 
16C-D). 
 
Figure 16. SLAP/SLAP2 deficiency enhances procoagulant activity under flow. Unaltered 
adhesion and aggregate formation of Slap-/-/Slap2-/- platelets on collagen under flow ex vivo. 
Heparinized whole blood was perfused over immobilized fibrillar collagen at a shear rate of 1000 s-1 
and surface coverage (A) and relative aggregate volume (B) (estimated by the integrated fluorescence 
intensity (IFI) of fluorescently labeled platelets per visual field) were determined. Representative 
phase-contrast (A) and fluorescence (B) images after 2 min washing with Tyrode-HEPES buffer are 
depicted. (C) Unaltered surface coverage by collagen-adherent platelets in WT and 
Slap-/-/Slap2-/- blood. Representative phase-contrast images are depicted. (D) Increased 
phosphatidylserine (PS) exposure of Slap-/-/Slap2-/- platelets, as demonstrated by annexin-A5-DyLight 
488 staining of platelets. Procoagulant index indicates the ratio of surface coverage of PS-exposing 
platelets (annexin-A5-DyLight 488 staining of platelets) to the total surface covered by platelets. 
Results in all panels are representative of 2 independent experiments with n ≥ 6. Bars: 50 µm 
**P < .01. (Cherpokova et al., Blood 2015)146 
 Enhanced (hem)ITAM-dependent procoagulant activity of Slap-/-/Slap2-/- platelets was 





different agonists (Figure 17). Notably, combined stimulation of GPVI and GPCR was 
required to induce high PS exposure in WT platelets (Figure 17). In stark contrast, 
stimulation with GPVI-specific agonists alone (CRP or convulxin) was sufficient to induce 
significant procoagulant activity in Slap-/-/Slap2-/- platelets (Figure 17). 
 
Figure 17. SLAP/SLAP2 deficiency is associated with increased PS exposure. (A) Washed 
platelets were stimulated with 0.1 U/ml thrombin, 20 µg/ml CRP, a combination of both thrombin and 
CRP, 1 µg/ml convulxin, or 0.12 µg/ml rhodocytin, stained with saturating amounts of annexin-A5-
DyLight 488 and directly analyzed by flow cytometry. Results are representative of 2 independent 
experiments with n = 5. (B) Washed platelets were stimulated with 1 µg/ml convulxin, 1.2 µg/ml 
rhodocytin, 20 µg/ml CRP, 0.1 U/ml thrombin or a combination of both thrombin and CRP, stained with 
saturating amounts of annexin-A5-DyLight 488 and anti-GPIX-DyLight 649 derivatives and directly 
analyzed by flow cytometry. Results are expressed as MFI ± SD (n = 4 mice per group) and are 
representative of 2 independent experiments. thr., thrombin; CVX, convulxin; CRP, collagen-related 
peptide; RC, rhodocytin. **P < .01; ***P < .001. (Cherpokova et al., Blood 2015)146 
 PS exposure triggers powerful platelet procoagulant activity and provides high affinity 
binding sites for key coagulations factors.14 This in turn enhances the assembly of the tenase 
and prothrombinase complexes and leads to rapid thrombin generation.148 In agreement with 
enhanced PS-exposure, lack of SLAP/SLAP2 resulted in an altered maximal amount of 
newly generated thrombin (Figure 18B) and significantly accelerated response upon 
stimulation with (hem)ITAM-specific agonists (Figure 18C). The overall amount of produced 
thrombin was comparable to the values in WT control samples (Figure 18A). Importantly, 
SLAP/SLAP2 deficiency did not affect plasma coagulation, as confirmed by unaltered 
activated plasma thromboplastin time and prothrombin time in Slap-/-/Slap2-/- mice compared 







Figure 18. SLAP/SLAP2 deficiency enhances (hem)ITAM-dependent thrombin generation in 
platelets. Citrate-anticoagulated platelet-rich plasma was left unstimulated (PRP), or platelets were 
activated by incubation with convulxin (CVX) (1 µg/ml), collagen-related peptide (CRP) (20 µg/ml), 
rhodocytin (RC) (1 µg/ml) or the Ca2+ ionophore A23187 (A23) (10 µM) for 10 min at 37°C. Thrombin 
generation was triggered with tissue factor/CaCl2. (A) Endogenous thrombin potential (ETP). (B) 
Quantification of thrombin peak height. (C) Quantification of time to peak. n = 3 for A23187; n = 7 for 
CRP and RC; n = 10 for PRP and CVX. *P < .05; **P < .01; ***P < .001. (Cherpokova et al., Blood 
2015)146 
 
3.1.4. SLAP/SLAP2 limit thrombus formation 
In a next set of experiments, the role of SLAP and SLAP2 in hemostasis and thrombosis was 
studied. Combined deficiency of SLAP and SLAP2 did not affect platelet hemostatic 
functions (mean tail bleeding time: 188 ± 62 s in WT mice vs. 213 ± 90 s in 
Slap-/-/Slap2-/- mice, P = 0.5; Figure 19A). 
PS exposure and thrombin generation have been demonstrated to play a key role in the 
progression of thrombus growth in mouse models of arterial thrombosis.149,150 To assess the 
extent to which the above described hyperreactive platelet phenotype affects thrombotic 
events in vivo, Slap-/-/Slap2-/- and WT mice were subjected to two models of occlusive arterial 
thrombosis. These experiments were performed by Dr. Martina Morowski. In the first model, 
the abdominal aorta is mechanically injured and thrombus formation occurs mainly through 
collagen-dependent mechanisms.151 The severity of injury was reduced and correspondingly, 
stable vessel occlusion was achieved in only 20% of the WT mice. In marked contrast, the 
majority (89%) of Slap-/-/Slap2-/- mice formed stable vessel occlusion which also occurred 
significantly faster (Slap-/-/Slap2-/- mice: 282 ± 151 s vs. 713 ± 131 s in the WT; Figure 19B). 
In a second model, the carotid artery was injured by topical application of FeCl3. Thrombus 
formation is driven by both collagen- and thrombin-dependent mechanisms in this model.151 
Stable vessel occlusion occurred in 93% of all tested Slap-/-/Slap2-/- mice, whereas 60% of 
the WT mice (9 out of 15) were not able to form occlusive thrombi within the observation 
period of 30 min (P < .01; mean time to occlusion: WT: 607 ± 146 s; Slap-/-/Slap2-/- mice: 
483 ± 149 s; Figure 19C). Importantly, similar results were obtained upon adoptive platelet 
transfer of Slap-/-/Slap2-/- platelets into platelet-depleted WT mice, thus excluding a 





occlusion in 30% of mice transfused with WT platelets, vessel occlusion in 92% of mice 
transfused with Slap-/-/Slap2-/- platelets, P < .01, Figure 19D). 
In the model of FeCl3-induced injury of the carotid artery, the applied concentration of 
FeCl3 was reduced to a critical threshold at which stable occlusion was not observed in the 
majority of the WT animals (Figure 19C). Notably, application of a low concentration of FeCl3 
resulted in the formation of occlusive platelet-rich thrombi in Slap-/-/Slap2-/- mice which did not 
differ morphologically from those observed in WT control mice treated with a higher 
concentration of FeCl3 (Figure 20). These data indicated that thrombus formation in 
Slap-/-/Slap2-/- mice is initiated at a significantly lower threshold of vessel damage. Together, 
these findings demonstrated that SLAP/SLAP2 deficiency in platelets results in a 
prothrombotic phenotype, confirming the notion that these adapter proteins negatively 
regulate platelet activation in vivo and thereby efficiently prevent occlusive thrombus 
formation and infarction. 
 
Figure 19. SLAP/SLAP2 limit thrombus 
formation. (A) SLAP/SLAP2 deficiency does not 
influence hemostatic function in 
Slap-/-/Slap2-/- mice as demonstrated by unaltered 
tail bleeding times of Slap-/-/Slap2-/- mice. Each 
symbol represents 1 animal. (B) The abdominal 
aorta was mechanically injured using forceps 
(compression for 10 s) and blood flow was 
monitored by an ultrasonic flow probe until 
complete vessel occlusion for at least 5 min, or 
for a maximum of 30 min. Each symbol 
represents 1 animal. (C) The right carotid artery 
of WT and Slap-/-/Slap2-/- mice was injured by 
topical application of 2.5% FeCl3 for 90 s and 
blood flow was monitored with a Doppler flow 
probe until complete vessel occlusion for at least 
2 min, or for a maximum of 30 min. Each symbol 
represents 1 animal. (D) WT mice were treated 
with platelet-depleting anti-GPIbα antibodies. 
Platelet-depleted WT mice were transfused with 
WT or Slap-/-/Slap2-/- (DKO) platelets and 7.5% 
FeCl3 were topically applied to the right carotid 
arteries of these mice for 1 min. Time to complete vessel occlusion was determined as described for 







Figure 20. Occlusive thrombi in Slap-/-/Slap2-/- mice consist of platelets and are 
indistinguishable from WT thrombi. (A) The right carotid artery of WT and Slap-/-/Slap2-/- mice was 
injured by topical application of 5% FeCl3 for 1 min, or 10% FeCl3 for 1 min (only WT mice) and blood 
flow was monitored with a Doppler flow probe until complete vessel occlusion for at least 2 min, or for 
a maximum of 30 min. Note that carotid arteries of WT mice were injured with a higher concentration 
of FeCl3 to induce formation of occlusive thrombi with the same kinetics as in Slap-/-/Slap2-/- mice. 
Injured vessels were excised, fixed and stained with toluidine blue. Bar: 200 µm. (B) Ultrastructural 
analysis of occlusive thrombi by TEM. Note that thrombi formed in the absence of SLAP and SLAP2 
consisted of platelets and did not differ from occlusive thrombi in WT mice. Bar: 1.1 µm. Images are 
representative of 4-6 mice per group. (Cherpokova et al., Blood 2015)146 
 
3.1.5. SLAP/SLAP2 deficiency in platelets dramatically aggravates 
neurological damage after focal cerebral ischemia 
Ischemic stroke is a complex disease with multiple cellular interactions involved in the 
progression of thromboembolic vessel occlusion to infarct development.12 Although the exact 
mechanisms by which platelets contribute to the development of ischemic brain infarction are 
still poorly understood, there is increasing evidence that GPVI (and GPIb) plays a major role 
in this process.12,30,32 To determine the effect of SLAP/SLAP2 deficiency on cerebral infarct 
development, Slap-/-/Slap2-/- and WT mice were subjected to the transient middle cerebral 
artery occlusion (tMCAO) model of acute stroke where the origin of the middle cerebral artery 
is occluded by a filament for 30 min, thereby reducing cerebral flow by >90%.32,141 Surgery 
was carried out by Dr. Peter Kraft and Dr. Michael Schuhmann from the Department of 
Neurology (University of Würzburg). 
In agreement with previous reports,141 WT mice developed small infarctions after only 
30 min of ischemia. In sharp contrast, infarct volumes in Slap-/-/Slap2-/- mice were increased 
by ~92% compared to WT mice (58.8 ± 33.5 mm3 in WT vs. 113.1 ± 14.3 mm3 in 





relevant, as it was associated with an overall impairment of neurological and motor function, 
demonstrated by the significantly worsened outcome in the Bederson score and grip test, 
respectively (Figure 21B-C). The dramatic increase in infarct volume was accompanied by 
increased intracerebral thrombosis, as demonstrated by the markedly elevated number of 
occluded vessels (Figure 21D). Consistent with the higher proportion of occluded vessels, 
immunohistochemical and Western blot analyses revealed increased accumulation of 
fibrin(ogen) in the infarcted basal ganglia and cortices of Slap-/-/Slap2-/- mice (data not 
shown). 
 
Figure 21. SLAP/SLAP2 deficiency dramatically aggravates neurological damage after focal 
cerebral ischemia. Infarct volumes (A) and functional outcome (B, C) 24 h after focal cerebral 
ischemia in WT and Slap-/-/Slap2-/- mice were investigated in a murine model of ischemic stroke. Mice 
were subjected to 30 min of tMCAO. (A) Brain infarct volumes in WT (n = 9) and 
Slap-/-/Slap2-/- (n = 12) mice were measured by planimetry (left panels). Results represent mean ± SD. 
Representative images of 3 coronal brain sections stained with TTC 24 h after 30 min tMCAO (right 
panel). Arrows indicate infarcted areas in Slap-/-/Slap2-/- mice. (B) Bederson score and (C) grip test 
were determined 24 h after tMCAO. Each symbol represents 1 animal. (D) SLAP/SLAP2 deficiency 
dramatically increases microvascular thrombosis after 30 min of tMCAO. Representative hematoxylin 
and eosin stains from the ipsilesional hemispheres of WT (n = 6) and Slap-/-/Slap2-/- (n = 8) mice (left 
panel) and determination of the percentage of occluded vessels (right panel). Number of thrombotic 
vessels was significantly increased in Slap-/-/Slap2-/- mice (arrows), whereas the microvascular 
patency was largely preserved in WT mice (arrowheads). Bar: 50 µm. *P < .05; **P < .01; ***P < .001. 
(Cherpokova et al., Blood 2015)146 
To specifically investigate the role of platelet SLAP and SLAP2 in the progression of 
ischemic stroke, adoptive platelet transfer into platelet-depleted WT mice was performed. 
Importantly, the transfused platelet populations did not show any signs of activation and were 
free of leukocytes, as tested by flow cytometry, microscopical inspection and automated 
blood cell analysis. Furthermore, flow cytometric and transmission EM analyses confirmed 
that the platelet suspensions were also free of (leukocyte- or platelet-derived) microparticles 
(data not shown). Strikingly, infarct volumes in WT mice transfused with 





transfused with WT platelets (123.0 ± 23.4 mm3 vs. 62.6 ± 31.8 mm3; P < .001; Figure 22A), 
and this was accompanied by severe neurological deficits (Figure 22B-C). These findings 
demonstrated that SLAP/SLAP2 activity in platelets is critically involved in limiting infarct 
growth following focal cerebral ischemia. 
Figure 22. SLAP/SLAP2 deficiency in platelets 
induces a dramatic increase in infarct volume 
in a model of ischemic stroke. Infarct volumes 
(A) and functional outcome (B, C) 24 h after focal 
cerebral ischemia in WT mice reconstituted with 
WT or Slap-/-/Slap2-/- (DKO) platelets after 
depletion of endogenous platelets were 
investigated in a murine model of ischemic 
stroke. Mice were subjected to 30 min of tMCAO. 
(A) Brain infarct volumes in platelet-depleted WT 
mice transfused with WT (n = 12) or 
Slap-/-/Slap2-/- (n = 8) platelets were measured by 
planimetry (left panels). Results represent mean 
± SD. Representative images of 3 coronal brain 
sections stained with TTC 24 h after 30 min 
tMCAO (right panel). Arrows indicate infarcted 
areas in WT mice recipients of 
Slap-/-/Slap2-/- platelets. (B) Bederson score and 
(C) grip test were determined 24 h after tMCAO. 
Each symbol represents 1 animal. *P < .05; 
***P < .001. (Cherpokova et al., Blood 2015)146 
In a control experiment, WT mice received leukocytes isolated from the blood of 
Slap-/-/Slap2-/- or WT mice and were then subjected to a 30 min tMCAO. Both groups of mice 
developed only small infarcts, clearly demonstrating that leukocytes are not responsible for 
the increased susceptibility of Slap-/-/Slap2-/- mice towards ischemic stroke (Figure 23). 
Figure 23. Adoptive transfer of 
Slap-/-/Slap2-/- leukocytes into WT mice does 
not alter infarct size. Infarct volumes in WT 
mice transfused with WT or Slap-/-/Slap2-/- (DKO) 
white blood cells (WBC) were investigated in a 
murine model of ischemic stroke. Mice were 
subjected to 30 min of tMCAO. Brain infarct 
volumes were measured by planimetry (left 
panels). Results represent mean ± SD. 
Representative images of 3 coronal brain 
sections stained with TTC 24 h after 30 min of tMCAO (right panel). n = 5 animals per group. 
(Cherpokova et al., Blood 2015)146 
Furthermore, induction of local cytokine production, infiltration by T cells (which have 
been shown to contribute to infarct growth in this model)152-154 complement activation and the 
stability of the blood-brain barrier were comparable between WT and Slap-/-/Slap2-/- mice 
24 h after 30 min of tMCAO (data not shown). Together, these results further corroborated 
the notion that enhanced thrombotic, rather than proinflammatory, activity is a major 
determinant of the increased susceptibility of SLAP/SLAP2-deficient mice towards ischemic 





3.2. In vivo depletion of GPVI in SLAP/SLAP2-deficient mice is associated 
with prolonged severe thrombocytopenia 
The central platelet collagen receptor GPVI can be specifically and irreversibly removed from 
the surface of circulating mouse platelets in vivo by treatment with monoclonal antibodies 
(JAQ1-3).39,40 GPVI immunodepletion in mice leads to a prolonged GPVI-knockout-like 
phenotype with absence of the receptor for more than two weeks upon treatment with a 
single bolus injection of the antibody.39,40 Loss of the receptor is associated with a transient 
thrombocytopenia, but a long-term antithrombotic protection in different models of 
experimental arterial thrombosis and is accompanied by only moderately increased bleeding 
in vivo.39,155,156 GPVI is therefore regarded as an attractive potential target for antithrombotic 
therapy.13,38 
Antibody-induced GPVI down-regulation in vivo is currently considered to occur through 
two principal mechanisms: ectodomain shedding and internalization followed by intracellular 
degradation.41,43 Both mechanisms require signaling through the ITAMs in the FcRγ-chain.41 
Moreover, key downstream signaling molecules, such as LAT and PLCγ2, are indispensable 
for shedding, whereas receptor down-regulation by internalization and degranulation still 
occurs in the absence of both proteins.41 SLAP proteins contribute essentially to the down-
regulation of TCR and BCR expression levels by targeting components of the TCR and BCR 
complexes for degradation after stimulation and internalization.80-82 This raises the possibility 
that SLAP/SLAP2 may be involved in similar mechanisms underlying the degradation of the 
GPVI/FcRγ complex after internalization. SLAP/SLAP2-deficient mice were used to 
investigate this hypothesis in the following section of this thesis. 
 
3.2.1. SLAP and SLAP2 are dispensable for antibody-induced GPVI down-
regulation 
To study the role of SLAP and SLAP2 in antibody-induced GPVI down-regulation, Slap-/-, 
Slap2-/- and WT mice were treated with the monoclonal anti-GPVI antibody JAQ1 (4 µg/g 
body weight (BW) intravenously (i.v.)) and platelet counts, JAQ1 binding to the platelet 
surface and GPVI surface protein expression were monitored by flow cytometry. Consistent 
with previous reports,39-41 antibody treatment was in all 3 groups accompanied by a transient 
thrombocytopenia with a maximal drop in peripheral platelet counts 30 min after JAQ1 
injection (Figure 24A). Surface-bound JAQ1 was detected only at very early time points after 
antibody administration, suggesting rapid removal of the JAQ1-GPVI complex from the 
platelet surface (Figure 24B-C) associated also with clearance of the FcRγ chain (Figure 





but peripheral platelet counts remained at ~50-60% of control values in the following 3 weeks 
after treatment (Figure 24A). Collectively, these data demonstrated that SLAP and SLAP2 
each are dispensable for antibody-induced GPVI down-regulation. 
 
Figure 24. SLAP and SLAP2 are dispensable for antibody-induced GPVI down-regulation. (A) 
Relative platelet counts in WT (●), Slap-/- (▼) and Slap2-/- (▲) mice at the indicated time points after 
treatment with 4 µg/g BW JAQ1-IgG. Platelet counts are expressed as percentage of vehicle-treated 
control mice. (B) Detection of surface-bound JAQ1 by an anti-rat IgG antibody in vitro, prior to (0 h), 
30 min and 24 h after JAQ1-IgG treatment. (C) Determination of GPVI surface expression by flow 
cytometry. (A-C) Results are expressed as MFI ± SD (n ≥ 4 mice per group) and are representative of 
3 independent experiments. (D) Western blot analysis of total GPVI and FcRγ expression levels 24 h 
after JAQ1-IgG treatment. GPIIIa levels served as loading control. Blots are representative of 2 
independent experiments. 
 
3.2.2. Antibody-induced GPVI down-regulation results in prolonged severe 
thrombocytopenia in Slap-/-/Slap2-/- mice 
The results presented in the first part of this thesis clearly demonstrated a functional 
redundancy of SLAP and SLAP2 in the modulation of platelet (hem)ITAM signaling. It was 
thus hypothesized that both adapter proteins may play redundant roles in antibody-induced 





prolonged thrombocytopenia in Slap-/-/Slap2-/- mice which lasted over 4 weeks before 
peripheral platelet counts recovered to initial values (Figure 25A). Importantly, antibody 
treatment led to rapid loss of GPVI/FcRγ and JAQ1-GPVI complex (Figure 25B-D), revealing 
that JAQ1-induced GPVI down-regulation occurs independently of both SLAP and SLAP2. 
 
Figure 25. SLAP/SLAP2 deficiency is associated with prolonged severe thrombocytopenia 
following antibody-induced GPVI down-regulation. (A) Relative platelet counts in WT (black 
circles) and Slap-/-/Slap2-/- (gray circles) mice at the indicated time points after treatment with 
4 µg/g BW JAQ1-IgG. Platelet counts are expressed as percentage of vehicle-treated control mice. (B) 
Detection of surface-bound JAQ1 by an anti-rat IgG antibody in vitro, prior to (0 h), 30 min and 24 h 
after JAQ1-IgG treatment. (C) Determination of GPVI surface expression by flow cytometry. (A-C) 
Results are expressed as MFI ± SD (n ≥ 4 mice per group) and are representative of 6 independent 
experiments. (D) Western blot analysis of total GPVI and FcRγ expression levels at the indicated time 
points after JAQ1-IgG treatment. GPIIIa levels served as loading control. Dividing lines denote gaps 
between different sections of the same membrane. Blots are representative of 2 independent 
experiments. 
Although combined deficiency of SLAP and SLAP2 proved dispensable for GPVI down-
regulation, the striking phenotype of acquired thrombocytopenia in Slap-/-/Slap2-/- mice after a 
single bolus injection of JAQ1 was investigated in more detail. In the next set of experiments, 
the influence of elevated GPVI expression levels in Slap-/-/Slap2-/- mice on the observed 
phenotype was examined by studying effects of JAQ1 treatment in Slap-/-/Slap2-/-/Gp6+/- mice 
which exhibited GPVI expression levels reduced by 50% compared to litter-matched 





thrombocytopenia in Slap-/-/Slap2-/-/Gp6+/- mice (Figure 26), demonstrating that 
thrombocytopenia severity occurs largely independently of GPVI surface expression levels. 
 
Figure 26. Prolonged severe thrombocytopenia following antibody-induced GPVI down-
regulation occurs largely independently of GPVI surface expression levels. (A) Relative platelet 
counts in WT (black circles), Slap-/-/Slap2-/-/Gp6+/+ (light gray circles) and Slap-/-/Slap2-/-/Gp6+/- (dark 
gray circles) mice at the indicated time points after treatment with 4 µg/g BW JAQ1-IgG. Platelet 
counts are expressed as percentage of vehicle-treated control mice. (B) Detection of surface-bound 
JAQ1 by an anti-rat IgG antibody in vitro, prior to (0 h), 30 min and 24 h after JAQ1-IgG treatment. (C) 
Determination of GPVI surface expression by flow cytometry. (A-C) Results are expressed as 
MFI ± SD (n ≥ 5 mice per group) and are representative of 3 independent experiments. 
 To investigate whether the Fc-part of the JAQ1 antibody is required for GPVI down-
regulation and the concomitant transient thrombocytopenia to occur, WT and SLAP/SLAP2-
deficient mice were treated with JAQ1-F(ab’)2 (4 µg/g BW, i.v.) and effects on peripheral 
platelet counts and GPVI expression were monitored by flow cytometry. F(ab’)2-fragments 
induced GPVI-immunodepletion, but, importantly, had no significant effects on peripheral 
platelet counts in WT animals (Figure 27), thus demonstrating that the transient 
thrombocytopenia associated with JAQ1-induced GPVI down-regulation occurs through Fc-
dependent mechanisms. By contrast, GPVI immunodepletion by JAQ1-F(ab’)2-fragments 
caused a rapid platelet count drop in SLAP/SLAP2-deficient mice and, similarly to the IgG-
treatment, eventually resulted in severe thrombocytopenia (Figure 27). Notably, treatment 





prevents JAQ1-induced thrombocytopenia and the generation of soluble GPVI (sGPVI), but 
does not affect GPVI down-regulation through internalization/intracellular degradation (data 
not shown and David Stegner, unpublished), could not ameliorate acute thrombocytopenia in 
Slap-/-/Slap2-/- mice (data not shown). Taken together, these findings strongly suggested that 
interactions of the JAQ1-GPVI complex with FcγR-bearing cells may not be the major 
determinant of JAQ1-induced prolonged thrombocytopenia in Slap-/-/Slap2-/- mice. 
Figure 27. Prolonged severe thrombocytopenia following antibody-induced GPVI down-
regulation occurs through an Fc-independent mechanism in SLAP/SLAP2-deficient mice. (A) 
Relative platelet counts in WT (black circles), Slap-/-/Slap2-/-/Gp6+/+ (light gray circles) and 
Slap-/-/Slap2-/-/Gp6+/- (dark gray circles) mice at the indicated time points after treatment with 
4 µg/g BW JAQ1-F(ab’)2. Platelet counts are expressed as percentage of vehicle-treated control mice. 
(B) Detection of surface-bound JAQ1 by an anti-rat IgG antibody in vitro, prior to (0 h), 1 h and 48 h 
after JAQ1-F(ab’)2 treatment. (C) Determination of GPVI surface expression by flow cytometry. (A-C) 
Results are expressed as MFI ± SD (n = 4 mice per group) and are representative of 2 independent 
experiments. (D) Western blot analysis of total GPVI and FcRγ expression levels 24 h after JAQ1-
F(ab’)2 treatment. GPIIIa levels served as loading control. 
 Importantly, JAQ1 could not induce aggregation of WT platelets by itself, but only upon 
cross-linking of surface-bound JAQ1 by an anti-rat IgG secondary antibody (Figure 28A and 
Nieswandt et al., 200022, 2001157). In marked contrast, the antibody mediated irreversible 
aggregation of Slap-/-/Slap2-/- platelets in vitro (Figure 28A). Of note, unbound JAQ1 was 
detectable in the plasma of both WT and Slap-/-/Slap2-/- mice for up to 2 weeks post treatment 





JAQ1 (0.2 µg/g BW, ~5 µg JAQ1/mouse) induced severe thrombocytopenia in 
Slap-/-/Slap2-/- mice and even doses as low as 1 µg JAQ1/mouse led to a platelet count drop 
by 50% (data not shown). Importantly, JAQ1 treatment did not interfere with (pro-)platelet 
production in vitro and ultrastructure, development and localization of MKs following JAQ1 
treatment were unaltered in WT and Slap-/-/Slap2-/- mice (data not shown and Daniela 
Semeniak, Harald Schulze, unpublished). In addition, peripheral platelet count recovery upon 
induction of immune thrombocytopenia by anti-GPIbα- or anti-GPIIb/IIIa-antibodies took 
place at a comparable rate in WT and Slap-/-/Slap2-/- mice (data not shown). Collectively, 
these data indicated that rapid activation of platelets followed by their clearing from the 
circulation likely contributes to the observed JAQ1-induced prolonged severe 
thrombocytopenia in Slap-/-/Slap2-/- mice. 
Figure 28. JAQ1 induces aggregation of Slap-/-/Slap2-/- platelets in vitro. (A) Washed platelets 
were activated with JAQ1-IgG and light transmission was recorded on a Fibrintimer 4-channel 
aggregometer. Addition of an anti-rat IgG secondary antibody induced clustering of GPVI in WT 
platelets and subsequent platelet aggregation. Aggregation traces representative of experiments with 
n = 10 different JAQ1 batches yielding similar results are depicted. Arrows indicate addition of the 
respective antibody. (B) Detection of unbound JAQ1 IgG in the plasma of WT (black circles) or 
Slap-/-/Slap2-/- (light gray circles) mice treated with 4 µg/g BW JAQ1-IgGbiotin. Results are expressed as 
MFI ± SD (n = 3 mice per group) and are representative of 2 independent experiments, as previously 
described in the Master thesis “Studies on the ITAM signaling machinery in megakaryocytes and 
platelets in SLAP/SLAP2-deficient mice” (Deya Cherpokova, 2011). 
 In a next set of experiments, it was investigated whether prolonged thrombocytopenia 
occurs also upon immunodepletion of the second (hem)ITAM-bearing receptor on mouse 
platelets CLEC-2. In contrast to JAQ1, the monoclonal anti-CLEC-2 antibody INU1 induces 
aggregation of WT mouse platelets in vitro and leads to a more severe thrombocytopenia in 
WT mice in vivo with platelet count recovery within 4 days and CLEC-2 loss for > 5 days post 
treatment.44,49,59 Importantly, peripheral platelet counts and surface CLEC-2 expression 
recovered to initial values in Slap-/-, Slap2-/- and Slap-/-/Slap2 -/- mice with similar kinetics like 
in WT control mice (Figure 29). These data demonstrated, firstly, that SLAP and SLAP2, as 





CLEC-2 down-regulation. Secondly, the findings confirmed that the prolonged severe 
thrombocytopenia in Slap-/-/Slap2 -/- mice occurs specifically upon immunodepletion of GPVI. 
Figure 29. SLAP and SLAP2 are dispensable for antibody-induced CLEC-2 down-regulation. 
Relative platelet counts in WT (black circles), Slap-/- (▼) and Slap2-/- (▲) and Slap-/-/Slap2-/- (light gray 
circles) mice at the indicated time points after treatment with 4 µg/g BW INU1-IgG. Platelet counts are 
expressed as percentage of vehicle-treated control mice. (B) Determination of CLEC-2 surface 
expression by flow cytometry. Results are expressed as MFI ± SD (n ≥ 4 mice per group) and are 
representative of 2 independent experiments in Slap-/- and Slap2-/- mice and 4 independent 
experiments in Slap-/-/Slap2-/- mice. 
 
3.2.3. SLAP/SLAP2 are dispensable for LAT- and Syk-independent GPVI 
immunodepletion 
Cellular activation by JAQ1 and subsequent rapid platelet removal might mask effects of 
SLAP/SLAP2 deficiency on antibody-induced GPVI down-regulation. To specifically 
investigate the role of SLAP/SLAP2 in receptor internalization and subsequent proteolytic 
degradation, Slap-/-/Slap2-/- mice were intercrossed with Lat-/- mice (Figure 15) in which 
ectodomain shedding is abolished and antibody-induced GPVI down-regulation occurs 
exclusively through internalization.41 Consistent with previous studies,41 JAQ1-treatment had 
no effects on platelet counts in Lat-/- mice, whereas a transient platelet count drop down to 
< 50% was observed in Slap-/-/Slap2-/-/Lat-/- mice (Figure 30A). Although the generation of 
sGPVI was abolished in Slap-/-/Slap2-/-/Lat-/- mice (Figure 30D), loss of the JAQ1-GPVI 
complex from the platelet surface (Figure 30B-C) and intracellular degradation of GPVI 
occurred within a few hours after antibody treatment (Figure 30E), suggesting that 







Figure 30. SLAP/SLAP2 are dispensable for LAT-independent antibody-induced GPVI down-
regulation. (A) Relative platelet counts in WT (black circles), Lat-/- (white circles), Slap-/-/Slap2-/- (light 
gray circles) and Slap-/-/Slap2-/-/Lat-/- (dark gray circles) mice at the indicated time points after 
treatment with 4 µg/g BW JAQ1-IgG. Platelet counts are expressed as percentage of vehicle-treated 
control mice. (B) Detection of surface-bound JAQ1 by an anti-rat IgG antibody in vitro, prior to (0 h), 
1 h and 24 h after JAQ1-IgG treatment. (C) Determination of GPVI surface expression by flow 
cytometry. (A-C) Results are expressed as MFI ± SD (n = 4 mice per group) and are representative of 
3 independent experiments. (D) Plasma levels of sGPVI at the indicated time points after treatment 
with JAQ1-IgG were determined using an ELISA system. Background levels detected on 
Gp6-/- platelets were subtracted. Results are representative of 2 independent experiments which were 
performed by Dr. Markus Bender. (E) Western blot analysis of total GPVI and FcRγ expression levels 
at the indicated time points after treatment with JAQ1-IgG. GPIIIa levels served as loading control. 
Blots are representative of 2 independent experiments. 
To assess the contribution of GPVI signaling to receptor down-regulation in more detail 
and to further characterize the conditions under which JAQ1-induced thrombocytopenia 
occurs in a SLAP/SLAP2-deficient background, Slap-/-/Slap2-/- mice were intercrossed with 
MK-/platelet-specific Syk KO mice (Sykfl/fl Pf4-Cre+)59 to generate Slap-/-/Slap2-/-/Sykfl/fl Pf4-Cre+ 
animals (Figure 31A). Notably, JAQ1 administration did not induce thrombocytopenia in Syk-
deficient mice, irrespective of concomitant deficiency of SLAP/SLAP2 (Figure 31B), 
demonstrating that Syk is essential for JAQ1-induced thrombocytopenia to occur in 






Figure 31. Platelet-specific Syk deficiency prevents JAQ1-induced thrombocytopenia in 
Slap-/-/Slap2-/- mice. (A) Western blot analysis demonstrating absence of SLAP, SLAP2 and Syk in 
Slap-/-/Slap2-/-/Sykfl/fl Pf4-Cre+ platelets. GAPDH expression was used as loading control. (B) Relative 
platelet counts in WT (black circles), Sykfl/fl Pf4-Cre+ (white circles), Slap-/-/Slap2-/-/Sykfl/fl Pf4-Cre- (light gray 
circles) and Slap-/-/Slap2-/-/Sykfl/fl Pf4-Cre+ (dark gray circles) mice at the indicated time points after 
treatment with 2 µg/g BW JAQ1-IgGbiotin. Experiments were simultaneously performed, but results are 
depicted on different graphs for clarity. Results are expressed as MFI ± SD (n = 4 mice per group) and 
are representative of 2 independent experiments. 
 Despite abolished ectodomain shedding in Syk-deficient mice, GPVI was consistently 
removed from the platelet surface, albeit with slower kinetics as compared to WT mice 
(Figure 32B). This was further confirmed by Western blot analyses of the total amount of 
GPVI and JAQ1 which steadily decreased in both Sykfl/fl Pf4-Cre+ and Slap-/-/Slap2-/-/Sykfl/fl Pf4-Cre+ 
platelets (Figure 33). The discrepancy in the rates of intracellular clearing of the JAQ1-GPVI 
complex were likely due to considerable differences in (total) GPVI expression levels 
between both mutant mouse strains. These findings indicated that SLAP/SLAP2 are 
dispensable for Syk-independent internalization of GPVI upon receptor immunodepletion. 
 Collectively, the data presented in the first and second part of this thesis demonstrated 
that SLAP and SLAP2 have essential overlapping functions in the control of the (hem)ITAM 
signaling cascade in mouse platelets which may have important implications in thrombotic 
and thrombo-inflammatory disease states. Although both adapter proteins were dispensable 
for the targeted down-regulation of (hem)ITAM receptors to occur, SLAP and SLAP2 seem to 
play redundant roles in the prevention of therapeutically undesired thrombocytopenia 





Figure 32. SLAP/SLAP2 are dispensable for Syk-independent antibody-induced GPVI down-
regulation. (A) Plasma levels of sGPVI upon treatment with 2 µg/g BW JAQ1-IgGbiotin were 
determined using an ELISA system. Background levels detected on Gp6-/- platelets were subtracted. 
Note the differences in the Y-axis scale between the left and the right panel. (B) Surface expression of 
GPVI on the platelet surface in WT (black circles), Sykfl/fl Pf4-Cre+ (white circles), 
Slap-/-/Slap2-/-/Sykfl/fl Pf4-Cre- (light gray circles) and Slap-/-/Slap2-/-/Sykfl/fl Pf4-Cre+ (dark gray circles) mice 
was determined by flow cytometry using an anti-rat IgG-FITC antibody. Start values were determined 
by in vitro incubation of platelets with JAQ-IgG followed by detection with an anti-rat IgG antibody and 
were set to 100%. Experiments were simultaneously performed, but results are depicted on different 
graphs for clarity. Results are expressed as MFI ± SD (n = 4 mice per group) and are representative of 
2 independent experiments. 
Figure 33. SLAP/SLAP2 are dispensable for Syk-independent intracellular clearing of 
JAQ1-GPVI upon antibody-induced receptor down-regulation. Western blot analysis of JAQ1 
levels and total GPVI and FcRγ expression levels at the indicated time points after treatment with 
2 µg/g BW JAQ1-IgGbiotin. GPIIIa levels served as loading control. Experiments were simultaneously 
performed, but samples were loaded onto different gels for clarity. Blots are representative of 2 





3.3. Combined deficiency of RhoA and Cdc42 causes abnormal 
megakaryocyte development, severe macrothrombocytopenia and 
defective tubulin organization 
Rho GTPases, such as RhoA, Cdc42 and Rac1, have been established as key regulators of 
cytoskeletal rearrangements in platelets, but their specific roles and possible functional 
redundancies during platelet biogenesis and preceding reorganization of the MK actin and 
tubulin cytoskeleton are only beginning to be understood. For instance, a redundant function 
of Rac1 and Cdc42 has recently been demonstrated in the regulation of microtubule 
dynamics and (pro-)platelet formation,127 emphasizing the existence of overlapping roles of 
Rho GTPases in these processes. In this part of the thesis, putative functional redundancies 
between RhoA and Cdc42 in platelet production and function were investigated. 
 
3.3.1. Combined deficiency of RhoA and Cdc42 leads to severe 
macrothrombocytopenia 
To study the consequences of combined loss of RhoA and Cdc42 specifically in the 
MK-/platelet-lineage, mice carrying both the RhoA135 and the Cdc42136 genes flanked by loxP 
sites - RhoAfl/fl/Cdc42fl/fl - were intercrossed with transgenic mice carrying the Cre-
recombinase under the control of the MK-/platelet-specific PF4 promoter.137 Resulting 
double-deficient RhoAfl/fl/Cdc42fl/fl Pf4-Cre+ (further referred to as RhoA-/-/Cdc42-/-) and littermate 
control mice RhoAfl/fl/Cdc42fl/fl Pf4-Cre- (further referred to as WT) were used in all studies. In 
some experiments, conditional single deficient mice - RhoAfl/fl Pf4-Cre+ (RhoA-/-) and 
Cdc42fl/fl Pf4-Cre+ (Cdc42-/-) - were used in parallel in order to better discriminate between 
redundant and non-redundant functions of both GTPases. 
 In agreement with previous studies,112,113 RhoA-/- and Cdc42-/- mice displayed only 
moderately decreased platelet counts, whereas double deficiency of RhoA and Cdc42 
(Figure 34A) resulted in severe thrombocytopenia with peripheral platelet counts lower than 
25% of WT mice (1026 ± 113/nl in WT vs. 234 ± 44/nl in RhoA-/-/Cdc42-/- mice, Figure 34B 
and Table 3-3). Consistent with previous reports,112,113 flow cytometric and transmission 
electron microscopy (TEM) analyses revealed only slightly increased size of 
Cdc42-/- platelets and a moderate increase in size and a roundish shape of RhoA-/- platelets, 
whereas, importantly, subcellular morphology and granule distribution were largely unaltered 
in the mutant cells (Figure 34C-D). In stark contrast, RhoA/Cdc42 deficiency resulted in a 







Figure 34. RhoA/Cdc42 deficiency results in severe macrothrombocytopenia. (A) Western blot 
analysis demonstrating absence of RhoA and Cdc42 in MK-/platelet-specific RhoA/Cdc42 KO mice. 
GPIIIa expression was used as loading control. Peripheral platelet counts (B) and relative platelet size 
(C) of WT (black bars), RhoA-/- (white bars), Cdc42-/- (dark gray bars) and RhoA-/-/Cdc42-/- (light gray 
bars) mice were determined by flow cytometry. Values were normalized to WT levels which were set 
to 100%. Resuts are expressed as MFI ± SD (n = 4 mice per group) representative of 3 independent 
experiments. (D) TEM analysis of resting WT, RhoA-/-,112 Cdc42-/- 127 and RhoA-/-/Cdc42-/- platelets. 
Bars: 2.5 µm for WT and RhoA-/-/Cdc42-/- platelets, 1 µm for RhoA-/- platelets and 0.5 µm for 
Cdc42-/- platelets. *P < .05; **P < .01; ***P < .001. 
 WT RhoA-/-/Cdc42-/- 
Platelets (nl-1) 1026 ± 113 234 ± 44‡ 
MPV (fl) 5.04 ± 0.10 7.24 ± 0.48‡ 
WBC (nl-1) 4.40 ± 0.97 4.67 ± 1.75 
RBC (x 103 nl-1) 710 ± 125 695 ± 56 
HCT (%) 34.80 ± 6.09 33.83 ± 2.33 
HGB (g dl-1) 10.70 ± 1.84 9.92 ± 0.69 
Table 3-3. Analysis of basic blood parameters in WT and RhoA-/-/Cdc42-/- mice. Heparinized 
whole blood was analyzed on a Sysmex KX-21N™ Hematology Analyzer. Results express mean ± SD 
(n ≥ 6 mice per group) and are representative of 5 independent experiments. MPV: mean platelet 
volume; WBC: white blood cells; RBC: red blood cells; HCT: hematocrit; HGB: hemoglobin. ‡ P < .001. 
 Detailed analysis of resting RhoA-/-/Cdc42-/- platelets by TEM revealed severe defects in 
the tubulin structure and the microtubule coils in the marginal band were not or only barely 
visible (Figure 35A). These findings were confirmed by immunohistochemical analysis of the 





and tips of proplatelets (Figure 35B, lower panel). TEM analysis further revealed 
heterogeneous size and shape of resting RhoA-/-/Cdc42-/- platelets which were virtually 
devoid of granules or contained structures reminiscent of empty granules or vacuoles instead 
(Figure 35C). Collectively, these results revealed critical overlapping functions of RhoA and 
Cdc42 in platelet production, granule biogenesis and microtubule organization. 
 
Figure 35. RhoA-/-/Cdc42-/- platelets display abnormal ultrastructure and severely altered 
microtubule organization. (A) TEM analysis of microtubule distribution in resting platelets. 
Arrowheads indicate marginal microtubule coils which are clearly visible in WT platelets, in contrast to 
RhoA-/-/Cdc42-/- platelets. Bars: 1 µm. (B) Analysis of the actin cytoskeleton (F-actin: red – Phalloidin-
Atto647N) and tubulin structure (green – anti-α-Tubulin-Alexa488) in platelets spread on fibrinogen for 
30 min (upper panel) or in proplatelet forming fetal liver cell-derived MKs (lower panel). Bars: 5 µm 
(upper panel); 10 µm (lower panel). (C) Representative TEM images of resting 
RhoA-/-/Cdc42-/- platelets demonstrating the heterogeneous nature of different mutant platelets with 
respect to size, shape, granule and vacuole content. Arrows point at protrusions. Bars: 1 µm. DKO: 
RhoA-/-/Cdc42-/-; δ-G: dense granule; α-G: α-granule; EG: empty granules; PFG: partially filled 
granules; V: vacuoles. 
 
3.3.2. Combined deficiency of RhoA and Cdc42 results in defective 
hemostasis, but largely preserved thrombus formation in vivo 
Next, the effect of RhoA/Cdc42 deficiency on platelet function was assessed. Flow 
cytometric analysis of the surface expression of major platelet receptors revealed reduced 
expression of subunits of the GPIb-V-IX complex and of GPVI in RhoA-/-/Cdc42-/- platelets 





RhoA-/-/Cdc42-/- platelets displayed severe defects in integrin αIIbβ3 activation which were 
stronger than the reductions observed in RhoA and Cdc42 single KO platelets (Figure 36A, 
left panel). In particular, RhoA-/-/Cdc42-/- platelets (and Cdc42-/- platelets) were refractory 
especially to stimulation with the ITAM-specific agonists CRP and convulxin, which could, at 
least in part, be explained by the reduced expression of GPVI (Table 3-4 and Figure 36B) 
that has been demonstrated to be affect particularly platelet activation with CRP.158 
Remarkably, however, α-granule secretion was largely preserved in 
RhoA-/-/Cdc42-/- platelets, especially after stimulation of GPCRs, as demonstrated by flow 
cytometric analysis of degranulation-dependent P-selectin exposure (Figure 36A, right panel) 
and analysis of secreted platelet VWF and PF4 by ELISA systems (Figure 36C). These 
findings were particularly surprising because of the striking morphology of the 
RhoA-/-/Cdc42-/- platelets and the large number of mutant platelets virtually devoid of (α-) 
granules (Figure 34, Figure 35). Notably, the secretion defect downstream of G13 and Gq in 
RhoA-/- platelets112 was overcome by a concomitant loss of Cdc42 which has previously been 
demonstrated to negatively regulate platelet degranulation.113 Of note, 
RhoA-/-/Cdc42-/- platelets did not show any signs of preactivation under resting conditions or 
upon in vitro stimulation with the weak agonist epinephrine which can potentiate existing 
platelet activation157 (Figure 36). Taken together, these findings indicated the existence of 
both overlapping and distinct functions of RhoA and Cdc42 in platelet activation. 
 WT RhoA-/- Cdc42-/- RhoA-/-/Cdc42-/- 
GPIb 308 ± 17 271 ± 33 235 ± 13† 205 ± 6† 
GPV 202 ± 10 218 ± 2 168 ± 6* 170 ± 9* 
GPIX 344 ± 15 346 ± 28 279 ± 10† 252 ± 22† 
CD9 983 ± 28 910 ± 121 935 ± 18 925 ± 36 
GPVI 47 ± 3 54 ± 6 37 ± 3* 36 ± 6* 
CLEC-2 97 ± 9 104 ± 5 103 ± 3 107 ± 9 
α2 39 ± 1 40 ± 3 37 ± 1 38 ± 2 
β1 108 ± 5 116 ± 14 91 ± 1* 111 ± 7 
αIIbβ3 388 ± 28 441 ± 58 362 ± 32 344 ± 32 
Table 3-4. Analysis of surface expression of glycoproteins in WT, RhoA-/-, Cdc42-/- and 
RhoA-/-/Cdc42-/- platelets. Diluted whole blood was stained with saturating amounts of fluorophore-
labeled antibodies and platelets were analyzed by flow cytometry. Results express MFI ± SD (n = 4 
mice per group) and are representative of 3 independent experiments. Statistical analyses represent 







Figure 36. Markedly impaired integrin activation, but largely preserved α-granule release in 
RhoA-/-/Cdc42-/- platelets. (A) Flow cytometric analysis of activated integrin αIIbβ3 (binding of 
JON/A-PE) (left panel) and degranulation-dependent P-selectin exposure (right panel) upon 
stimulation with the indicated agonists in WT (black bars), RhoA-/- (white bars), Cdc42-/- (dark gray 
bars) and RhoA-/-/Cdc42-/- (light gray bars) platelets. Results are expressed as MFI ± SD (n = 4 mice 
per group) and are representative of 3 independent experiments. (B) Western blot analysis of total 
GPVI expression levels in WT, RhoA-/-, Cdc42-/- and RhoA-/-/Cdc42-/- platelets. GPIIIa levels served as 
loading control. Dividing lines denote gaps between different sections of the same membrane. Blots 
are representative of 2 independent experiments with n = 2-4 samples per genotype. (C) ELISA-
measurement of secreted PF4 and VWF in the supernatant of WT and RhoA-/-/Cdc42-/- platelets 
activated with 0.1 U/ml thrombin for 15 min. Results are expressed as MFI ± SD and are 
representative of 2 independent experiments with n = 4. U46, U-46619; A/U, ADP + U-46619; thr., 
thrombin; CVX, convulxin; CRP, collagen-related peptide; epin., epinephrine; PF4, platelet factor 4; 
RC, rhodocytin; VWF, von Willebrand factor. Statistical analyses represent comparison to WT 
platelets.*P < .05; **P < .01; ***P < .001. 
 To investigate the effects of RhoA/Cdc42 deficiency on platelet spreading, thrombin-
activated WT and RhoA-/-/Cdc42-/- platelets were allowed to spread on fibrinogen - a process 
dependent on integrin αIIbβ3 induced outside-in signaling for adhesion and cytoskeletal 
remodeling.16 Thrombin-activated RhoA-/-/Cdc42-/- platelets spread on fibrinogen to a similar 
extent and with similar kinetics to WT platelets (Figure 37) and were also able to centralize 
α-granules (data not shown). However, spread RhoA-/-/Cdc42-/- platelets were either devoid 
of or only exhibited disrupted marginal microtubule coils and a more diffuse F-actin pattern 
(Figure 35B, upper panel). Together, these results indicated that RhoA and Cdc42 are 
dispensable for spreading of platelets on fibrinogen, but both Rho GTPases are significantly 






Figure 37. Unaltered spreading of RhoA-/-/Cdc42-/- platelets on fibrinogen upon activation. 
Washed platelet from WT and RhoA-/-/Cdc42-/- mice were allowed to spread on immobilized human 
fibrinogen (100 µg/ml) after activation with 0.01 U/ml thrombin for the indicated time periods. (Upper 
panel) Statistical analysis of the percentage of platelets in the respective stage. (Lower panel) 
Representative differential interference contrast images of spread platelets. Results are representative 
of 2 independent experiments with n = 3 samples per genotype. Bar: 5 µm. 
 To assess the impact of RhoA/Cdc42 deficiency on hemostasis, tail bleeding times were 
determined (Figure 38A). RhoA-/-/Cdc42-/- mice displayed a severe hemostatic defect 
characterized by the inability to arrest bleeding within an observation period of 20 min (mean 
tail bleeding time in WT mice: 438 ± 224 sec). The hemostatic function in RhoA/Cdc42-
deficient mice was more severely affected than in the respective single KO mice,112,113 
demonstrating a functional redundancy of RhoA and Cdc42 in the formation and stabilization 
of a hemostatic plug. 
 Importantly, previous studies have shown that RhoA deficiency is associated with 
thrombus instability and resultant frequent embolization of occlusive thrombi, leading to a 
profound protection in models of arterial thrombosis,112 whereas loss of Cdc42 induces 
accelerated formation of occlusive thrombi.113 To examine the extent to which the above 
described defects influence thrombotic events in vivo, RhoA-/-/Cdc42-/- and WT mice were 
subjected to two models of occlusive arterial thrombus formation. In the first model, thrombus 
formation after injury of small mesenteric arterioles by FeCl3 was monitored by intravital 
fluorescence microscopy. Surprisingly, both the beginning of thrombus formation (data not 
shown) and the subsequent formation of stable occlusive thrombi followed similar kinetics in 
WT and RhoA-/-/Cdc42-/- mice (Figure 38B). In a second model of occlusive arterial 
thrombosis, the carotid artery – a medium-sized vessel in which moderate shear rates 
prevail - was injured by topical application of FeCl3. Unexpectedly, 63% of the 





occlusion time was significantly increased in these animals (RhoA-/-/Cdc42-/- mice: 
634 ± 144 s vs. 345 ± 106 s in WT mice; Figure 38C). These findings are in agreement with a 
previous report, demonstrating a significant increase in the mean occlusion times of the 
chemically injured carotid artery in mice in which platelet counts were reduced to 
200-299 platelets/nl (~20-30% of control).138 Importantly, platelet counts in 
RhoA-/-/Cdc42-/- mice, in which no occlusive thrombus formation was observed, were reduced 
to less than 20% of those in littermate controls simultaneously subjected to this model and 
thus close to the threshold platelet count required for occlusive thrombus formation to occur 
in the carotid artery.138 Therefore, a second group of RhoA-/-/Cdc42-/- mice received platelets 
from 2 donor RhoA-/-/Cdc42-/- mice each to reach platelet counts of ≥ 30% compared to WT 
controls. Notably, mean occlusion times in these animals did not significantly differ from 
those in littermate controls (RhoA-/-/Cdc42-/- mice transfused with RhoA-/-/Cdc42-/- platelets: 
415 ± 150 s vs. 345 ± 106 s in WT mice; Figure 38C). Collectively, these results 
demonstrated largely unaltered susceptibility of RhoA-/-/Cdc42-/- mice to arterial thrombosis 
models despite severely defective hemostasis and further emphasized divergent roles for 
platelet RhoA and Cdc42 in thrombosis and hemostasis. 
Figure 38. Defective hemostasis, but largely 
preserved thrombus formation in vivo in 
RhoA-/-/Cdc42-/- mice. (A) Infinite tail bleeding 
times in RhoA-/-/Cdc42-/- mice. Each symbol 
represents 1 animal. (B) Mesenteric arterioles 
were injured with 20% FeCl3 and thrombus 
formation of fluorescently labeled platelets was 
monitored in vivo by intravital fluorescence 
microscopy. Time to complete vessel occlusion 
(stable vessel occlusion for at least 1 min) is 
depicted. Each symbol represents 1 animal. (C) 
The right carotid artery of WT and 
RhoA-/-/Cdc42-/- mice was injured by topical 
application of 15% FeCl3 for 90 s and blood flow 
was monitored with a Doppler flow probe until 
complete vessel occlusion for at least 2 min, or 
for a maximum of 30 min. Each symbol 
represents 1 animal. White circles indicate 
occlusion times of RhoA-/-/Cdc42-/- mice which 
received platelets from 2 donor 
RhoA-/-/Cdc42-/- mice each to reach peripheral 
platelet counts of ≥ 30% of WT controls. 
**P < .01; ***P < .001; n.s., not significant. 
 
3.3.3. RhoA-/-/Cdc42-/- mice display reduced platelet life span, but unaltered 
platelet production upon platelet depletion 
In a next set of experiments, the effects of combined RhoA/Cdc42 deficiency on the rate of 
platelet clearance and platelet production were investigated. RhoA-/-/Cdc42-/- platelets 





considerably shorter than that of both RhoA-/- platelets and Cdc42-/- platelets (Figure 39A). 
Interestingly, platelet count recovery rates following anti-GPIbα antibody-mediated platelet 
depletion were similar in RhoA-/-/Cdc42-/- and WT mice, thus excluding a global defect in 
platelet production in RhoA-/-/Cdc42-/- mice (Figure 39B). Consistent with these findings, an in 
vitro proplatelet formation assay revealed unaltered numbers of proplatelet-forming MKs in 
cultures derived from fetal liver cells (FLCs) (Figure 39C) and these data were confirmed with 
in vitro cultured BM-derived MKs (data not shown). 
 
Figure 39. Rapid platelet clearance from the circulation, but unaltered platelet production upon 
platelet depletion in RhoA-/-/Cdc42-/- mice. (A) Life span of WT (black bars), RhoA-/- (white bars), 
Cdc42-/- (dark gray bars) and RhoA-/-/Cdc42-/- (light gray bars) platelets in the circulation was 
determined by flow cytometry by quantifying the percentage of fluorescently labeled GPIX+ platelets at 
the indicated time points after injection of a DyLight 488-conjugated anti-GPIX-derivative. Results are 
expressed as MFI ± SD and are representative of 3 independent experiments with n = 4 mice per 
genotype. (B) WT and RhoA-/-/Cdc42-/- mice were treated with a single bolus injection of platelet-
depleting anti-GPIbα-antibodies and peripheral platelet counts were measured at the indicated time 
points until initial values were reached. Results are expressed as MFI ± SD and are representative of 
2 independent experiments with n = 5 mice per genotype. (C) Determination of proplatelet formation in 
FLC-MK cultures (embryonic day 14.5, day 4 of culture). (Left panel) Each symbol represents the 
mean percentage of proplatelet-forming MKs per visual field (under 20-fold magnification of a light 
microscope) derived from 1 embryo. Visual fields (n ≥ 10) containing a minimum of 10 differentiated 
MKs without contact inhibition were analyzed and the mean percentage of proplatelet-forming MKs 
determined (n = 14 WT and n = 10 RhoA-/-/Cdc42-/- embryos from 4 females). (Right panel) 
Representative differential interference contrast images of proplatelet-forming MKs. Bar: 50 µm. 





3.3.4. RhoA/Cdc42 deficiency results in severely altered ultrastructure of 
bone-marrow megakaryocytes (BM MKs) 
Despite unaltered proplatelet production in vitro (Figure 39C), the observation that platelet 
counts were dramatically reduced in RhoA-/-/Cdc42-/- mice and the morphology of circulating 
platelets was severely altered implied the existence of functional defects in 
RhoA-/-/Cdc42-/- MKs in vivo. Therefore, maturation and ultrastructure of MKs in situ – i.e. in 
their natural microenvironment - were examined. 
 Hematoxylin and eosin-stained BM sections revealed increased numbers of BM MKs in 
Cdc42-/- and RhoA-/-/Cdc42-/- mice (Figure 40A-B). Importantly, however, it was difficult to 
unambiguously identify RhoA-/-/Cdc42-/- MKs in these sections because of altered 
morphology and decreased delineation from adjacent BM cells. To overcome this difficulty in 
analysis, RhoA-/-/Cdc42-/- MKs were visualized on cryosections stained with anti-GPIb 
antibodies. These analyses demonstrated a significant increase in BM MK numbers in the 
mutant mice (Figure 40C-D). Surprisingly, plasma Thpo levels, which are generally 
considered to be inversely related to platelet counts,159,160 were only slightly elevated (Figure 
40F), as measured by an ELISA system. Importantly, the ploidy of BM MKs was not affected 
by the combined deficiency of RhoA and Cdc42, thus ruling out a general defect in 
endomitosis in the absence of RhoA and Cdc42 (Figure 40E). 
To examine the morphology of BM MKs, sections of femora from WT, RhoA-/-, 
Cdc42-/- and RhoA-/-/Cdc42-/- mice were analyzed by TEM (Figure 41A). Mature WT and 
RhoA-/- MKs displayed unaltered ultrastructural morphology with clearly visible demarcation 
membrane system (DMS), a reservoir for future proplatelet and platelet membranes,100,101 
and a peripheral zone, demarcating the MKs from surrounding cells. Cdc42-/- MKs exhibited 
slightly reduced membrane invaginations. In marked contrast, RhoA-/-/Cdc42-/- MKs showed a 
severely altered appearance with no membrane invaginations, increased numbers of 
vacuoles and no demarcation from surrounding cells which, similarly to the analysis of 
hematoxylin and eosin-stained BM sections, made it difficult to unambiguously identify BM 
MKs (Figure 41A). Detailed TEM analysis of RhoA-/-/Cdc42-/- BM MKs revealed aberrant 
membrane development (Figure 41Biv), highly disordered DMS (Figure 41Bi, iii) and 
structures reminiscent of empty granules which did not display the opacity of normal granules 
(Figure 41Bii). Together, these data demonstrated impaired membrane development and 
proplatelet formation in the absence of RhoA and Cdc42 and revealed critical overlapping 






Figure 40. Increased BM MK numbers in RhoA-/-/Cdc42-/- mice. (A) Representative hematoxylin 
and eosin-stained BM sections of WT, RhoA-/-, Cdc42-/- 127 and RhoA-/-/Cdc42-/- mice. Arrowheads 
point at MKs. Bars: 50 µm. (B) Quantification of the number of BM MKs per visual field (328 x 246 µm) 
in WT (black bars), RhoA-/- (white bars), Cdc42-/- (dark gray bars) and RhoA-/-/Cdc42-/- (light gray bars) 
mice. Results are expressed as MFI ± SD (n = 7-8 mice per genotype). (C) Confocal images of 
immunostained BM of WT and RhoA-/-/Cdc42-/- femora. MKs, proplatelets and platelets were 
visualized by anti-GPIbα staining (green). Endothelial cells were labeled with an anti-CD105 antibody 
(red) and nuclei were counterstained with DAPI. Bars: 50 µm. (D) Quantification of the number of BM 
MKs per visual field in WT (black bars) and RhoA-/-/Cdc42-/- (light gray bars) mice. Results are 
expressed as MFI ± SD (n = 3 for WT and n = 7 for RhoA-/-/Cdc42-/- mice). (E) Functional endomitosis 
in RhoA-/-/Cdc42-/- mice. BM MK ploidy was assessed in whole BM single cell suspensions in situ (i.e. 
without further MK cultivation) by flow cytometry using an MK-/platelet-specific FITC-conjugated anti-
GPIIb/IIIa-antibody in combination with propidium iodide staining to determine DNA content. Results 
are expressed as MFI ± SD and are representative of 3 independent experiments with n = 4 mice per 
genotype. (F) Plasma thrombopoietin levels in WT and RhoA-/-/Cdc42-/- mice were determined by an 
ELISA system. Results are expressed as MFI ± SD (n = 4 per genotype). Statistical analyses 
represent comparison to WT platelets. **P < .01; ***P < .001; n.s., not significant. 
 The aberrant morphology and the absence of characteristic membrane invaginations in 
BM MKs raised the possibility that extramedullary hematopoiesis may occur in 
RhoA-/-/Cdc42-/- mice. The spleen is a major site of platelet clearance as part of the reticulo-
endothelial system, but may also contribute to platelet production in case of BM damage or 
dysfunction. Indeed, dramatically increased numbers of MKs forming clusters in the red pulp 
were identified in sections from spleens of RhoA-/-/Cdc42-/- mice, whereas splenic MK 





42). Of note, RhoA-/-/Cdc42-/- mice did not develop splenomegaly despite the marked 
increase in MK numbers in the spleen. 
 
Figure 41. RhoA-/-/Cdc42-/- BM MKs display severely altered ultrastructure. (A) TEM analysis of 
BM MKs. (Upper panel) Overview. Bars: 5 µm. (Lower panel) Detailed view. Bars: 1 µm. Note loss of 
delineation to adjacent cells, aberrant DMS and increased vacuole numbers in RhoA-/-/Cdc42-/- BM 
MKs. Cdc42-/- MK images from Pleines et al.127 (B) Representative detailed images of different 
RhoA-/-/Cdc42-/- BM MKs. Bars: 1 µm. DMS: demarcation membrane system; N: nucleus; PFG: 
partially filled granules; PZ: peripheral zone; V: vacuoles. 
 
Figure 42. Increased numbers of splenic MKs in RhoA-/-/Cdc42-/- mice. (A) Representative 
hematoxylin and eosin-stained sections of the spleen of WT and RhoA-/-/Cdc42-/- mice. Arrowheads 
point at MKs. Bars: 50 µm. (B) Quantification of the number of BM MKs per visual field (328 x 246 µm) 
in WT (black bars), RhoA-/- (white bars), Cdc42-/- (dark gray bars) and RhoA-/-/Cdc42-/- (light gray bars) 
mice. Results are expressed as MFI ± SD (n = 7-8 mice per genotype). Statistical analyses represent 






3.3.5. Accelerated clearance of circulating platelets significantly 
contributes to the severe thrombocytopenia in RhoA-/-/Cdc42-/- mice 
The significant elevation of MK numbers in the spleen suggested that the MKs residing there 
may be actively involved in thrombopoiesis. To test this directly, WT and 
RhoA-/-/Cdc42-/- mice (Figure 43A) were splenectomized and platelet count and size were 
subsequently monitored by flow cytometry (Figure 43B-C). Peripheral platelet counts slightly 
increased, whereas a mild reduction in platelet size was observed in WT mice, but otherwise 
splenectomy had no effect on platelet morphology (Figure 43B-C). Of note, splenectomy had 
no long-term effect on platelet counts, but the size of circulating platelets increased even 
further in RhoA-/-/Cdc42-/- mice (Figure 43B-D). Resting RhoA-/-/Cdc42-/- platelets still 
displayed a distinct appearance characterized by a predominantly roundish shape and large 
vacuoles (Figure 43D). However, TEM analysis revealed the presence of a few discoid-
shaped platelets with normal granule content and distribution (Figure 43D). 
Figure 43. Splenectomy does not ameliorate the severe macrothrombocytopenia observed in 
RhoA-/-/Cdc42-/- mice. (A) Western blot analysis demonstrating absence of RhoA and Cdc42 in 
platelets from splenectomized MK-/platelet-specific RhoA/Cdc42-deficient mice. GAPDH expression 
was used as loading control. Peripheral platelet counts (B) and relative platelet size (C) of WT (black 
bars), and RhoA-/-/Cdc42-/- (light gray bars) mice were determined by flow cytometry at the indicated 
time points after splenectomy. Values were normalized to WT levels which were set to 100%. Results 
are expressed as MFI ± SD (n = 4 mice per group). (D) TEM analysis of resting WT and 
RhoA-/-/Cdc42-/- platelets isolated on d 29 after splenectomy. Bars: 1 µm. δ-G: dense granule; α-G: 





 Subsequently, circulating platelets were characterized with respect to surface 
glycoprotein expression and functional responses upon stimulation with different agonists. 
Expression levels of several prominent platelet surface receptors were slightly increased in 
RhoA-/-/Cdc42-/- platelets which was, however, probably due to the significantly increased 
platelet size in splenectomized RhoA-/-/Cdc42-/- mice (Table 3-5).  
 WT RhoA-/-/Cdc42-/- 
GPIb 241 ± 8 227 ± 13 
GPV 238 ± 11 272 ± 16* 
GPIX 345 ± 6 370 ± 17 
CD9 940 ± 12 1235 ± 106* 
GPVI 48 ± 1 40 ± 2‡ 
CLEC-2 132 ± 6 164 ± 5‡ 
α2 40 ± 3 46 ± 2* 
β1 98 ± 3 138 ± 12† 
αIIbβ3 384 ± 9 476 ± 39* 
Table 3-5. Analysis of surface expression of glycoproteins in WT and RhoA-/-/Cdc42-/- platelets 
in splenectomized mice. Diluted whole blood was collected from WT and RhoA-/-/Cdc42-/- mice 7 d 
after splenectomy and stained with saturating amounts of fluorophore-labeled antibodies. Platelets 
were analyzed by flow cytometry. Results express MFI ± SD (n = 4 mice per group) and were 
reproduced also at later time points after splenectomy (d 29 after surgery). * P < .05; † P < .01; 
‡ P < .001. 
 Importantly, splenectomy essentially ameliorated defective integrin αIIbβ3 activation, 
specifically upon activation with GPCR-specific agonists (Figure 44A, left panel). 
Surprisingly, circulating platelets in RhoA-/-/Cdc42-/- mice displayed an overall increase in 
degranulation-dependent α-granule release, as demonstrated by analysis of P-selectin 
exposure by flow cytometry (Figure 44A, right panel). Removal of the spleen considerably 
improved the life span of RhoA-/-/Cdc42-/- platelets (Figure 44B), but had no effects on the 
severe bleeding diathesis (Figure 44C). Collectively, these results indicated that splenectomy 
significantly altered both morphology and functionality of RhoA-/-/Cdc42-/- platelets ex vivo, 
but this treatment did not yield any significant improvement of platelet counts or hemostatic 
function in the mutant mice. 
In a final set of experiments, the effect of splenectomy on MK morphology was examined 
by TEM. Removal of the spleen did not have any major influence on BM MK development in 
WT mice (Figure 45i). Although the ultrastructure of a few RhoA-/-/Cdc42-/- MKs was still 
characterized by absence of DMS and granules and by an increased number of vacuoles 
(Figure 45ii), several RhoA-/-/Cdc42-/- BM MKs displayed key features of mature MKs, 
including clearly defined peripheral zone and membrane invaginations and normal 





of terminally differentiated MKs in the process of proplatelet release in splenectomized 
RhoA-/-/Cdc42-/- mice (Figure 45iv). These findings were in accordance with the partially 
restrored morphology of circulating RhoA-/-/Cdc42-/- platelets after spleen removal. 
Figure 44. Splenectomy is associated with reduced platelet clearance, but does not ameliorate 
defective hemostatic function in RhoA-/-/Cdc42-/- mice. (A) Flow cytometric analysis of activated 
integrin αIIbβ3 (binding of JON/A-PE) (left panel) and degranulation-dependent P-selectin exposure 
(right panel) upon stimulation with the indicated agonists in WT (black bars) and RhoA-/-/Cdc42-/- (light 
gray bars) platelets. Results are expressed as MFI ± SD (n = 4 mice per group). Experiments were 
carried out on d 29 after splenectomy. (B) Life span of WT (black bars) and RhoA-/-/Cdc42-/- (light gray 
bars) platelets in the circulation was determined by quantifying the percentage of fluorescently labeled 
GPIX+ platelets at the indicated time points after injection of a DyLight 488-conjugated anti-GPIX-
derivative by flow cytometry. Results are expressed as MFI ± SD (n = 4 mice per group). Experiments 
started on d 14 after splenectomy. (C) Tail bleeding times in splenectomized WT and 
RhoA-/-/Cdc42-/- mice on d 7 after surgery. Each symbol represents 1 animal. *P < .05; **P < .01; 
***P < .001. 
 
Figure 45. Splenectomy partially rescues ultrastructural defects of BM MKs in 
RhoA-/-/Cdc42-/- mice. TEM analysis of BM MKs of splenectomized WT and RhoA-/-/Cdc42-/- mice on 
d 29 after surgery. Bars: 2.5 µm. Note proplatelet formation and release (arrows) and presence of 
granules in RhoA-/-/Cdc42-/- BM MKs. DMS: demarcation membrane system; N: nucleus; G: granules 





 To further elucidate the mechanisms underlying rapid clearance of circulating platelets in 
RhoA-/-/Cdc42-/- mice, macrophages were selectively depleted in mutant and WT mice by 
clodronate treatment. Macrophage depletion led to a two-fold increase in peripheral platelet 
counts in RhoA-/-/Cdc42-/- mice compared to vehicle-treated littermate mutant mice which was 
accompanied by a significant reduction in platelet size (Figure 46A-B). These results 
suggested that the severe thrombocytopenia in RhoA-/-/Cdc42-/- mice was, at least partially, 
dependent on accelerated platelet clearing by macrophages. 
 
Figure 46. Macrophage depletion slightly ameliorates the severe macrothrombocytopenia in 
RhoA-/-/Cdc42-/- mice. Peripheral platelet counts (A) and size (B) were monitored over time after 
clodronate-encapsulated liposome-mediated macrophage depletion in WT and RhoA-/-/Cdc42-/- mice 
by flow cytometry. Values for platelet counts were normalized to WT control levels (WT mice treated 
with PBS liposomes) which were set to 100%. Values for platelet size were normalized to WT levels 
(WT mice treated with clodronate-liposomes) which were set to 100%. Results are expressed as 
MFI ± SD (n = 4-6 mice per group) and are representative of 2 independent experiments. Statistical 
significance solely indicates differences in clodronate-treated vs. vehicle-treated RhoA-/-/Cdc42-/- mice. 
*P < .05; **P < .01; ***P < .001; n.s., not significant. 
 Together, the results summarized in this part of the thesis indicated that RhoA and Cdc42 
cooperatively control final steps of megakaryopoiesis and platelet hemostatic functions. 
However, both GTPases play opposing roles in the control of platelet degranulation and 







Platelets fulfill a vital function in hemostasis, as they form a hemostatic plug to stop 
posttraumatic blood loss. The platelet activation process at sites of vascular injury needs to 
be tightly controlled, since excessive platelet reactivity in the setting of pathological thrombus 
formation may lead to life-threatening vessel occlusion. Currently available treatment options 
in acute ischemic disease states are limited and antiplatelet agents are contraindicative in 
many cases because of increased incidence of bleeding complications that often outweighs 
therapeutic benefits. The adverse effects of clinically used platelet inhibitors on primary 
hemostasis emphasize the necessity to identify and characterize novel pharmacological 
targets for antiplatelet drugs with a powerful, yet safe antithrombotic profile. 
 In recent years, several major platelet surface receptors, including the (hem)ITAM-
bearing receptors GPVI and CLEC-2, have been identified as critical regulators of platelet 
adhesion and activation and have emerged as promising novel targets in antiplatelet drug 
design due to their role in the initiation of thrombotic and thrombo-inflammatory signaling 
cascades. However, the role of GPVI and CLEC-2 is not restricted to their involvement in 
thrombosis and primary hemostasis. The past decade has witnessed significant progress in 
our understanding of the role of both platelet receptors in a plethora of (patho)physiological 
processes, including inflammation, atherosclerosis, lymphatic vessel development and tumor 
progression.30,53,54 This knowledge raises awareness about the possibility of severe side-
effects of therapeutic agents interfering with the (hem)ITAM signaling pathway. Furthermore, 
recent findings underscore the demand to better characterize the mechanisms by which 
platelet receptor signaling governs the initiation and progression of complex thrombotic and 
thrombo-inflammatory disease states. 
 Powerful platelet activation eventually culminates in substantial cytoskeletal 
rearrangements and secretion from α- and dense granules – processes that are strictly 
controlled by Rho GTPases, most notably RhoA, Cdc42 and Rac1. The tight regulation of the 
actin cytoskeleton, microtubule dynamics and degranulation is essential for maintenance of 
intact platelet function in hemostasis. In addition, cytoskeletal rearrangements are pivotal 
during critical steps of MK maturation which precede platelet generation. Therefore, there is 
an increasing demand to further investigate the contribution of Rho GTPases in the 







4.1. SLAP/SLAP2 prevent excessive platelet (hem)ITAM signaling in arterial 
thrombosis and ischemic stroke in mice 
The results presented in the first part of this thesis establish SLAP and SLAP2 as negative 
regulators of surface expression and signaling of the ITAM receptor GPVI and the hemITAM 
receptor CLEC-2 in mouse platelets. However, single deficiency of either adapter protein had 
only a minor effect on platelet (hem)ITAM signaling (Figure 7, Figure 8), whereas the 
combined loss of SLAP and SLAP2 resulted in a marked platelet hyperreactivity to 
(hem)ITAM-coupled agonists in vitro (Figure 9, Figure 10). This powerful cellular activation 
translated into a significant prothrombotic phenotype (Figure 19) and dramatically increased 
susceptibility to focal cerebral ischemia in vivo (Figure 21). The results clearly demonstrate a 
functional redundancy of the two adapter proteins in the regulation of platelet (hem)ITAM 
signaling and reveal a crucial function of SLAP and SLAP2 in the control of thrombotic and 
thrombo-inflammatory events. 
Involvement of SLAP in the regulation of surface expression levels of ITAM-coupled 
immune cell receptors, such as the TCR and BCR, is well-established.75 In vivo studies have 
demonstrated an important role for SLAP in regulating TCR expression during a specific T 
lymphocyte developmental stage (CD4+CD8+) at which repertoire selection takes place.86 
Similarly, SLAP is required for the fine-tuning of BCR levels and signal strength during B cell 
development.87 Importantly, increased GPVI receptor density did not significantly contribute 
to the marked hyperreactivity, as overshooting ITAM signaling was observed also in 
SLAP/SLAP2 deficient Gp6+/- platelets which express lower GPVI surface levels than WT 
control platelets (Figure 11). The experimental data summarized in this study suggest that 
the mechanism by which GPVI signaling is inhibited by SLAP proteins involves, at least in 
part, competition with Src family kinases (SFKs) for binding to the GPVI/FcRγ signaling 
complex. In support of this model, immunoprecipitations of the SFK Lyn contained 
substantially more GPVI in activated platelets in the absence of SLAP/SLAP2 (Figure 13) 
and tyrosine phosphorylation of downstream signaling proteins was also elevated (Figure 
12). Collectively, these results establish SLAP/SLAP2 as negative regulators of ITAM 
signaling in platelets, presumably through competition with Lyn for binding to the GPVI 
cytosolic tail. 
These results further implicate the existence of an important naturally occurring 
mechanism to dampen ITAM signaling in platelets to prevent excessive thrombotic activity 
which critically depends on the involvement of SLAP and SLAP2 and likely involves other 
adapter proteins. This assumption is supported by studies in mouse platelets lacking c-Cbl, 
an adapter protein that promotes protein ubiquitination, which showed increased aggregation 





tyrosine phosphorylation of the FcRγ-chain, Syk, LAT and PLCγ2.161 c-Cbl has been 
demonstrated to function as an E3 ligase mainly for activated protein tyrosine kinases of the 
Src and Syk family162 and has been associated with Syk ubiquitination in platelets.163 Given 
the fact that c-Cbl and SLAP function in intersecting biochemical pathways in immune cells, 
and their cooperation in a SLAP/c-Cbl complex mediating ubiquitination-dependent down-
regulation of TCR and BCR levels is well-established,74,81,82 it is tempting to speculate that 
interactions between members of both families of adapter proteins also exist in platelets and 
may be crucial for dampening of ITAM signaling. This inhibitory pathway functionally opposes 
another group of adapter proteins, including LAT, SLP-76, Grb2 and Gads, which are 
involved in the signal transduction cascade downstream of Syk and support platelet 
activation in vitro and in vivo.147,164-167 
SLAP/SLAP2 also powerfully inhibit signaling downstream of the second (hem)ITAM-
bearing receptor in mouse platelets CLEC-2 (Figure 14). Surprisingly, SLAP/SLAP2 
deficiency resulted in LAT-independent enhanced PLCγ2 phosphorylation upon CLEC-2 
stimulation (Figure 15) which demonstrates that SLAP/SLAP2 likely interfere with proximal 
molecules in the hemITAM signaling pathway. Although the exact molecular mechanisms 
remain elusive, SLAP/SLAP2 appear to attenuate the CLEC-2 signaling cascade by tight 
regulation of the signal strength required for the phosphorylation and activation of key 
effector molecules, including PLCγ2. Consequently, deficiency of both proteins substantially 
lowers the threshold47,147 necessary for powerful cellular activation to occur. Modulation of 
CLEC-2 signaling by SLAP and SLAP2 may therefore have a major physiological 
significance in other processes beyond the obvious implications in thrombosis and 
hemostasis, but this assumption clearly needs further experimental proof. 
 Another set of experiments demonstrated that SLAP/SLAP2 significantly contribute to 
dampening collagen-induced procoagulant activity in platelets and ensuing thrombin 
generation (Figure 16, Figure 17, Figure 18). These results are in line with earlier studies 
indicating that key components of the GPVI/ITAM signaling cascade, including the 
FcRγ−chain, LAT, Syk and PLCγ2, as well as GPVI-induced increase in cytosolic Ca2+ 
concentration, are critically involved in collagen-dependent PS exposure.14,139,149 Increasing 
evidence suggests that platelet procoagulant activity, in particular by propagation of the 
contact phase of coagulation, plays an important role in initiating arterial thrombus 
formation.168 In agreement with their critical function for inhibiting PS exposure and thrombin 
generation in vitro, SLAP and SLAP2 are essential to prevent overshooting thrombotic and 
thrombo-inflammatory processes in vivo (Figure 19, Figure 21, Figure 22). 
Although the exact mechanisms by which platelets contribute to the development of brain 





ischemic stroke does not solely result from local thrombotic vessel occlusion. In fact, 
ischemic stroke has been increasingly recognized as a complex disease in which platelets 
orchestrate multiple molecular and cellular interactions, involving immune cells, endothelial 
cells and the contact activation system, finally leading to disruption of the blood-brain barrier 
and neurological damage.12,169 Importantly, recent studies on the involvement of platelet-
receptor interactions in acute experimental stroke have surprisingly demonstrated that 
interference with early steps of platelet adhesion and activation, but notably not aggregation, 
significantly reduces secondary infarct growth without adverse effects on intracerebral 
bleeding.32 Unexpectedly, inhibition of final steps of platelet aggregation via blockade of 
GPIIb/IIIa was associated with increased mortality due to intracranial hemorrhage in mice32 
and humans.170,171 By contrast, the importance of initial platelet adhesion and activation steps 
involving the GPIb-VWF axis in the progression of ischemic stroke is now well-
established.30,32,172-174 Likewise, GPVI also appears to play a crucial role in the 
pathophysiology of acute stroke, as shown by profound protection of GPVI-depleted mice in 
the tMCAO model of ischemic stroke32 and indirect evidence indicating increased GPVI 
activity in acute stroke patients.175,176 The mechanisms by which GPVI promotes stroke 
progression remain elusive. As demonstrated in other experimental models of disease, such 
as rheumatoid arthritis, GPVI triggers microparticle formation and thus promotes the release 
of pro-inflammatory cytokines, including IL-1α,34 which has been demonstrated to contribute 
to inflammation-mediated brain injury.177 Thus, GPVI likely initiates a thrombo-inflammatory 
signaling cascade in acute ischemic stroke. The findings in Slap-/-/Slap2-/- mice further 
corroborate the hypothesis that GPVI/ITAM-mediated activation processes are of central 
importance during stroke development.  
Ischemic stroke triggers a profound local inflammatory reaction characterized by the 
recruitment of different immune cell types. Importantly, previously neglected players in stroke 
progression – T cells – have been recently identified as essential pathogenic factors in early 
experimental stroke development.152-154 The use of constitutive SLAP/SLAP2-deficient mice 
in the initial stroke experiments (Figure 21) raised the possibility that the observed phenotype 
may at least partially depend on altered T cell activity. Due to the lack of conditional SLAP or 
SLAP2 knockout mice, an adoptive platelet transfer approach was developed which 
unambiguously attributed the detrimental role of SLAP/SLAP2 in ischemic stroke to their 
expression in platelets (Figure 22). Of note, the exact mechanisms by which SLAP/SLAP2 
prevent excessive GPVI activation remain elusive and probably at least partially differ from 
those involved in classical thrombus formation. Further studies on the involvement of 
SLAP/SLAP2 in the control of platelet interactions with immune and/or endothelial cells and 





Together, these data emphasize a central role of GPVI in the course of acute ischemic 
disease states and thereby establish modulators of GPVI activity, such as SLAP/SLAP2, as 
central factors in the pathology of atherothrombosis and ischemic stroke. 
 
4.2. Antibody-induced GPVI down-regulation is associated with prolonged 
severe thrombocytopenia in Slap-/-/Slap2-/- mice 
GPVI has emerged as an attractive potential target for antithrombotic therapy, as its 
blockade, antibody-induced depletion, competitive inhibition or genetic deficiency provided 
powerful protection from experimental arterial thrombosis without affecting platelet 
hemostatic functions.13,38,151,155 However, the mechanisms by which the targeted down-
regulation of GPVI occurs in vivo are still incompletely understood and require further 
characterization. Because SLAP and SLAP2 are involved in the control of internalization and 
degradation of ITAM-containing receptor complexes on immune cells, especially TCR and 
BCR, it was hypothesized that SLAP family members may also be involved in the antibody-
induced endocytosis of the GPVI/FcRγ receptor complex. The results summarized in the 
second part of this thesis demonstrated that SLAP and SLAP2 are dispensable for GPVI 
down-regulation following administration of the monoclonal antibody JAQ1 (Figure 24). 
Unexpectedly, treatment of Slap-/-/Slap2-/- mice with JAQ1 induced sustained severe 
thrombocytopenia (Figure 25, Figure 26). Importantly, administration of F(ab’)2 fragments 
induced thrombocytopenia in Slap-/-/Slap2-/- mice, but notably, not in WT animals, with the 
same intensity as the intact IgG (Figure 27). F(ab’)2 antibody fragments lack the Fc-part and 
thus exert their effects in an Fc-independent fashion. The results suggested that FcγR-
bearing cells in the reticulo-endothelial system are not primarily involved in anti-GPVI-
induced platelet destruction in Slap-/-/Slap2-/- mice. 
Importantly, JAQ1 triggered sustained and irreversible aggregation of 
Slap-/-/Slap2-/- platelets (Figure 28). Of note, binding of JAQ1 to GPVI in WT platelets has 
been shown to induce subliminal signaling associated with phosphorylation of Syk and 
PLCγ2 which only slightly exceeds basal phosphorylation of both proteins and is not sufficient 
to induce powerful cellular activation.178 Aggregation of WT platelets can be mediated only 
upon cross-linking of surface-bound JAQ1 by an anti-rat IgG secondary antibody.22,157 
The proline-rich region (PRR) in the cytosolic part of GPVI mediates binding of the SFKs 
Lyn and Fyn.25,26 Lyn is required for the rapid platelet activation upon ligand engagement of 
GPVI.27,179 Interestingly, a recent study demonstrated that GPVI-bound Lyn is held in the 
active state.27 Still, it remains enigmatic how GPVI is constitutively associated with active Lyn 





to the cell membrane which enables GPVI to keep activated Lyn in close proximity of the 
FcRγ-chain, but prevents initiation of signal transduction in the absence of a strong 
stimulus.27 Importantly, functional cooperation between Lck-bound PRR on CD3ε and SLAP 
have been implicated in the control of TCR expression levels during the CD4+CD8+ stage of 
thymocyte development.180 SLAP/SLAP2 deficiency enhanced interactions of Lyn and 
activated GPVI (Figure 13). It is conceivable that SLAP proteins compete with Lyn for binding 
to the GPVI/FcRγ complex and lack of SLAP/SLAP2 presumably alters Lyn activation state 
and localization and facilitates the SFK-dependent initiation of powerful cellular activation 
even upon binding of a weak GPVI activating agent, such as JAQ1. 
 In mice, JAQ1-induced GPVI down-regulation is thought to occur through two principal 
mechanisms – ectodomain shedding, leading to the generation of soluble GPVI, and 
internalization.39,41,42 Both mechanisms require intact signaling via the ITAM on the 
FcRγ-chain.41 Recent findings suggest that GPVI immunodepletion is not an entirely cell-
autonomous process and imply that cell types other than platelets are involved in the 
removal of the receptor from the cell surface and the concomitantly occurring transient 
thrombocytopenia (Ref.39,41,42 and David Stegner, unpublished). Antibody-opsonized platelets 
become temporarily sequestered to the liver and spleen where the actual loss of the receptor 
takes place (Ref.39 and David Stegner, unpublished). In contrast to WT platelets, 
Slap-/-/Slap2-/- platelets became activated upon JAQ1-binding and were immediately removed 
from the circulation. JAQ1 was detectable in the circulation for up to 10-14 days upon a 
single bolus injection of the antibody (Figure 28) and antibody concentration of 1-2 µg/ml 
were still sufficient to induce thrombocytopenia in SLAP/SLAP2-deficient mice (data not 
shown). Interestingly, similar pharmacokinetics and long-term unresponsiveness of 
circulating platelets to collagen were observed in cynomolgus monkeys treated with an 
anti-GPVI antibody purified from the plasma of a patient with auto-anti-GPVI antibodies.43 
Importantly, JAQ1 did not affect the ability of MKs to produce platelets in vitro and in vivo 
(data not shown). Taken together, these results support the hypothesis that powerful cellular 
activation and subsequent clearance of activated platelets from the circulation is the 
predominant mechanism by which the sustained thrombocytopenia in Slap-/-/Slap2-/- mice 
occurs. Importantly, it cannot be ruled out that JAQ1 treatment and the ensuing persistent 
thrombocytopenia affect the function of FcRγ-bearing immune and endothelial cells which 
could further contribute to enhanced removal of circulating platelets, but this hypothesis 
needs to be tested by additional studies. 
Remarkably, the phenomenon of prolonged severe thrombocytopenia was specific for 
antibody-induced GPVI down-regulation, as peripheral platelet counts returned with similar 





GPIbα (which induces Fc-independent thrombocytopenia)130 or GPIIb/IIIa(which induces Fc-
dependent thrombocytopenia)130 (Figure 29 and data not shown). Mechanistically, the JAQ1-
induced thrombocytopenia occurred in a Syk-dependent manner (Figure 31). By contrast, 
transient thrombocytopenia was observed in LAT-deficient Slap-/-/Slap2-/- mice (Figure 30). 
Notably, downstream signaling and PLCγ2 phosphorylation were partially preserved in LAT-
deficient Slap-/-/Slap2-/- platelets (Figure 15), but not in Syk-deficient Slap-/-/Slap2-/- platelets 
(data not shown) following GPVI activation, demonstrating that intact signaling downstream 
of GPVI is required for the JAQ1-induced thrombocytopenia to occur in 
Slap-/-/Slap2-/- platelets. However, GPVI down-regulation via receptor internalization still 
occurred in Syk-deficient Slap-/-/Slap2-/- platelets (Figure 32, Figure 33), albeit with slower 
kinetics than in WT platelets. Firstly, these findings demonstrate that Syk-independent GPVI 
internalization still occurs, although platelets are completely refractory to GPVI stimulation. 
Secondly, the critical signaling event during targeted down-regulation of GPVI presumably 
takes place further upstream of Syk, probably at the level of SFKs, as demonstrated for other 
(hem)ITAM-bearing receptors, including TCR and CLEC-2, for which SFKs, but not Syk 
family kinase members, are needed to down-regulate the respective (hem)ITAM-containing 
receptor.59,81 
Interactions between SLAP/SLAP2 and Syk have been extensively studied in T and B 
cells. SLAP has been demonstrated to associate with the Syk family kinases ZAP-70 and 
Syk upon TCR activation.79 Furthermore, co-expression of SLAP-2 and Syk or ZAP-70 
induces the down-regulation of the kinase.73,74 Functional cooperation between SLAP and 
ZAP-70 during thymocyte development has been shown to ensure that only cells with intact 
TCR signaling can survive in the periphery.86 Similar mechanisms may apply to platelets in 
which SLAP is required to dampen Syk activity and prevent excessive GPVI signaling in 
different settings. 
Collectively, these data emphasize the importance of evaluating the expression and 
function of proteins which modulate key steps of the GPVI signaling cascade prior to and 
during targeted down-regulation. This may help to avoid undesired side-effects of anti-GPVI 
treatment related to antibody-induced severe thrombocytopenia. 
 
4.3. RhoA and Cdc42 have both distinct and overlapping functions in 
platelet production and action 
Constitutive deficiency of RhoA, Cdc42 and Rac1 in mice resulted in early embryonic lethality 
which hampered studies in primary knockout cells.109,181,182 Meanwhile, the lethal phenotype 





ubiquitously expressed Rho GTPases without the danger of off-target effects related to the 
use of inhibitors, overexpression or knockdown approaches. Despite the new avenues which 
the conditional knockout systems have opened, little is known about specific functions of Rho 
GTPases during MK maturation and platelet generation. In this thesis, the role of the Rho 
GTPases RhoA and Cdc42 in platelet production and function has been investigated using 
conditional MK-/platelet-specific single- and double-deficient mice (Cre/loxP system). 
 The significantly decreased peripheral platelet counts in RhoA112 and Cdc42113 single 
deficient mice implicated important roles of both proteins in platelet production. Not 
surprisingly, double deficiency of RhoA and Cdc42 led to a further decrease in peripheral 
platelet counts (Figure 34). Importantly, thrombocytopenia in these mice was accompanied 
by a significant increase in platelet size and severely altered ultrastructure, characterized by 
a heterogeneous cell population with increased vacuole numbers and varying granule 
content (Figure 34, Figure 35). Of note, subcellular morphology and granule distribution were 
preserved in the single deficient platelets (Figure 34 and Pleines et al., 2010,113 2012112). 
Unexpectedly, RhoA/Cdc42-deficient platelets were still largely functional in different 
experimental settings in vitro and in vivo (Figure 36, Figure 37, Figure 38B, C). Remarkably, 
RhoA-/-/Cdc42-/- platelets were capable of granule secretion and concomitant deficiency of 
Cdc42 even compensated for the degranulation defect in RhoA-/- platelets after Gq/13 
stimulation (Figure 36). RhoA likely facilitates degranulation, whereas Cdc42 appears to 
inhibit granule secretion in platelets, indicating that both GTPases may play opposing roles in 
exocytosis in platelets. However, the mechanisms by which Rho GTPases regulate 
exocytosis remain elusive and may be cell type-specific.183 For instance, Cdc42 positively 
regulates exocytosis in tumor cells,184 but reduces insulin secretion in pancreatic β-cells.185 
Central to the involvement of Rho GTPases in facilitating or inhibiting secretion processes is 
their role in the control of associations between the exocyst complex and IQGAP1.183 
IQGAP1 is a scaffold protein which has been established as a major regulator of actin 
dynamics and tubulin multimerization.186,187 Importantly, Rac1/Cdc42-deficient MKs displayed 
decreased IQGAP1 expression,127 whereas RhoA-/-/Cdc42-/- MKs exhibited unaltered 
IQGAP1 expression compared to WT MKs (data not shown), suggesting that Rac1 and RhoA 
may differentially regulate IQGAP1 expression in the absence of Cdc42 in mature MKs, but 
clearly, exact mechanisms remain to be investigated. 
 Importantly, the largely unaltered α-granule release in RhoA/Cdc42-deficient platelets in 
vitro translated into preserved occlusive arterial thrombus formation in vivo (Figure 38B, C), 
despite severe thrombocytopenia (Table 3-3 and Figure 34B). This represents a further 
important difference between RhoA/Cdc42 double deficiency and combined Rac1/Cdc42 
deficiency which was associated with a profound protection in a model of arterial 





arterial thrombus formation. Notably, RhoA-/-/Cdc42-/- platelets displayed severely impaired 
hemostatic functions (Figure 38A). These findings implied that the formation of a hemostatic 
plug which prevents excessive blood loss and the formation of an occlusive thrombus may 
follow different mechanisms in the absence of RhoA and Cdc42. Furthermore, these data 
demonstrated overlapping functions of RhoA and Cdc42 in the maintenance of intact 
hemostasis and non-redundant roles in the development of pathological vessel occlusion. 
 RhoA/Cdc42-deficient proplatelets and platelets exhibited a profound defect in 
microtubule organization (Figure 35A, B). Microtubules are essentially involved in the 
transport of granules and organelles to the proplatelets104 and in the determination of final 
platelet size in the blood.188 Importantly, platelets isolated from mice lacking the 
hematopoietic-specific β1 tubulin isoform were characterized by reduced microtubule coils in 
the marginal band despite compensatory overexpression of two alternative tubulin 
isoforms -  β2 and β5.189 Furthermore, β1 tubulin-deficient mice suffered from 
thrombocytopenia due to defective proplatelet generation and platelets did not display the 
characteristic discoid shape.189 Likewise, common downstream effector molecules of RhoA 
and Cdc42, such as the formin protein mDia1, are critically involved in the regulation of 
tubulin stabilization.190 Only recently, it has been demonstrated that mDia1 knockdown 
mediates increased proplatelet production and reduced stress fiber formation.191 Conversely, 
expression of constitutively active mDia1 inhibited proplatelet formation and overexpression 
of mDia1 induced loss of microtubule stability.191 Similar to the phenotype observed in 
RhoA/Cdc42-deficient proplatelet-forming MKs (Figure 35B), proplatelet tips of 
Rac1-/-/Cdc42-/- MKs were virtually devoid of tubulin, but interestingly, Rac1/Cdc42-deficient 
platelets displayed increased microtubule coil numbers.127 Collectively, increasing 
experimental evidence suggests that besides the well-documented role of Rho GTPases in 
actin remodeling and stress fiber formation, converging pathways downstream of RhoA, 
Cdc42 and Rac1 which involve key effector molecules, such as mDia1, have a major 
contribution to the stabilization of microtubules in MKs and platelets. Clearly, the cross-talk 
between Rho GTPases, effector molecules and critical modulators of their activity needs to 
be better characterized in the course of future studies. 
 RhoA/Cdc42 deficiency was associated with markedly altered morphology of BM MKs 
(Figure 41). Single deficiency of RhoA or Cdc42 had no or only minor alterations in the 
ultrastructure, suggesting that RhoA and Cdc42 have redundant functions in the regulation of 
MK morphology, granule distribution and development of DMS or compensatory mechanisms 
circumvent the mutation. Indeed, little is known about the specific roles of RhoA and Cdc42 
during late steps of megakaryopoiesis. It has been suggested that Cdc42 may positively 
regulate proplatelet formation during late MK maturation.99 Importantly, the DMS was dilated 





2013127). A more direct piece of evidence for this assumption came from a study in GPIbβ-
deficient mice.192 Of note, Cdc42 has been demonstrated to be a key regulator of filopodia 
formation downstream of the VWF-GPIb axis in platelets.113 GPIbb-/- MKs displayed larger 
proplatelet territories which resembles the phenotype of Cdc42-deficient MKs.127,192 In 
addition, GPIbβ deficiency was associated with reduced proplatelet formation in vitro, 
elevated BM MKs counts in vivo and numbers of microtubule coils in the marginal band of 
circulating platelets were increased.192 By contrast, several studies suggested that RhoA 
inhibits proplatelet formation, presumably by two independent signaling cascades: the above 
mentioned RhoA/mDia1 pathway191 and the RhoA/ROCK/myosin IIA pathway which has 
been demonstrated to inhibit in vitro proplatelet formation.121-123,125 These findings have been 
controversially discussed because of the discrepancy to the fact that RhoA-deficient mice 
displayed moderately decreased platelet counts.112,126 Since increased platelet clearance in 
RhoA-/- mice did not significantly contribute to the phenotype,112,126 an alternative explanation 
could be that premature platelet release and/or mislocalization of MKs may contribute to the 
observed thrombocytopenia, but this hypothesis needs to be tested. The data presented in 
this thesis support the notion that RhoA and Cdc42 cooperatively regulate late steps of 
megakaryopoiesis. 
 The severe thrombocytopenia and the constant pressure to produce and rapidly release 
platelets may provide an alternative explanation for the profound ultrastructural alterations in 
RhoA/Cdc42-deficient BM MKs. Interestingly, the ultrastructure of RhoA-/-/Cdc42-/- BM MKs 
(Figure 41) strongly resembles typical features of the morphology of MKs of patients 
suffering from chronic thrombocytopenia. The ultrastructure of BM MKs of such patients is 
characterized by cytoplasmic vacuolization and dilation of the DMS, leading to the production 
of large platelets devoid of granules.193,194 The severe thrombocytopenia in RhoA/Cdc42-
deficient mice likely resulted from both increased recycling of circulating platelets (Figure 
39A) and decreased in vivo platelet production. Paradoxically, in vitro proplatelet formation 
was unaltered in RhoA/Cdc42-deficient MKs derived from fetal liver cells (Figure 39C). In 
vitro proplatelet production systems have been instrumental for studies on MK differentiation, 
proplatelet extension and proplatelet formation,3 but one significant limitation of this assay is 
that it does not reproduce the natural environment of the MKs with all its activating and 
inhibitory clues. Unexpectedly, platelet production following a strong challenge introduced by 
depletion of circulating platelets followed similar kinetics in WT and RhoA-/-/Cdc42-/- mice 
(Figure 39B), indicating that platelet production is not inhibited in general manner in the 
knockout mice. 
 The assumption that increased platelet recycling significantly contributed to the severe 
thrombocytopenia observed in RhoA-/-/Cdc42-/- mice was supported by the fact that 





of the spleen - a site of platelet clearance – did not lead to further platelet count drop (Figure 
43B). These findings indicated that extramedullary thrombopoiesis probably does not take 
place in RhoA-/-/Cdc42-/- mice. However, splenectomy improved the life span (Figure 44B) 
and the ultrastructure of BM MKs (Figure 45) and circulating platelets (Figure 43D). These 
unexpected effects on morphology may be due to the fact that decreased platelet removal 
lowers the pressure for BM MKs to produce platelets. However, this hypothesis requires 
further investigation. For instance, the effects of chronic thrombocytopenia on the 
development of WT BM MKs need to be assessed in the future in order to be able to 
discriminate between a phenotype derived from the actual mutation and more general effects 
of thrombocytopenia. 
 Taken together, these data emphasize important overlapping functions of RhoA and 
Cdc42 in platelet biogenesis and reveal redundant and non-redundant roles of both proteins 
in granule secretion and hemostasis. Additional studies will be required to better characterize 
distinct and overlapping pathways, the cross-talk between them and the involvement of 
downstream effector molecules. 
 
4.4. Concluding remarks and future plans 
The findings summarized in this thesis shed new light on the mechanisms involved in the 
regulation of the (hem)ITAM signaling cascade in platelets. SLAP/SLAP2 negatively regulate 
GPVI and CLEC-2 expression and signaling, possibly by interacting with common proximal 
key signaling molecules. These putative interactions have important implications in the 
modulation of platelet reactivity and prevent excessive cell activation in the pathological 
settings of experimental occlusive arterial thrombosis and ischemic stroke. Although caution 
is required with regard to the direct translation of findings obtained in knockout mouse 
models to the human system, the data presented in this thesis suggest that down-regulation 
or inactivation of SLAP proteins may significantly contribute to the progression of ischemic 
cardiovascular and cerebrovascular syndromes in patients. Conversely, approaches to 
enhance SLAP/SLAP2 activity or to avoid their inactivation might be beneficial in the 
prevention of thrombotic and thrombo-inflammatory disease conditions. However, further 
studies are required to better characterize the mechanisms regulating SLAP/SLAP2 activity 
and to evaluate the suitability of both adapter proteins as pharmacological targets. Notably, 
such modulation of SLAP/SLAP2 expression and activity may have important implications 
also during targeted down-regulation of (hem)ITAM receptors. In particular, tightly controlled 
regulation of downstream signaling by SLAP proteins appears to be essential to prevent 





 Platelet adhesion receptors, including GPIb and GPVI, have only recently been identified 
as key players in the development of ischemic stroke. The findings obtained in 
Slap-/-/Slap2-/- mice are the first to provide more direct evidence for the role of GPVI 
expression and the downstream signaling cascade in stroke progression. However, further 
experimental data are required to elucidate the principal pathomechanisms that govern 
secondary infarct growth in conditions of hyperreactive GPVI signaling. Furthermore, 
SLAP/SLAP2 might be critically involved in the modulation of (hem)ITAM receptor signaling 
in more classical inflammatory settings, including for instance, inflammation-induced 
hemorrhage. Importantly, one obvious limitation of experimental data obtained in 
SLAP/SLAP2-deficient mice used in the present thesis is the fact that these animals are 
constitutive knockout mice. This impairs conclusions about the exact contribution of different 
cell types in the progression of complex thrombo-inflammatory diseases. Generation of 
conditional knockout mice would help to determine how expression of SLAP/SLAP2 in 
different cells affects the severity of (thrombo-)inflammatory disorders. 
 Rho GTPases have been established as critical regulators of cytoskeletal 
rearrangements. More recently, these proteins have been increasingly recognized as 
important modulators of the final steps of megakaryopoiesis. Data summarized in this thesis 
demonstrate that the Rho GTPases RhoA and Cdc42 have several overlapping, but also 
unexpected non-redundant functions in the control of platelet production and function. The 
most widely accepted current model of thrombopoiesis suggests that mature MKs reside in 
the vicinity of vascular sinusoids in which they extend and release proplatelets.91 However, 
what remains elusive are the mechanisms that are responsible for the final localization of the 
MKs close to the blood vessels in the BM and how interactions between differentiated MKs 
and sinusoidal endothelial cells are regulated. Work in our laboratory has only recently led to 
the hypothesis that RhoA may act as a negative regulator of MK migration, polarization and 
directed proplatelet formation in vivo. These functions of RhoA appear to be critically 
counterbalanced by the GPIb-Cdc42 axis. These findings assign a critical role for RhoA and 
Cdc42 as master regulators of efficient thrombopoiesis in vivo and the underlying molecular 
pathways of the interdependence between both GTPases are the current subject of intensive 
research. 
Furthermore, studies on the role of RhoB in platelet production and function are planned. 
RhoB is a Rho GTPase which is highly homologous to and shares many common effector 
molecules with RhoA.106 RhoB is involved in vesicle trafficking and studies in cell types other 
than MKs and platelets suggested functional redundancies between RhoA and RhoB in cell 
polarization and motality.106,195 Initial experiments in our laboratory demonstrated that the 
expression of RhoB is upregulated in RhoA-deficient platelets, but the functional 
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ADAM a disintegrin and metalloproteinase 
ADP adenosine diphosphate 
ATP adenosine triphosphate 
AU arbitrary units 
BCR B cell receptor 
BFU burst-forming unit 
BM bone marrow 
BSA bovine serum albumin 
BW body weight 
CD cluster of differentiation 
Cdc42 cell division control protein 42 homolog 
CEACAM1 carcino-embryonic antigen-related cell adhesion molecule-1 
CFU colony-forming unit 
CLEC-2 C-type lectin-like receptor 2 
CRP collagen-related peptide 
CSF-1R colony-stimulating factor-1 receptor 
ctrl control 
d day 
DAG diacyl glycerol 
DAPI 4’,6-diamidino-2-phenylindole 
DIC differential interference contrast 
DKO double knockout 
DMS demarcation membrane system 
DNA deoxyribonucleic acid 
ECL enhanced chemiluminescence 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetate 
EGTA ethylene glycol tetraacetate 
ELISA enzyme-linked immunosorbent assay 
FcR Fc receptors 
FCS fetal calf (bovine) serum 
FITC fluorescein isothiocyanate 
FLC fetal liver cells 
g gravity 
GAP GTPase-activating proteins 
GDI guanine nucleotide-dissociation inhibitor 
GDP guanosine diphosphate 
GEF guanine nucleotide-exchange factor 
GP glycoprotein 
GPCR G protein-coupled receptor 
GTP guanosine-5'-triphosphate 
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IMDM Iscove's Modified Dulbecco's Medium 
IP immunoprecipitation 
IP3 inositol-3,4,5-trisphosphate 
ITAM immunoreceptor tyrosine-based activation motif 
ITIM immunoreceptor tyrosine-based inhibitory motif 
ITSM immunoreceptor tyrosine-based switch motif 
kDa kilodalton 
KO knockout 
LAT linker for activation of T cells 
MCA middle cerebral artery 
MFI mean fluorescence intensity 
min minute 
MK megakaryocyte(s) 
MLC myosin light chain 
MOPS 3-(N-morpholino)propanesulfonic 
MPV mean platelet volume 
n.d. not detectable 
n.s. not significant 
NA numerical aperture 
o/n overnight 
OCS open canalicular system 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PECAM-1 platelet endothelial cell adhesion molecule-1 
PF4 platelet factor 4 
PFA paraformaldehyde 
PGI2 prostaglandin I2, prostacyclin 
PIP2 phosphatidylinositol-4,5-bisphosphate 
PKC protein kinase C 
PLC phospholipase C 
PRP platelet-rich plasma 
PRR proline-rich region 
PS phosphatidylserine 
PVDF polyvinylidene difluoride 
Rac1 Ras-related C3 botulinum toxin substrate 1 
RBC red blood cells 
RhoA Ras homolog gene family, member A 
ROCK Rho-associated protein kinase 
RT room temperature 
RTK receptor tyrosine kinase 
s seconds 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SFKs Src family kinases 
sGPVI soluble GPVI 
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SHIP SH2 domain-containing inositol 5-phosphatase 
SHP SH2 domain-containing protein tyrosine phosphatase 
SLAP Src-like adapter protein 
SLP-76 SH2-containing leukocyte protein 76 
Syk spleen tyrosine kinase 
TBS Tris-buffered saline 





TEM transmission electron microscopy 
TF tissue factor 
Thpo thrombopoietin 
TLT-1 TREM-like transcript-1 
TMB 3,3,5,5-tetramethylbenzidine 
tMCAO transient middle cerebral artery occlusion 
TTC 2,3,5-triphenyltetrazolium chloride 
VWF von Willebrand factor 
WB Western blot 
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